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GENERAL CHARACTERISTICS OF MUMPS 
Clinical mumps was first described by Hippocrates in the 5th century BC during a 
mumps outbreak on the island of Thasos (1). A causative agent for mumps was 
not demonstrated until 1934, when Johnson and Goodpasture showed that mumps 
is caused by a virus present in saliva of infected patients (2,3). The name mumps 
may be derived from the old English verb that means to grimace, grin, or mumble 
(4). In the pre-vaccination era, mumps was an endemic childhood disease with 
epidemic peaks every 2-5 years and the majority of cases among those aged 5-9 
years (5). A Dutch seroepidemiological study from the pre-vaccine era shows that 
over 90% of children had acquired mumps before the age of 14 years and that only 
5% of adults were seronegative (6). Classic mumps is characterized by parotitis 
and is usually a mild disease, although in the pre-vaccination era up to 15% of the 
mumps patients developed meningitis (7). Other complications included 
encephalitis, orchitis, oophoritis, mastitis, pancreatitis and deafness. Introduction of 
the measles, mumps, and rubella (MMR) vaccination in the Netherlands in 1987 
has greatly reduced the morbidity rates of mumps as well as the number of 
hospitalizations due to mumps (8,9). However, during the last decade various 
mumps outbreaks occurred among MMR vaccinated populations in the 
Netherlands as well as in other countries worldwide, including the United States, 
Canada, Australia, Spain, Israel, Germany and Belgium (10–18). The majority of 
mumps patients in the recent mumps outbreaks among MMR vaccinated persons 
were adolescents and some outbreaks were specifically associated with 
educational settings or student events (15,19–21). 
GENOME ORGANIZATION AND PROTEIN FUNCTIONS 
Mumps virus is a paramyxovirus that belongs to the Rubulavirus genus. The virus 
is enveloped and consists of a nonsegmented, negative-sense RNA genome of 
15,384 nucleotides that includes 7 genes. Each gene encodes a single protein, 
with the exception of the V/P/I gene that encodes 3 different proteins (Figure 1). 
The viral genome is surrounded by the viral capsid, that consists of the 
nucleoprotein (N), the large protein (L) and the phosphoprotein (P) (Figure 1) 
(22,23). The L protein and the P protein are subunits of the viral RNA-dependent 
RNA polymerase and form replication complexes along with the N protein (24,25). 
The matrix protein (M), the haemagglutinin-neuraminidase protein (HN) and the 
fusion protein (F) form the viral envelope (Figure 1). The M protein links the 
replication complex to the viral membrane and is essential for virus assembly (26). 
The HN protein plays a critical role in viral entry via sialic acid binding. 
Furthermore, the protein acts as a neuraminidase by removal of sialic acid from 
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progeny virus particles to facilitate viral spread and promotes fusion activity of the 
F protein via cleavage (27–30). The HN protein is the major antigenic protein and 
various B cell and T cell epitope regions within the HN protein have been mapped 
(31,32). The F protein is important for both membrane fusion and virus-like particle 
production (26). Data on the antigenicity of the F protein is limited, but some B cell 
epitope regions have been mapped (33). The entropy for both the HN protein and 
the F protein is relatively low, which suggests that changes in these proteins might 
be a result of selection pressure (34). The SH protein is a membrane protein that is 
not essential for viral replication (35). This protein is important for viral 
pathogenesis, because it blocks apoptosis through inhibition of the tumor necrosis 
factor α (TNF-α) pathway, probably via its cytoplasmic tail (36–39). The mumps 
virus V protein plays also a role in mumps virus pathogenesis, because this protein 
blocks the interferon (IFN) and interleukin-6 (IL-6) signalling pathways (40–42). 
The role of the I protein in the virus life cycle is unknown. The V and I proteins are 
encoded by the same gene as the P protein. Via a process called “RNA editing” the 
generated mRNA is translated into 3 different open reading frames (ORFs), 
encoding the 3 proteins (43,44). 
MUMPS VIRUS GENOTYPES 
Based on the nucleotide sequences of the SH gene and HN gene, 12 mumps virus 
genotypes have been defined so far, named A-N. Because the earlier proposed 
genotypes E and M are not validated by the phylogenetic analysis based on the 
most updated dataset, these genotypes do not longer exist (45). Mumps virus 
surveillance is usually performed based on solely SH gene sequences. However, 
the intra-genotypic variation in this gene is low, especially with respect to genotype 
G strains, as was shown during recent mumps outbreaks (34,46,47). Although the 
geographic and temporal distribution of mumps virus strains has not been well 
characterized, some global distribution through time has been described (34,45). 
Genotype G strains were first detected in the late 1990s and have been continually 
detected in many countries since then, contrary to most of the other genotypes that 
were only reported during a more defined period (34). Mumps virus genotype G 
strains caused many of the recent mumps outbreaks among persons vaccinated 
with the Jeryl Lynn mumps virus strain, that belongs to genotype A. Therefore, the 
recent mumps outbreaks among MMR vaccinated persons raise questions 
regarding potential differences between mumps virus genotype G strains and other 
wild type strains as well as differences between genotype G strains and the 
vaccine strain. 
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Figure 1. Schematic representation of the mumps virus genome structure, virion structure and 
replication cycle. The V and I proteins are non-structural proteins and are therefore not shown in the 
virion structure. N, nucleoprotein; V, V protein; P, phosphoprotein; I, I protein; M, matrix protein; F, 
fusion protein; SH, small hydrophobic protein; HN, haemagglutinin-neuraminidase protein; L, large 
protein. 
CLINICAL MANIFESTATIONS 
The clinical hallmark of mumps is parotitis. Parotitis can be unilateral or bilateral 
and occurs in up to 98% of the clinical mumps cases (48–51). Other symptoms 
include fever, malaise, abdominal pain, nausea, headache and vomiting (48,50). 
However, many mumps virus infections run an asymptomatic course; about one 
third of the mumps virus infections are asymptomatic in unvaccinated persons (45). 
It has been suggested that the proportion of asymptomatic mumps virus infections 
is higher among MMR vaccinated persons, but the data about asymptomatic 
mumps virus infections are limited (52,53). The most common complication in adult 
males is orchitis. The clinical manifestations of orchitis are milder in vaccinated 
3’ 5’N SHFV/P/I M HN L
GENERAL INTRODUCTION 
 11 
patients than in unvaccinated patients and sterility after orchitis is rare (54,55). In 
adult females, oophoritis is reported at low frequencies (56). Other complications 
associated with mumps include meningitis, encephalitis, pancreatitis, mastitis and 
deafness (Table 1) (48,56). Myocarditis and nephritis have been rarely reported as 
complications associated with mumps (57). Long term complications and deaths 
associated with mumps are rare. Mumps virus reinfections have been reported, but 
are usually milder than primary mumps virus infections (58). 
Table 1. Complications reported in mumps patients. 
 
 
 
 
 
 
 
* Percentage orchitis cases among males aged 12 years or older. 
† Percentage oophoritis and mastitis cases among females aged 12 years or older. 
References (5,9,48,50,56,59–61). 
MUMPS VIRUS PATHOGENESIS 
Mumps virus is transmitted via direct contact or by airborne droplets and the 
incubation period varies between 2 and 4 weeks (62,63). The virus has been 
isolated from saliva from 7 days before until 8 days after onset of symptoms, which 
shows that the virus can be transmitted before disease onset (64). Mumps virus 
binds to sialic acid to enter the polarized epithelial cells in the upper respiratory 
tract from both sides (65). Apical entry facilitates transmission of virus to 
neighbouring cells, whereas infection from the basolateral side is probably 
important for secondary infection via the bloodstream (65). Mumps virus is 
predominantly released from the apical side of epithelial cells, which enables virus 
replication in the glandular epithelium and mumps virus shedding in saliva (65). So 
far, it is unclear how mumps virus breaks through the epithelial barrier. It has been 
suggested that mumps virus targets T cells, because the virus has a high affinity 
for T cells and efficiently replicates in these cells (66). Migrating mumps virus-
infected T cells could facilitate spread from the respiratory tract to other sites of the 
body and might therefore play an important role in disease pathogenesis (66). 
Mumps virus infected cells might escape host immunosurveillance via degradation 
 Mumps patients (%) 
Complications Unvaccinated patients 
Patients who received 2 
doses of MMR vaccine 
Meningitis 0.4%-10%  0.1%-1% 
Encephalitits 0%-0.7% 0% 
Pancreatitis 0%-4%  0%-0.6% 
Orchitis* 8%-38%  2%-7% 
Oophoritits† 0%-4% 0.8% 
Mastitis† 0%-31% 0% 
Deafness 0%-4% 0.1% 
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of STAT1 and STAT3 by the mumps virus V protein. In this way, IFN and IL-6 
signalling are blocked and the virus can evade both innate and adaptive antiviral 
responses (40–42,67,68). Furthermore, blockage of the IFN pathway enhances 
mumps virus replication, as IFN inhibitors promote mumps virus replication in vitro 
(69). However, the effect of the V protein on the magnitude of the IFN and IL-6 
response is unclear, because IFN and IL-6 levels appear to be elevated in mumps 
patients, especially in patients with meningitis and/or encephalitis (70). 
     The mechanism behind the development of mumps parotitis and orchitis is 
unknown. It has been hypothesized that these complications result from 
lymphocytic infiltration and destruction of periductal cells that lead to blockage of 
the ducts in the salivary glands and the semeniferous tubules of the testes, 
respectively (71). The hypothesis that orchitis is caused by an immune mediated 
reaction is strengthened by the relatively rapid development of orchitis after MMR 
vaccination as was reported for 2 persons who were exposed to mumps in the past 
(72). The rapid development of post-vaccine orchitis in these cases may be a 
result of pre-existing immune responses in the testis, which react immediately 
upon exposure to mumps virus antigen. On the other hand, replicating mumps 
virus has been isolated from the testis and semen, which indicates that orchitis is 
the result of direct invasion of the testicular cells (73,74). Mumps virus shedding in 
urine is caused by dissemination of mumps virus to the kidneys and is associated 
with abnormal renal function (75,76). As these data show, further studies are 
required to obtain more knowledge about mumps virus pathogenesis and the 
potential role of T cells. 
IMMUNOLOGICAL RESPONSES 
Mumps virus elicits the production of mumps virus-specific immunoglobulin (Ig)M 
and IgG by antibody-secreting B cells (ASCs). Primary immune responses are 
characterized by production of IgM, followed by low-avidity IgG. IgM peaks about 
one week after the onset of disease and declines during the first month, whereas 
IgG peaks about 3 weeks after the onset of disease and is detectable for many 
years (77–81). In secondary responses, IgM is often absent and high levels of 
high-avidity IgG are produced. Besides the production of antibodies by ASCs, 
memory B cells are generated. These memory B cells can rapidly produce 
antibodies during reinfection. Compared with the primary antibody response, the 
response during reinfection is typically faster and of greater magnitude (82). 
Mumps virus infection elicits relatively poor B cell memory, which may be a basis 
for susceptibility to reinfection (83). In the upper respiratory tract, mumps virus also 
elicits antibody responses at mucosal sites. Mumps-specific secretory antibodies, 
predominantly IgA, are produced in saliva after natural mumps virus infection (84). 
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IgA peaks about 1-2 weeks after onset of disease and is detectable for up to 10 
weeks in saliva of mumps patients (84). Furthermore, mumps virus induces 
secretory IgA responses in the nasal cavity, which suggests that the nasal cavity is 
also an important protective barrier (71,85). 
     Besides humoral immune responses, cell mediated immunity is probably also 
important for elimination of mumps virus (71). Mumps-specific cytotoxic T cell 
responses peak about 2-4 weeks after onset of disease and the decline in 
cytotoxic T cell activity differs greatly between individuals (86). Cellular responses 
may be long-lasting, because significant lymphoproliferative responses, mumps-
specific IFNγ and IL-10 production, and CD4+ T cells were measured in adults who 
had a clinical mumps virus infection during childhood (81,87). The development of 
T cell responses upon mumps virus infection is probably independent of humoral 
responses, as there is no significant correlation between humoral responses and 
cellular responses both shortly after vaccination and on the long term (81,88). 
Furthermore, cellular immune responses may be sufficient to protect from mumps 
virus infection, because persons without detectable mumps-specific IgG 
concentrations do not always contract mumps infection upon heavy exposure to 
the virus (89). 
MEASLES, MUMPS, AND RUBELLA VACCINATION 
Many different mumps virus strains have been used as component of the vaccine 
worldwide. The predominant mumps vaccine strains include Jeryl Lynn, RIT 4385, 
Urabe Am9, Leningrad-3, L-Zagreb, Rubini and S79 (90). In addition, a few other 
vaccine strains are used on a limited scale (63). The Rubini strain is the only strain 
that is recommended not to be used in national immunization programs (NIPs), 
because of its low effectiveness as compared with the other mumps vaccine 
strains, which could be attributed to the high number of passages used for 
attenuation (63,91). The vaccine strain used in the United States and in various 
European countries, including the Netherlands, is the Jeryl Lynn strain (90). In this 
thesis, we will focus on this widely used mumps vaccine strain when we discuss 
MMR vaccination. 
     The Jeryl Lynn strain was isolated in 1963 from a 5-year-old mumps patient, 
named Jeryl Lynn. Mumps virus was attenuated by passage in embryonated hens’ 
eggs and in cell cultures of chick embryo (92). Nowadays, the nucleotide sequence 
of Jeryl Lynn is known and it appears that the vaccine is a mixture of 2 
independently replicating mumps virus strains, designated JL2 and JL5 (93–95). 
The ratio of JL2 to JL5 is about 1:5 (94). Comparison of the nucleotide sequences 
of minor variant JL2 and major variant JL5 shows 414 nucleotide changes, 
resulting in 87 amino acid changes (96). This large number of differences suggests 
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that the variants derive from separate wild type mumps virus strains rather than 
from a common isolate (94). 
     MMR vaccination, with the Jeryl Lynn strain as mumps component, was 
introduced into the Dutch NIP in 1987 in a 2-dose vaccination schedule at 14 
months and 9 years of age. Until 2008 all MMR vaccines administered via the NIP 
were produced by the Netherlands Vaccine Institute (NVI). From then onwards, 
Priorix (GSK) and MMR-Vaxpro (Sanofi Pasteur MSD) are used as MMR vaccine 
in the NIP. The high vaccination coverage of >95% for 1 dose and >92% for 2 
doses of MMR resulted in a rapid decline in the number of reported mumps cases 
after introduction of the MMR vaccine into the NIP (8,97–99). However, mumps 
outbreaks among MMR vaccinated persons occurred in various countries 
worldwide during the last decade (12,15,17,18,100). Vaccine effectiveness (VE) for 
2 MMR doses ranges from 66% to 95%, depending on the study population and 
exposure setting (18,19,21,101–106). Although the recent mumps outbreaks 
among MMR vaccinated persons show that the MMR vaccine does not fully protect 
against mumps virus infection, the vaccine provides protection against 
complications. VE for 2 MMR doses is estimated as 72%-81% against orchitis, 
which is the major complication reported during the recent mumps outbreaks 
(9,50,59,107). 
     MMR vaccination induces both humoral and cellular immune responses (87,88). 
Mumps-specific IgG concentrations in the blood are long-lasting, although antibody 
concentrations induced by MMR vaccination are lower than antibody 
concentrations induced upon mumps virus infection (81,108). A 20-year follow-up 
study shows that the decrease in both antibody concentration and avidity after 
MMR vaccination is bigger for mumps than for measles and rubella (109). Mumps 
vaccination induces strong memory T cell immunity, as lymphoproliferative 
responses, mumps-specific IFNγ and IL-10 production and the number of mumps-
specific CD4+ T cells are high in adults who received MMR vaccination during 
childhood (81,87). Since the cellular responses seem to last longer than the 
humoral responses, the waning in humoral responses as seen in adults who had 
received MMR vaccination during childhood does not necessarily mean that these 
adults become susceptible to mumps virus infection (81). Further studies are 
needed to investigate the importance of cellular immune responses induced by the 
mumps vaccine in protection against mumps virus infection. 
MUMPS OUTBREAKS AMONG MMR VACCINATED PERSONS 
During the last decade, various mumps outbreaks among MMR vaccinated 
persons occurred worldwide. These outbreaks were mainly caused by mumps 
virus genotype G strains. The first mumps virus genotype G outbreak in the 
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Netherlands occurred in 2004 in a highly vaccinated student population at an 
international hotel school and was followed by another small outbreak in 2005 
(16,110). After a mumps virus genotype D outbreak within an orthodox religious 
community with low vaccination coverage between 2007 and 2009, the next 
mumps virus genotype G outbreak in the Netherlands among MMR vaccinated 
persons started at the end of 2009 and was scaled-up by a large student party in 
February 2010, followed by a nationwide outbreak (17,19,111). 
     It is unlikely that the recent mumps outbreaks were caused by primary vaccine 
failure, because MMR vaccination results in high seroconversion rates (112,113). 
Furthermore, MMR vaccinated mumps patients have mumps-specific antibody 
responses prior to infection (53). Therefore, it is more probable that the recent 
mumps outbreaks were a result of secondary vaccine failure. MMR vaccination 
was introduced into the NIP in 1987, including a catch-up campaign for children 
born between 1983 and 1985 (98). The predominant age group affected during the 
mumps outbreaks were the adolescents between 18 and 25 years of age, so the 
majority of the mumps patients were in the first cohort of children who received an 
MMR vaccination in the 1980s. Since mumps incidence rapidly decreased after 
introduction of MMR vaccination into the NIP, these persons probably had never 
been exposed to mumps virus until the start of the mumps outbreaks in 2009. In 
the absence of natural mumps, the vaccine-induced immune responses were not 
boosted and therefore waned after the second MMR dose at 9 years of age 
(20,109,113,114). This hypothesis is supported by findings from a large Dutch 
cross-sectional population-based serosurveillance study performed in 2006-2007 
(the so-called Pienter2 study), in which a small drop in seroprevalence to 87% was 
observed for the age cohort of 15-21 years (80). Furthermore, the risk for mumps 
disease during mumps outbreaks is positively associated with the time interval 
since last MMR vaccination and pre-outbreak antibody levels in serum are lower in 
mumps patients than in non-patients (53,115). 
     The recent mumps outbreaks among persons vaccinated with the Jeryl Lynn 
strain were mainly caused by mumps virus genotype G strains, whereas the Jeryl 
Lynn strain belongs to genotype A. A mismatch in both B cell epitopes and T cell 
epitopes between the vaccine strain and circulating wild type strains may 
contribute to the vaccine failure during the recent mumps outbreaks (32). 
Serological studies have shown that mumps virus genotype G strains are 
neutralized by vaccine-induced antibodies, although the level of neutralization is 
lower than for the vaccine strain (53,116). Investigation of differences in mumps 
virus surface proteins between the vaccine strain, genotype G and other wild type 
genotypes could contribute to the current understanding of mumps virus 
neutralization. 
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     Since many of the mumps outbreaks were among students, the social 
behaviour of this group could play a role in the occurrence of the recent mumps 
outbreaks (19,117). It is believed that mumps virus transmission occurs through 
close contact, such as inhalation of infectious droplets or contact with 
contaminated surfaces (117). Many students live in a close contact environment, 
whereas prolonged exposure to someone with mumps is associated with an 
increased risk for mumps (118). Moreover, dormitory residents and attendees of 
large social events, including student parties, were at increased risk for mumps 
during the recent outbreaks (19,20,119). In these settings, sharing drinks and 
dancing in close proximity could enable mumps virus transmission via salivary 
droplets. Students in the Netherlands often travel between university cities, which 
may facilitate spread of the virus during a mumps outbreak. This was the case in 
2010, when a student party in Leiden resulted in mumps virus spread to other 
university cities (17). However, further studies about mumps virus transmission in 
outbreak settings are needed to better understand factors that play a role in 
mumps virus transmission and to evaluate potential measures during future 
mumps outbreaks more effectively. 
THESIS OUTLINE 
The aim of this thesis is to provide insights into possible causes for the recent 
mumps outbreaks among MMR vaccinated persons in the Netherlands. In this 
way, our research contributes to the evaluation of the MMR vaccine in the light of 
the recent mumps outbreaks worldwide and can be used to inform public health 
decisions. Specifically, the objectives of this thesis are to: 
1) Investigate the role of epidemiological, virological and immunological factors in 
the occurrence of the recent mumps outbreaks; 
2) Track mumps virus transmission using sequencing as a tool; 
3) Study the effect of MMR vaccination on the development of mumps virus 
infection and severity of disease. 
This thesis has been divided in 4 parts. In Part II the recent mumps outbreaks in 
the Netherlands and the molecular characterization of the circulating mumps virus 
strains are discussed, to investigate possible epidemiological and virological 
causes for the recent mumps outbreaks and to study mumps virus transmission. In 
Chapter 2, we analysed the epidemiology of a nationwide mumps epidemic in the 
Netherlands during 3 outbreak seasons, to study potential changes in transmission 
patterns over time and to investigate the effect of MMR vaccination on the risk for 
complications. In this way, we could provide information for future mumps 
prevention efforts. Additionally, the mumps virus strains that circulated during the 
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recent mumps outbreaks were phylogenetically analysed to study whether cases 
were caused by endemic circulation or not (Chapter 3). One of the sequence types 
became predominant during the outbreak and we investigated if solely 
epidemiological factors could explain this predominance or if its predominance was 
a result of virological differences between the mumps virus strains. Therefore, we 
increased the molecular resolution by adding F gene and HN gene sequencing to 
the recommended SH gene sequencing. Combining the nucleotide sequences from 
these genes enabled us to study mumps virus transmission, even in the absence 
of an epidemiological link (Chapter 4). Next, in Chapter 5, differences in the 
mumps virus surface proteins between the vaccine strain and wild type strains 
were studied to find a possible explanation for the occurrence of mumps genotype 
G outbreaks among MMR vaccinated persons. 
     In Part III the effect of MMR vaccination on mumps virus infection and severity 
of disease is evaluated. Paired pre- and post-outbreak mumps-specific IgG 
concentrations were measured in MMR vaccinated students to study attack rates 
and risk factors for mumps virus infection (Chapter 6). We also compared pre-
outbreak mumps-specific IgG concentrations and strain-specific neutralization 
between mumps virus infected and non-infected students to identify a potential 
correlate of protection (Chapter 7). Furthermore, we compared clinical and 
laboratory data between mumps patients who had received 2 MMR doses and 
unvaccinated mumps patients to investigate if the MMR vaccine provides 
protection against mumps virus transmission and complications in mumps patients 
(Chapter 8). 
     In Part IV the implications of the data presented in this thesis are discussed 
(Chapter 9). 
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ABSTRACT 
To analyse the epidemiology of a nationwide mumps epidemic in the Netherlands, 
we reviewed 1,557 notified mumps cases in persons who had disease onset during 
September 1, 2009-August 31, 2012. Seasonality peaked in spring and autumn. 
Most case-patients were males (59%), 18-25 years of age (67.9%), and vaccinated 
twice with measles-mumps-rubella vaccine (67.7%). Nearly half (46.6%) of cases 
occurred in university students or in persons with student contacts. Receipt of 2 
doses of vaccine reduced the risk for orchitis, the most frequently reported 
complication (vaccine effectiveness [VE] 74%, 95% CI 57%-85%); complications 
overall (VE 76%, 95% CI 61%-81%); and hospitalization (VE 82%, 95% CI 53%-
93%). Over time, the age distribution of case-patients changed, and proportionally 
more cases were reported from nonuniversity cities (p<0.001). Changes in age and 
geographic distribution over time may reflect increased immunity among students 
resulting from intense exposure to circulating mumps virus. 
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INTRODUCTION 
Mumps is an acute illness caused by mumps virus (family Paramyxoviridae) and 
characterized by fever, swelling, and tenderness of ≥1 salivary gland, usually the 
parotid gland. Complications associated with mumps include orchitis (inflammation 
of the testes), meningitis, pancreatitis, and deafness. Mumps virus is spread in 
respiratory droplets, and the incubation period is 15-24 days (median 19) (1). 
Vaccination for mumps has been in use in industrialized countries for decades 
(2). The Netherlands began mumps vaccination in 1987, using the measles, 
mumps, and rubella combination vaccine (MMR). The vaccine, containing the 
Jeryl-Lynn mumps virus strain, is administered in a 2-dose schedule at 14 months 
and 9 years of age. Vaccination coverage of ≥1 dose of MMR has consistently 
been ≥93% since the introduction of the vaccination program (3). After the MMR 
program was launched, the incidence of mumps in the Netherlands decreased 
considerably; nevertheless, during the 2000s, several mumps outbreaks were 
detected. In 2004, an outbreak occurred among students at an international school 
(4), and in 2007–2008, an outbreak was detected mainly in a religious community 
that had low vaccination coverage (5). Since the end of 2009, a countrywide 
epidemic has been ongoing, affecting mainly student populations (6,7). 
Mumps was notifiable in the Netherlands before 1999 and was made notifiable 
again in December 2008 (5). Mumps surveillance reports are released biweekly or 
monthly and include data on age and sex distribution, geographic distribution, 
vaccination, and contact status of case-patients. The report is distributed to public 
health professionals, including epidemiologists, virologists, and local-level health 
professionals, but comprehensive spatiotemporal characterization of the 
surveillance data has not been conducted. To provide information for future mumps 
prevention efforts, we used this surveillance data to assess the rates of illness and 
complications associated with the ongoing outbreak, to understand who is at risk 
for infection, and to assess whether transmission patterns have changed over time. 
METHODS 
We reviewed data on mumps cases reported to the registration system for 
notifiable infectious diseases in the Netherlands (OSIRIS) during September 1, 
2009–August 31, 2012. Notification criteria for mumps include >1 related symptom 
(i.e., acute onset of painful swelling of the parotid or other salivary glands, orchitis, 
or meningitis) and laboratory confirmation of infection or an epidemiologic link to a 
laboratory confirmed case (7). In addition to basic demographic information, 
notification data reported to OSIRIS included vaccination status and student or 
contact with student status. The questions on student/student contact status were 
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made more specific on April 19, 2010. For cases reported before that date, the 
information for the new variable was obtained from open-format questions. 
Laboratory confirmation criteria included >1 of the following: detection of mumps-
specific IgM; detection of viral RNA; or isolation of the virus on cell culture. 
Genotyping targeting the gene encoding the small hydrophobic protein was 
performed on specimens submitted to the National Institute for Public Health and 
the Environment by using an in-house method. 
We used the χ2 test for comparison of proportions and testing for trends over 
time and calculated a 3 week moving average to characterize trends and 
seasonality. Vaccine effectiveness (VE) was estimated as 1 – odds ratio. The odds 
ratio, which describes the association between complications/hospitalizations and 
vaccination status, was adjusted for age and sex (when outcome was orchitis, 
adjustment was done for age only) and estimated by using logistic regression. 
Associations with p values of <0.05 were considered statistically significant, and all 
reported p values are 2-tailed. Stata software version 12 (StataCorp, College 
Station, TX, USA) was used for the analyses. 
 
 
Figure. Numbers of notified mumps cases, by week of onset, The Netherlands, September 1, 2009-
August 31, 2012 (N=1,557 cases). Seasons and number of cases (n) are indicated; black line indicates 
3-week moving average. 
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RESULTS 
During September 1, 2009–August 31, 2012, a total of 1,557 cases of mumps were 
reported in the Netherlands (Figure); 1,254 (80.5%) of these were laboratory 
confirmed. Laboratory confirmation was most often by detection of viral RNA 
(68.8%), followed by antibody detection (21.9%) and virus isolation (7.3%). In 2% 
of cases, 2 methods were combined for diagnosis. 
Most case-patients were male (59%) and 18–25 years of age (67.9%). The 
average annual incidence per 100,000 population was 0.5 for the 0–3-year age 
group, 0.8 for the 4–14-year age group, 4.5 for the 13–17-year age group, 21.4 for 
the 18–25-year age group, and 0.9 for the >25-year age group. Of the 1,474 cases 
for which patient vaccination status was reported, 998 (67.7%) case-patients had 
received 2 doses of MMR; 157 (10.6%) had received 1 dose, and 242 (16.4%) 
were unvaccinated. Genetic analysis of small hydrophobic gene sequences of 808 
mumps-positive samples showed that most (98.5%) outbreak strains belonged to 
the G5 subtype. 
Complications were reported in 126 cases (8.4% of 1,492 cases with known 
complication status) (Table 1). Most (78 [62%]) complications occurred in the 18–
25-year age group. Orchitis was the most frequent complication (109 [12.7%] male 
case-patients >12 years of age) and occurred significantly more often among 
unvaccinated casepatients than among case-patients who had received 1 vaccine 
dose (p=0.04); vaccination with 2 doses of MMR reduced the risk for orchitis even 
further (p<0.01). Other reported complications were meningitis (n=6), pancreatitis 
(n=3), thyroiditis (n=1), and encephalitis (n=1). Three case-patients had permanent 
unilateral hearing loss that was probably caused by mumps virus infection. 
Deafness and meningitis occurred more frequently among unvaccinated than 
vaccinated persons, but those numbers were probably too low for statistical 
significance (Table 1). 
A total of 31 patients (2.1% of 1,436 patients with known hospitalization status) 
were hospitalized. Risk for hospitalization was significantly lower among case-
patients who had received 2 MMR doses than for unvaccinated case-patients 
(p<0.01); VE for preventing hospitalization was 82% (Table 1). Of the 31 
hospitalized case-patients, 13 (42%) had orchitis. No deaths were reported.        
Three distinct epidemic seasons occurred during the outbreak: seasonal peaks 
in spring and late autumn and a decline in number of cases during summer and, to 
some extent, during the Christmas holidays (Figure). Data on sex, age, vaccination 
status, residence in a city with a university, student status, and contact with student 
status by season are shown in Table 2. Overall, the age distribution of mumps 
case-patients differed significantly between the seasonal peaks (p=0.007). The 
number of cases increased proportionally over time for the 13–17-year age group 
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(p=0.003) and the >25-year age group (p=0.042) and decreased over time for the 
18–25-year age group (p<0.001). The overall proportion of cases in vaccinated 
persons did not change (Table 2), and the proportion of complications or 
hospitalizations did not differ by season (data not shown). 
We found significant seasonal differences in the proportion of cases occurring 
in students and in persons with student contacts (p<0.001). During early spring 
2010, large clusters of cases were reported from university cities of Leiden and 
Delft, as described (6). However, during 2011 and 2012, proportionally more case-
patients were not students and had no contact with students than during 2010 
(p<0.001). The proportion of student case-patients enrolled in higher education 
other than university or case-patients who had contact with these nonuniversity 
students increased after 2010 (p<0.001). The absolute numbers of cases in these 
categories increased from 2010 to 2011 but stayed more or less constant, or 
decreased slightly, in 2012. The number of case patients who were university 
students or who had contact with university students decreased proportionally 
(p<0.001), and over time, proportionally more cases were reported from cities 
without universities (p<0.001). In addition, the total number of cases from 
nonuniversity cities was higher in 2012. 
Table 1. Association between rates of mumps complications and hospitalization and MMR status, the 
Netherlands, September 1, 2009-August 31, 2012* 
Complica-
tion 
No. 
MMR 
doses  
No. (%) 
compli-
cations 
Crude OR 
(95% CI) p value 
aOR† 
(95% CI) p value 
aVE† 
(95% CI) 
Orchitis§ 0 
1 
2 
36 (15.5) 
10 (6.6) 
46 (4.7) 
Ref 
0.46 (0.22-0.97) 
0.26 (0.16-0.41) 
 
0.04 
<0.01 
Ref 
0.46 (0.22-0.98) 
0.26 (0.15-0.43) 
Ref 
0.04 
<0.01 
Ref 
54 (2-78) 
74 (57-85) 
Deafness 0 
1 
2 
2 (0.9) 
0 
1 (0.1) 
Ref 
NA 
0.12 (0.01-1.3) 
 
NA 
0.1 
 
-  
- 
 
- 
- 
 
- 
- 
Meningitis 0 
1 
2 
2 (0.8) 
1 (0.6) 
2 (0.2) 
Ref 
0.76 (0.07-8.5) 
0.24 (0.03-1.7) 
 
0.8 
0.2 
 
- 
- 
 
- 
- 
 
- 
- 
All 
complica-
tions 
0 
1 
2 
44 (19.0) 
10 (6.6) 
55 (5.7) 
Ref 
0.30 (0.15-0.62) 
0.26 (0.17-0.39) 
 
<0.01 
<0.01 
Ref 
0.29 (0.14-0.62) 
0.24 (0.14-0.39) 
Ref 
<0.01 
<0.01 
Ref 
71 (38-86) 
76 (61-86) 
Hospitaliza-
tion 
0 
1 
2 
11 (4.8) 
3 (2.0) 
10 (1.1) 
Ref 
0.41 (0.11-1.5) 
0.22 (0.09-0.52) 
 
0.18 
<0.01 
Ref 
0.43 (0.11-1.6) 
0.18 (0.07-0.47) 
Ref 
0.2 
<0.01 
Ref 
57 (-60 to 89) 
82 (53-93) 
* Only case-patients with known complications and vaccination status were included in the analyses. 
OR, odds ratio; VE, vaccine effectiveness; Ref, referent; NA, not applicable; -, not analysed (insufficient 
sample size). 
† Adjusted for age (age groups <18 y, 18-25 y, >25 y) and sex, except orchitis, which was adjusted only 
for age. 
§ Includes only male case-patients >12 y of age. 
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Table 2. Demographic characteristics and student status for 1,557 patients with mumps, by annual 
epidemic season, the Netherlands, September 1, 2009-August 31, 2012* 
Characteristic 
No. (%) case-patients 
Season 1, 2009 
Sep 1-2010 Aug 
31, n=359 
Season 2, 2010 
Sep 1-2011 Aug 
31, n=689 
Season 3, 2011 
Sep 1-2012 Aug 
31, n=509 
Sex 
   M 
   F 
   Unknown 
 
205 (57.1) 
154 (42.9) 
0 
 
416 (60.4) 
271 (39.3) 
2 (0.3) 
 
296 (58.2) 
213 (41.8) 
0 
Age, y 
   0-3 
   4-12 
   13-17 
   18-25 
   >25 
   Unknown 
 
3 (0.8) 
5 (1.4) 
17 (4.7) 
270 (75.2) 
64 (17.8) 
0 
 
4 (0.6) 
22 (3.2) 
63 (9.1) 
468 (67.9) 
131 (19) 
1 (0.2) 
 
3 (0.6) 
16 (3.1) 
54 (10.6) 
318 (62.4) 
118 (23.2) 
0 
Vaccination status 
   0 doses 
   1 dose 
   2 doses 
   ≥3 doses 
   Vaccinated but unknown no. doses 
   Unknown 
 
57 (15.9) 
37 (10.3) 
225 (62.7) 
4 (1.1) 
24 (6.7) 
12 (3.3) 
 
115 (16.7) 
69 (10.0) 
436 (63.3) 
4 (0.6) 
25 (3.6) 
40 (5.8) 
 
70 (13.7) 
51 (10.0) 
337 (66.2) 
5 (1.0) 
15 (3.0) 
31 (6.1) 
Residence in a city with university† 
   Yes 
   No 
   Unknown 
 
258 (71.9) 
92 (25.6) 
9 (2.5) 
 
351 (50.9) 
322 (46.7) 
16 (2.3) 
 
243 (47.7) 
263 (51.7) 
3 (0.6) 
Student/contact with students 
   Not a student and no contact with     
   students 
   University student or contact with  
   university students 
   Other student‡ or contact with other  
   students 
   Unknown 
 
22 (6.1) 
 
229 (63.8) 
 
20 (5.6) 
 
88 (24.5) 
 
171 (24.8) 
 
275 (39.9) 
 
144 (20.9) 
 
99 (14.4) 
 
118 (23.2) 
 
221 (43.4) 
 
88 (17.3) 
 
82 (16.1) 
Incidence estimates§ 
   University students 
   Other students 
   Secondary school students 
 
92.9 
2.0 
0 
 
93.9 
14.7 
0.7 
 
80.2 
9.8 
5.4 
* Boldface indicates significance trends by χ2 test, calculated by using proportions excluding unknowns. 
† University cities: Amsterdam, Delft, Eindhoven, Enschede, Groningen, Leiden, Maastricht, Nijmegen, 
Rotterdam, Stichtse Vecht, Tilburg, Utrecht, and Wageningen. 
‡ Students enrolled in higher education other than university. 
§ Incidence per 100,000 students. Total student numbers by category obtained from www.cbs.nl. 
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DISCUSSION 
The epidemic of mumps in the Netherlands during late 2009 through 2012 affected 
mainly vaccinated students. However, vaccination evidently offered protection 
against mumps-associated complications. The epidemic showed a seasonal trend, 
although cases were identified throughout the years. Over time, age, student 
status, and geographic distribution changed, which suggests a slight shift in 
transmission trends from student populations to younger and older nonstudent 
populations and to cities without a university. This shift may relate to increased 
immunity in the primarily affected high-risk student population; exposure to wild-
type mumps virus may have boosted individual immunity and thus contributed to 
increased herd immunity.       
Mumps outbreaks among vaccinated populations have been reported in other 
countries during recent years: a 2006 outbreak in the United States (8), a 2009–
2010 outbreak in Canada (9), and a 2012 outbreak in the United Kingdom (10). 
Description of an outbreak in 2009–2010 in the northeastern United States among 
a highly vaccinated population of Orthodox Jews indicated that intense exposure 
among boys in a religious school facilitated the transmission of mumps virus, which 
overpowered the vaccine-induced protection (11,12). Similar to our findings, 
transmission in that outbreak shifted from adolescents to younger and older 
populations over time. The intense social crowding among students (e.g., large 
indoor social gatherings) partly explains why secondary vaccine failure occurred in 
the outbreak described in this study. A subgroup of students, including those living 
with many other students and members of university fraternities, may be at 
increased risk for infection (6,7). Crowding in nonstudent populations may not be 
as intense as among students, and mixing is usually with more heterogeneous age 
groups. In these circumstances, herd immunity is sufficient to prevent more 
widespread transmission. A lower rate of crowding may be one explanation for the 
relatively low numbers of cases among 4–12-year-olds, despite the generally lower 
IgG titers in this group than in adolescent students (13). Still, even though lower 
antibody levels do not automatically mean higher risk for mumps virus infection 
(14), a higher rate of illness would have been expected in the 4–12-year age 
group. An additional explanation for the lower apparent illness rate among these 
younger children might be a higher frequency of unapparent and subclinical 
infections, which would lead to many undiagnosed cases in this age group. 
Most of the persons affected in the epidemic were male, a finding also observed 
in other studies (15,16). The reasons for male predominance are unclear, but 
significantly higher mumps antibody titers in female than in male persons have 
been demonstrated (13,17); this finding, in turn, may be linked to gender-
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associated genetic differences in immune response. Behavioural differences 
between sexes may also play a role. 
Most cases occurred in persons who had received 2 doses of MMR, which 
suggests inadequate effectiveness of the vaccine. Recent studies indicate the 
effectiveness of MMR against mumps is moderate and lower than the clinical 
efficacy estimates (1,18). Postlicensure studies of 2 doses (Jeryl-Lynn strain) of 
MMR have provided a median VE estimate of 88% (range 79%–95%) (2). A recent 
study of an outbreak of mumps at a student party in the Netherlands estimated a 
VE of 68% for 2 doses of MMR (6). This estimate is, however, uncertain because 
of the low number of unvaccinated case-patients. We attempted to provide VE 
estimates against clinical mumps applying the screening method; however, 
because this method is most vulnerable to error when proportions of the population 
and case-patients vaccinated are high (19), as in this study, the estimates became 
inaccurate and thus are not included in our results. The possible causes for lower 
than expected VE include secondary vaccine failure (waning immunity), intense 
exposure to high virus inoculum, and a possible mismatch between the vaccine 
genotype and circulating strains (1,2,18,20). However, because the level of 
antibodies correlating with protection remains unknown (12,21), we are unable to 
further elucidate the role of these factors. 
Orchitis was the most common complication, consistent with previous outbreaks 
in a population with a similar age structure (1). However, orchitis occurred 
significantly more often among unvaccinated than vaccinated case-patients, and 
the vaccine was effective in preventing orchitis, which has previously been shown 
in a study based in part on the same study population (22) and in other studies 
(11,23). Vaccination also significantly reduced the risk for complications overall 
and for hospitalizations. A previous report described 3 cases of deafness (0.19% of 
all notified infections), 2 in unvaccinated persons (24). The frequency of 0.005% for 
unilateral deafness commonly cited in the literature (25) is considerably lower than 
that found in our study, but this difference is likely attributable to a different 
denominator population. A higher incidence of deafness has been reported from 
Japan using more appropriate denominators (26). 
One limitation of our study was the short time span for assessing changes over 
time. Mumps cases have continued to occur after our study period, but the number 
of cases reported after September 2012 (180 as of August 31, 2013) is much lower 
than that reported during the previous years. Recent numbers indicate that a 
similar trend in changing patterns of age and geographic distribution is ongoing; 
most of the more recent cases have occurred in nonstudents and in age groups 
other than 18–25 years (data not shown). However, because of lower case 
numbers, this comparison must be interpreted with caution. 
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A further limitation of our study is that it is likely that many mumps cases are not 
notified because they are subclinical infections or because of reluctance to seek 
medical care; thus, these cases are not included in our analyses. Furthermore, 
complications that occurred after the notification date are not included; however, 
because vaccination status is probably not associated with the reporting of 
complications, we regard our VE estimates against complications as unbiased. 
Although VE for mumps vaccination is not optimal for preventing clinical 
disease, our results support previous findings that vaccination limits the severity of 
disease. Because complications are the primary mumps-associated public health 
problem, these findings support the current vaccination recommendations. Still, this 
epidemic demonstrates that mumps virus can cause large outbreaks even in highly 
vaccinated populations. The observation that the incidence after the third season 
studied has been considerably lower than during previous seasons is consistent 
with the development of herd immunity among high-risk students resulting from the 
high rate of natural symptomatic and asymptomatic infections. However, the 
annual inflow of new susceptible students – unvaccinated and vaccinated – who 
start their studies could again lower overall immunity. A recent study suggested 
that use of a third MMR dose might be an effective control measure in certain 
outbreak situations (27). Introduction of a third MMR dose to the vaccination 
schedule has been considered in the Netherlands (6) but was not recommended 
because of relatively low overall illness rates associated with mumps and other 
factors, including an expected low vaccine uptake. Although the vaccine remains 
effective in most settings and significantly reduces the risk for complications, 
further research is needed to understand the limitations of MMR, and modeling is 
warranted to understand the dynamics of mumps virus transmission in future. 
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ABSTRACT 
During three seasons of mumps outbreaks in the Netherlands (September 2009–
August 2012), 822 mumps cases were laboratory-confirmed at the National 
Institute for Public Health and the Environment (RIVM). Most patients were 
vaccinated young adults. Given the protracted endemic circulation, we studied the 
genetic diversity and changes of mumps virus over a period of 3 years. 
Phylogenetic analysis of the small hydrophobic (SH) gene (316 bp) was performed 
on a representative set of 808 specimens that tested positive for mumps via PCR. 
Additionally, the haemagglutinin/neuraminidase (HN) gene (1749 bp) and fusion 
(F) gene (1617 bp) were sequenced for a subset of samples (n=17). Correlations 
between different sequence types and epidemiological and clinical data were 
investigated. The outbreaks in the Netherlands were dominated by two SH gene 
sequence types within genotype G, termed MuVs/Delft.NLD/03.10 (variant 1) and 
MuVs/Scheemda.NLD/12.10 (variant 2). Sequence analysis of the HN and F genes 
indicated that the outbreaks were initiated by separately introduced genetic 
lineages. The predominance of variant 2 by the end of the first outbreak season 
could not be explained by any of the epidemiological factors investigated. Orchitis 
was more frequently reported in males infected with variant 2, irrespective of age 
and vaccination status. These findings illustrate genetic heterogeneity of an 
emerging mumps genotype, and raise questions about the mechanisms driving 
mumps epidemiology and immunity in relation to vaccination. 
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INTRODUCTION 
Mumps is a highly contagious self-limiting infection that is spread via airborne 
droplets from the upper respiratory tract and by direct contact with saliva from an 
infected person. Disease often starts with non-specific symptoms, followed in 
~70% of cases by the characteristic unilateral or bilateral swelling of the parotid 
glands. Although mumps is mostly self-limiting, complications such as orchitis, 
pancreatitis, deafness, meningitis and encephalitis can occur (1). 
Following the introduction of the measles–mumps–rubella (MMR) vaccination 
containing the Jeryl Lynn mumps virus strain in the Netherlands in 1987, the 
incidence of mumps decreased significantly. However, during the past decade, 
several mumps outbreaks were observed in the Netherlands as well as in other 
countries that adopted the MMR vaccine in their national childhood immunization 
programmes. As the recent mumps outbreaks were mainly caused by genotype G, 
whereas the Jeryl Lynn vaccine strain belongs to genotype A, one hypothesis 
could be that the recent mumps outbreaks resulted from the escape of vaccine-
induced antibodies. However, WT mumps strains were effectively neutralized by 
vaccine-induced antibodies (2–5). There are also indications for a general lack of 
enduring humoral immunity, because mumps-specific antibodies induced by MMR 
vaccination were shown to wane both in concentration and in avidity (6). 
The first mumps outbreak in the Netherlands occurred in 2004 among a highly 
vaccinated student population at an international hotel school (7). The second 
mumps outbreak occurred between 2007 and 2009 within an orthodox religious 
community with low vaccination coverage (8). The most recent mumps outbreak 
started at the end of 2009 and was scaled-up by a large student party, after which 
many mumps cases were reported among students who had received two MMR 
doses during childhood. Thereafter, mumps virus persisted and spread throughout 
the country, and many cases were reported in student cities (9,10). 
Given the protracted endemic circulation of mumps in the Netherlands, we 
studied the genetic diversity and changes of mumps virus over a period of 3 years 
(September 2009–August 2012). Mumps genotypes are identified based on the 
sequence of 316 nt encoding the small hydrophobic (SH) protein (11). The SH 
protein seems not to be essential for viral infection and replication, but may 
interfere with tumour necrosis factor-α signalling, thus potentially influencing the 
host response to infection (12–14). Additionally, we chose to sequence the genes 
encoding the haemagglutinin/neuraminidase (HN) protein and the fusion (F) protein 
for a representative subset of patients to monitor possible molecular changes of 
immunologically relevant mumps proteins and to increase the molecular resolution 
between separate genetic lineages. The HN protein – the major glycoprotein of 
mumps virus – is a viral attachment protein that is considered to be an important 
CHAPTER 3 
	44 
target for neutralizing antibodies and therefore potentially under selective pressure 
from vaccine-derived immunity (15). The F protein is a surface protein that is 
involved in membrane fusion and viral entry (16). Combining phylogenetic 
analyses of the SH, HN and F gene sequences, we aimed to determine whether 
the different sequence types were a result of separate introductions of mumps 
virus or ongoing virus transmission and evolution. Furthermore, we analysed the 
molecular genetic data combined with the epidemiological and clinical data in order 
to investigate if solely epidemiological factors could explain the predominance of 
sequence types circulating during this outbreak and to determine the differences in 
clinical impact between the mumps virus strains. 
METHODS 
Clinical samples and patient data 
Clinical and epidemiological data of the mumps cases were obtained from an 
enhanced mumps surveillance by the RIVM in collaboration with municipal health 
services, as well as from confirmed cases reported by peripheral laboratories. The 
enhanced surveillance was based on the sampling of oral fluid and urine 
specimens from suspected cases, and these specimens were tested for the 
presence of mumps virus RNA by quantitative PCR. Serum, throat swabs and/or 
urine samples were collected for serology and virological testing. 
Laboratory-confirmed cases were reported by the municipal health services to 
the national registration system for notifiable infectious diseases in the Netherlands 
(Osiris) between 1 September 2009 and 31 August 2012. Notification criteria for 
mumps virus infection include at least one related symptom (acute onset of painful 
swelling of the parotid or other salivary glands, orchitis, or meningitis) and 
laboratory confirmation or an epidemiological link to a laboratory-confirmed case 
(10). 
From the laboratory database, cases were selected for whom oropharyngeal 
swabs, oral fluid or urine specimens were available. In total, during the study 
period, samples from 822 individuals were tested positive for mumps virus by the 
national laboratory at the RIVM. From these mumps-positive individuals, SH genes 
of 808 samples could be sequenced completely and adequately, and were 
therefore used for phylogenetic analysis. The HN and F gene sequences were also 
obtained from a selection of outbreak samples (n=17). Distribution of the 
epidemiological variables from the laboratory database was largely similar to the 
national Osiris database, which includes all laboratory-confirmed cases and cases 
that could be linked directly to a laboratory-confirmed case (n=1,557 for the study 
period). Data from the laboratory database were linked to the notification database 
by matching patients by dates of onset of disease, postal codes, gender and year 
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of birth. In accordance with Dutch law, no informed consent was required for this 
study. 
RNA extraction, cDNA synthesis and quantitative PCR 
RNA was extracted from specimens with either the High Pure Viral Nucleic Acid kit 
or the MagNA Pure 96 (Roche Diagnostics) following the manufacturer’s protocol. 
An aliquot of 20 ml RNA was transcribed into cDNA with 200 U murine leukemia 
virus reverse transcriptase (Applied Biosystems), 0.2 mM dNTP mix (Roche 
Diagnostics), PCR buffer (Applied Biosystems), 1.5 mM magnesium chloride 
(Applied Biosystems), 20 U RNase inhibitor (Applied Biosystems) and 2.5 mM 
random hexamers (Applied Biosystems). cDNA mix was incubated at room 
temperature for 10 min, 37˚C for 50 min, 95˚C for 5 min and then cooled down to 
4˚C. The SH gene was used as the target for the quantitative PCR up to March 
2010. For all samples tested from then onwards, the mumps F gene was used as 
the target. Quantitative PCR was performed with either the LightCycler 2.0 (until 
April 2011) or the LightCycler 480 (Roche Diagnostics). 
Sequencing 
For sequencing of the 316 nt encoding the SH gene, 20 ml cDNA from samples 
with positive PCR results was used as a template for the first PCR, which was 
followed by a nested PCR thaamplified 5 ml first PCR product. For the first PCR, 
primers BV6132 SH1 (nt 6133–6152) and BV2013 SH5 (nt 6539–6557) were used. 
Primers BV6138 SH3 (nt 6139–6159) and BV2011 SH6 (nt 6535–6555) were used 
for the nested PCR. After purification of the product with ExoSAP-IT (GE 
Healthcare), 4 ml amplified fragments was sequenced with primers BV6138 SH3 
(nt 6139–6159) and BV2011 SH6 (nt 6535–6555). 
For sequencing of the 1749 nt encoding the HN gene, a first PCR was 
performed with 20 ml cDNA and primers FW-HN1 (nt 6535–6555) and RV-HN1 (nt 
8442–8460), followed by a nested PCR with 5 ml first PCR product and primers 
FW-HN2 (nt 6539–6557) and RVHN2 (nt 8435–8454). Sequencing PCR was 
performed with 4 ml nested PCR product, which was first purified. The six primers 
used for the sequencing PCR were FW-HN2, FW-HN7172 (nt 7172–7191), RV-
HN7233 (nt 7212–7233), FW-HN7795 (nt 7795–7814), RVHN7842 (nt 7823–7842) 
and RV-HN2. 
For sequencing of the 1617 nt encoding the F gene, the sequence was divided 
into three overlapping parts. For the first PCR, 10 ml cDNA was added to a mix 
containing primers F-FW1A (nt 4292–4313) and F-RV1A (nt 4967–4989) for 
fragment 1, F-FW2A (nt 4863–4886) and F-RV2A (nt 5520–5541) for fragment 2, 
and F-FW3A (nt 5477–5500) and F-RV3A (nt 6174–6194) for fragment 3. For all 
fragments, a nested PCR with 5 ml first PCR product, and primers F-FW1B (nt 
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4298–4319) and F-RV1B (nt 4963–4985) for fragment 1, F-FW2B (nt 4930–4949) 
and F-RV2B (nt 5579–5600) for fragment 2 and F-FW3B (nt 5480–5502) and F-
RV3B (nt 6172–6191) for fragment 3 was performed. Sequencing PCR was 
performed with 4 ml nested PCR 
product, which was first purified. The six primers used for the sequencing PCR 
were F-FW1B, F-RV1B, F-FW2B, F-RV2B, F-FW3B and F-RV3B. For all 
sequencing PCRs, Big Dye Terminator version 3.1 was used (Applied 
Biosystems). PCR fragments were analysed on the 3730 DNA Analyser (Applied 
Biosystems). 
Phylogenetic analysis 
BioNumerics 7.1 software (Applied Maths) was used to compare both nucleotide 
and amino acid sequences and to recreate phylogenetic trees. Nucleotide 
sequences were translated with an online translation tool 
(http://web.expasy.org/translate/). 
Statistical analysis 
The x2 test was used for comparison of genotype G subtypes. To compare orchitis 
cases, logistic regression analysis was performed, adjusting for age and 
vaccination status of the patients. p<0.05 was considered statistically significant 
and all reported p values are two-tailed. SPSS (version 19) and GraphPad Prism 
(version 6) were used for all analyses. 
RESULTS 
Mumps diagnostics 
From 1 September 2009 to 31 August 2012, samples from 822 individuals were 
tested positive for mumps via either PCR (n=813) or serological analyses (n=7) or 
a combination of PCR and serology (n=2) at the National Institute for Public Health 
and the Environment (RIVM). All individuals positive for mumps virus had at least 
one mumps symptom, i.e. parotitis, orchitis or meningitis. Of the individuals with 
reported vaccination status (n=672), 86.3% were vaccinated at least once and 
73.8% had received at least two MMR vaccine doses. Of the 822 mumps-positive 
patients, complete and adequate SH gene sequences were generated from the 
samples of 808 patients (98.3%). Samples included oropharyngeal swabs, saliva 
and urine. Of patients for whom gender was known (n=791), 58.0% were males. 
Orchitis was the most frequently reported complication and was reported in 7.3% 
of the males who tested positive for mumps virus.  
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Diversity of mumps virus SH gene sequences 
Phylogenetic analysis based on the SH gene sequences of 808 mumps-positive 
patients revealed that the majority of the outbreak strains belonged to genotype G 
(98.51%). Other genotypes that were observed during the outbreak were J 
(0.99%), H (0.25%) and D (0.25%). Within genotype G, two large clusters were 
identified: MuVs/Delft.NLD/03.10 (22.11%) and MuVs/Scheemda.NLD/12.10 
(65.32%), further referred to as variants 1 and 2, respectively (Figure 1). 
Sequence changes among main clusters 
The SH gene sequence of variant 1 was identical to the SH gene sequences of 
genotype G mumps strains found in other countries, such as MuVs-GBR0300796-
G5 (17), MuV/New York.USA/40.09/4 and MuV/New York.USA/01.10. Variant 2 
differed in 2 nt from variant 1 (nt 167 and 205), resulting in one silent and one 
missense mutation, without any alterations in the amino acid character (aa 52, Ser 
à Asn). 
None of the recent SH nucleotide sequences registered in GenBank from 
mumps genotype G subtypes circulating before March 2010 were similar to the SH 
sequence of variant 2. However, the amino acid sequence was identical to a 
mumps isolate from the UK in 2005 (MuVs-GBR05-1700315-G5) (17). After the 
appearance of variant 2 in the Netherlands, mumps strains with identical SH 
sequences were found in Belgium and Germany. 
Distribution of genotypes over time 
Throughout the three mumps outbreak seasons (September 2009–August 2012), a 
shift in the distribution of the two major circulating clusters was observed. In the 
first mumps outbreak season, variant 1 was the most prevalent subtype detected 
(78.4%), whereas during the second and third seasons, variant 2 was most 
prevalent (74.2 and 87.8%, respectively). In addition to these two large genotype G 
clusters, smaller clusters were observed with a maximum of 21 sequenced cases 
per cluster (Figure 1). These subvariants appeared and circulated for a few 
months, but could not be related to specific student events (Figure 2). Identification 
of those clusters was based on changes in 1 or 2 nt in the SH gene background 
from either mumps variant 1 or 2 and they probably originated from one of those 
two dominant subtypes. Owing to these uncertainties, the subvariants were 
excluded from further analyses. 
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Figure 1. UPGMA (unweighted pair group method with arithmetic mean) tree based on the nucleotide 
sequence of the SH gene of 808 samples obtained between September 2009 and September 2012. 
The three different outbreak seasons are indicated by light grey, dark grey and black shading. 
Genotypes and variants are indicated on the right. For each cluster, the number of identical sequences 
is indicated in parentheses. Substitutions are shown for each subcluster, including nucleotide positions 
within the SH gene. The nucleotides that differ are indicated by single-letter codons. 
(n=176)
(n=520)
T119W
T192Y
A266G
G225A
T178C
T206C (n=3)
T283C (n=20)
C21T
A106G
A140C
A252G
T119G
T152C
G310A
T292C
G265A
G302A (n=2)
G302AG310A (n=2)
A270G
A267G
T97C (n=6)
T193C
A205C
G167RA205R
T152C
T216A
T115C
T201C
A71C
C231G
G210A (n=2)
C108T
C168T (n=21)
C168TC191T (n=7)
T222CT283C (n=2)
(n=3)
(n=4)
(n=2)
(n=2)
Sep 2009 – Aug 2010
Sep 2010 – Aug 2011
Sep 2011 – Aug 2012
M
uV
s/
D
el
ft
.N
LD
/0
3.
10
 (v
ar
ia
nt
 1
)
an
d 
su
bc
lu
st
er
s
M
uV
s/
Sc
he
em
da
.N
LD
/1
2.
10
 (v
ar
ia
nt
 2
)
an
d 
su
bc
lu
st
er
s
G
H
J
D
MuVs/Budel.NLD/44.10
MuVs/Groningen.NLD/40.10
MuVs/Enschede.NLD/10.11
MuVs/Utrecht.NLD/12.11
T278G
MUMPS VIRUS VARIANTS IN THE NETHERLANDS 
	 49 
Genotyping based on the HN gene 
Phylogenetic analysis based on the HN gene sequences showed different 
clustering compared with genotyping based on the SH gene. Genotype G variant 2 
had 6 nt substitutions compared with variant 1, resulting in one amino acid 
substitution (aa 203, Lys à Asn) (Figure 3A). The amino acid sequence of variant 
2 was identical to the amino acid sequences of the New York strains. In contrast to 
the SH gene of variant 1, the HN gene sequence was not identical to genotype G 
outbreak strains from New York. Combined, these data suggest that the two 
dominant clusters are distinct genetic lineages.  
Figure 2. Mumps genotype G variants by week of onset of disease from 1 September 2009 to 31 
August 2012. (A) Reported patients with MuVs/Delft.NLD/03.10 (variant 1) and subvariants. (B) 
Reported cases of MuVs/Scheemda.NLD/12.10 (variant 2) and subvariants. The sequences of the 
subvariants differed in 1 or 2 nt from the major genotype G variants 1 and 2 (see also Figure 1). The 
three epidemic seasons were defined as: 1 September 2009-31 August 2010 (season 1), 1 September 
2010-31 August 2011 (season 2) and 1 September 2011-31 August 2012 (season 3). 
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Genotyping based on the F gene 
In line with the phylogenetic analyses based on the SH and HN genes, F gene 
sequences of variants 1 and 2 were distinguishable. The New York strains formed 
a cluster with variant 2 sequences, whereas variant 1 contained 10 mutations at 
the nucleotide level, resulting in two amino acid substitutions (aa 14, Phe à Val 
and aa 97, Ser à Leu). However, aa 492 differed between New York strains (Val) 
and variant 2 (Gly), but this substitution was not found in variant 1 (Val) (Figure 
3B). Combined with the SH and HN gene sequence analyses, these data support 
the notion that the two dominant genotype G clusters in this outbreak were indeed 
distinct genetic lineages. 
Comparison of patient characteristics between the two major mumps 
genotype G clusters 
Patients infected with genotype G variants 1 and 2 were compared with respect to 
age, gender, region, vaccination status and clinical parameters to investigate 
whether the dominance of variant 2 during the second and third mumps outbreak 
seasons in the Netherlands could be explained by any of the epidemiological 
factors assessed in this study (Table). Most patients with either variant 1 or 2 were 
males, but males were more predominant among variant 2-infected patients  
(p=0.047). Age and vaccination status did not differ significantly between patients 
infected with one of the two genotype G variants (p>0.5). 
Proportionally more variant 1 cases compared with variant 2 cases were 
reported among students or student contacts and in cities with universities 
(p<0.001). During the first outbreak season, large clusters of variant 1 were 
reported in the Dutch student cities of Delft, Leiden, Groningen and Utrecht, 
whereas variant 2 circulated mainly in the student city of Groningen. During the 
second and third mumps outbreak seasons, large variant 2 clusters were reported 
in various regions of the country, including the major student cities, whereas only a 
few patients with variant 1 were reported during this period (Figures 1 and 2). 
Among fully MMR-vaccinated males infected with either mumps variant 1 or 2 
(n=249), there were 21 cases (8.4%) who developed orchitis. Eight other orchitis 
patients were unvaccinated (17.4% out of 46 unvaccinated males), one male with 
orchitis had received only one MMR dose and for three males the vaccination 
status was unknown. Orchitis was more frequently reported for cases infected with 
variant 2 compared with variant 1 (Table). When adjusting for age and vaccination 
status, the association between the mumps variants and occurrence of orchitis 
remained independently significant (p=0.045; odds ratio 3.5; 95% confidence 
interval: 1.03–12.1). Of the patients with mumps variant 1, three out of the 92 male 
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patients (3.3%) were reported with orchitis. One of these males was unvaccinated 
and the other two males were fully vaccinated. Regarding the variant 2 mumps 
strain, orchitis was reported in 30 out of the 306 male patients (9.8%) during the 
whole outbreak, including 19 fully vaccinated cases and six unvaccinated cases. 
When comparing only fully vaccinated cases, two out of 55 fully vaccinated male 
patients with variant 1 had orchitis (3.6%), compared with 19 out of 194 vaccinated 
male patients infected with variant 2 (9.8%) (p=0.147). 
 
 
 
 
Figure 3. UPGMA trees based on the nucleotide sequences of the HN and F genes of a subset of 17 
outbreak samples and isolates from the 2009-2012 outbreak. (A) UPGMA tree based on the nucleotide 
sequence of the HN gene. (B) UPGMA tree based on the nucleotide sequence of the F gene. Reference 
strains included in the analyses were MuV/New York.USA/40.09/4 and MuV/New York.USA/01.10. 
Percentages at the branches indicate bootstrap values (1000 replicates). Black and grey shading 
represent identical genotype G variants based on SH gene sequences, with all SH sequences identical 
to MuVs/Delft.NLD/03.10 (variant 1) in black and all SH sequences identical to 
MuVs/Scheemda.NLD/12.10 (variant 2) in grey. 
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DISCUSSION 
To find possible epidemiological explanations for the protracted endemic circulation 
of mumps genotype G in the Netherlands (September 2009–August 2012), we 
studied the genetic diversity and changes of mumps virus over a period of 3 years. 
Phylogenetic analysis based on SH gene sequences defined two major clusters 
within genotype G, termed variants 1 and 2, and background epidemiological and 
clinical data for patients infected with these two lineages differed. 
The proportion of students and the percentage of patients living in cities with a 
university was significantly larger in variant 1 patients compared with variant 2 
patients. This is probably explained by the fact that variant 2 was the dominant 
strain during the second and third outbreak seasons when mumps was also 
reported more often in nonstudent cities, whereas during the first outbreak season 
variant 1 was the dominant mumps strain and mumps was primarily circulating in 
the student cities (18). Students have more social contacts than nonstudents and 
they may therefore be more likely to transmit mumps. However, this difference 
does not explain the dominance of mumps variant 2 during the second and third 
outbreak seasons, because during these seasons proportionally fewer students 
were infected with mumps. 
Orchitis was reported in 8.3% of the males infected with either mumps variant 1 
or 2, which is comparable with the rates of orchitis in males reported during other 
recent mumps outbreaks among vaccinated adults (2,19). We found that orchitis 
was more often reported among males who were infected with variant 2. No 
epidemiological explanation or bias could be found that might explain these 
differences, which suggests that the risk for developing mumps-associated orchitis 
is higher for vaccinated individuals infected with mumps virus variant 2 compared 
with variant 1. Whether this is also accompanied by genotype-specific differences 
in viral pathogenesis and viral transmission needs to be determined. Single amino 
acid changes in the HN, F and polymerase proteins have been associated with 
neuroattenuation, but no association between specific mutations and orchitis has 
been described so far (20–22). 
Although mumps is a notifiable disease in the Netherlands, we expect that the 
majority of cases have not been reported. This probably results in an under-
representation of certain clusters within genotype G. Furthermore, it might be that 
patients suffering from orchitis are over-represented in our databases, since those 
patients are more likely to be reported than patients without any further 
complications. The high orchitis incidence during this outbreak is not related to a 
larger proportion of male patients, because after excluding orchitis cases, >50% of 
the patients still were males. 
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Table. Characteristics [n (%)] of mumps cases by mumps virus genotype G variant. 
Characteristic 
Variant 1 
(n=179) 
Variant 2 
(n=514) p value 
Gender 
   Male 
   Female 
   Unknown 
 
92 (51.4) 
86 (48.0) 
1 (0.6) 
 
306 (59.5) 
202 (39.3) 
6 (1.2) 
0.047 
Age (years) 
   0-3 
   4-12 
   13-17 
   18-25 
   >25 
   Unknown 
 
1 (0.6) 
2 (1.1) 
13 (7.3) 
120 (67.0) 
23 (12.8) 
20 (11.2) 
 
1 (0.2) 
9 (1.8) 
40 (7.8) 
320 (62.3) 
77 (15.0) 
67 (13.0) 
0.769 
Vaccination status (no. doses) 
   0 
   1 
   2 
   ≥3 
   Vaccinated but unknown dose 
   Unknown 
 
20 (11.2) 
15 (8.4) 
114 (63.7) 
1 (0.6) 
2 (1.1) 
27 (15.1) 
 
60 (11.7) 
41 (8.0) 
316 (61.5) 
6 (1.2) 
15 (2.9) 
76 (14.8) 
0.662 
Student and contact with students status 
   Not a student and no contact with student 
   University student or contact with university student 
   Other student or contact with other student 
   Unknown 
 
9 (5.0) 
96 (53.6) 
10 (5.6) 
64 (35.8) 
 
80 (15.6) 
212 (41.2) 
71 (13.8) 
151 (29.4) 
<0.0001 
Residence in a student city* 
   Student city 
   No student city 
   Unknown 
 
120 (67.0) 
58 (32.4) 
1 (0.6) 
 
266 (51.8) 
245 (47.7) 
3 (0.6) 
0.0004 
Orchitis cases† 
   Orchitis 
   No orchitis 
 
3 (3.3) 
89 (96.7) 
 
30 (9.8) 
276 (90.2) 
0.045‡ 
p values were calculated using the χ2 test excluding the unknowns. 
* Student cities include Amsterdam, Delft, Eindhoven, Enschede, Groningen, Leiden, Maastricht, 
Nijmegen, Rotterdam, Stichtse Vecht, Tilburg, Utrecht and Wageningen. 
† Only males were included. 
‡ Adjusted for vaccination status and age using logistic regression. 
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During the mumps outbreaks in the Netherlands between 2009 and 2012, 
primarily vaccinated young adults were affected, which points towards waning 
immunity (23). Furthermore, the mumps strains during the recent outbreak were 
from a different genotype than the vaccine strain. Poorer cross-protection in 
individuals with waning antibody concentrations or specific immunopathogenic 
factors might make mumps genotype G more infectious than other mumps 
genotypes. However, this has yet to be determined. 
Sequencing of the HN and F genes indicates that mumps genotype G variant 2 
may not have directly emerged from variant 1 in the recent mumps outbreak. The 
amino acid substitution in variant 1 compared with variant 2 and genotype G 
strains circulating in other countries was reported previously (24,25), but the 
function of this region in the HN gene has not been described. Although we found 
some mutations in the SH, HN and F gene sequences between two mumps 
genotype G subtypes that have different orchitis incidence rates, we have no 
indication that those particular mutations are associated with pathogenicity. More 
research is needed to assess whether the substitutions described above have an 
effect on neutralization of the virus resulting in a selective advantage. Furthermore, 
the discrepancy between phylogenetic analyses of the SH, HN and F gene 
sequences illustrates that sequencing of additional genes improves the resolution 
of the molecular data, especially for ongoing outbreaks in which one particular 
genotype such as genotype G is highly prevalent and frequent importations of the 
same genotype might occur. Further studies are needed to investigate if mumps 
genotype G variant 2 has a virological advantage over variant 1 with respect to 
viral transmission and pathogenesis. 
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ABSTRACT 
Various mumps outbreaks have occurred in the Netherlands since 2004, 
particularly among persons who had received 2 doses of measles, mumps, and 
rubella (MMR) vaccination. Genomic typing of pathogens can be used to track 
outbreaks, but the established genotyping of mumps virus based on the small 
hydrophobic (SH) gene sequences did not provide sufficient resolution. Therefore, 
we expanded the sequencing to include fusion (F) gene and haemagglutinin-
neuraminidase (HN) gene sequences in addition to the SH gene sequences from 
109 mumps virus genotype G strains obtained between 2004 and mid 2015 in the 
Netherlands. When the molecular information from these 3 genes was combined, 
we were able to identify separate mumps virus clusters and track mumps virus 
transmission. The analyses suggested that multiple mumps virus introductions 
occurred in the Netherlands between 2004 and 2015 resulting in several mumps 
outbreaks throughout this period, whereas during some local outbreaks the 
molecular data pointed towards endemic circulation. Combined analysis of 
epidemiological data and sequence data collected in 2015 showed good support 
for the phylogenetic clustering. 
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INTRODUCTION 
After introduction of the measles, mumps, and rubella (MMR) vaccination in the 
Netherlands in 1987, the incidence of mumps rapidly declined to less than 
1/100,000 per year in the 1990s (1). However, during recent years various mumps 
outbreaks have occurred in the Netherlands, particularly among adolescents who 
had received 2 MMR doses (2). Mumps outbreaks among MMR vaccinated 
persons were also reported in various other countries (3–6). Genotyping of the 
virus plays an important role in mumps virus surveillance. The molecular data 
serve to distinguish wild type mumps virus strains from vaccine strains and to track 
the geographic and temporal distribution at a global level (7). Based on the 
nucleotide sequences of the small hydrophobic (SH) gene and the haemagglutinin-
neuraminidase (HN) gene, 12 mumps virus genotypes have been defined so far 
(8). SH gene based typing is the reference method as the SH gene is considered 
to be the most variable gene in the mumps virus genome (9). However, genotype 
G strains show little diversity when using SH gene based typing and large clusters 
of mumps virus strains with identical SH gene sequences have been found in 
recent outbreaks in the Netherlands and elsewhere (10–12). 
     The first such outbreak in the Netherlands among a highly vaccinated 
population occurred in 2004 at an international hotel school (13). After this 
outbreak, mumps virus genotype G cases were repeatedly reported, but the 
incidence was relatively low. The second outbreak (2007-2009) occurred within an 
orthodox religious community with low vaccination coverage and was caused by 
mumps virus genotype D (14). During the largest mumps outbreak (2009-2012), 
which was caused by mumps virus genotype G, many twice MMR vaccinated 
students as well as non-students throughout the country were reported with 
mumps (2,10). Between 2013 and mid 2015, there were only small local mumps 
outbreaks as well as periods with sporadic mumps cases. The majority of these 
cases were due to mumps virus genotype G infections. These observations 
triggered the question whether mumps was endemic in the country, or if these 
outbreaks reflected repeated importations. 
     To address this question, we have sequenced the fusion (F) gene, SH gene and 
HN gene from 109 mumps virus genotype G strains obtained between 2004 and 
mid 2015 in the Netherlands to track mumps virus transmission and to identify 
possible mumps virus clusters, which was not possible based on the low resolution 
SH gene typing (10). The F gene and HN gene were chosen because these genes 
encode for surface proteins that play important roles in mumps virus pathogenesis 
and immunity. By combining sequences of the F gene, SH gene and HN gene, we 
have investigated whether the observed outbreaks resulted from locally circulating 
viruses or from new introductions. A well characterized mumps outbreak in 2015 
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was studied to investigate added value of molecular typing over epidemiological 
data. 
METHODS 
Clinical samples 
Clinical samples that yielded a complete mumps virus F gene, SH gene and HN 
gene sequence from patients diagnosed between 2004 and 2015 were used in this 
study (Table 1). In all samples mumps virus had been detected via polymerase 
chain reaction (PCR). Only 1 sample per mumps patient was included. Analysed 
samples included saliva samples, throat swabs and urine specimens, depending 
on availability. Epidemiological data about geographical location, source of 
transmission and day of onset of disease was retrieved from the national 
registration system for notifiable diseases in the Netherlands (Osiris) to provide 
background for analysis of robustness of clustering based on molecular data. In 
addition, epidemiological data from 67 mumps patients who were reported in Osiris 
in the first half of 2015 was used to study transmission. 
RNA extraction and cDNA synthesis 
RNA was extracted from specimens with either the High Pure Viral Nucleic Acid kit 
or the MagNA Pure 96 (Roche Diagnostics), according to manufacturer’s protocol. 
cDNA was synthesized using random hexameres (Invitrogen) as described 
previously (10) or using specific primers FW-F4351 and FW-HN6497 G together 
with Superscript III reverse transcriptase (Invitrogen; Supplementary table 1). 
Sequencing 
All primers used for sequencing are described in Supplementary table 1. The SH 
gene was amplified as described previously using primers BV6132 SH1 and 
BV2013 SH5 during the first PCR and primers BV6138 SH3 and BV2011 SH6 
during the nested PCR (10). Thereafter, sequencing of the 316 nt encoding the SH 
gene was performed using primers BV6138 SH3 and BV2011 SH6. Sequencing of 
the 1749 nt encoding the HN gene was initially performed as described previously, 
using primers FW-HN1, RV-HN1, FW-HN2, RV-HN2, RV-HN7233, FW-HN7795, 
RV-HN7842 and RV-HN2 (10). Samples from mumps virus genotype G strains for 
which HN gene sequencing failed were repeated using mumps virus genotype G 
specific primers FW-HN6497 G and RV-HN8482 G during the first PCR and 
primers FW-HN6534 and RV-HN8433 during the nested PCR. The nested PCR 
primers were also used to generate sequences, together with primers FW-HN7172, 
RV-HN7233, FW-HN7795 and RV-HN7842. The 1617 nt encoding the F gene 
were sequenced using primers F-FW1A and F-RV3A during the first PCR and 
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primers F-FW1B and F-RV3B during the nested PCR. Sequences were generated 
using primers F-FW1B, F-RV1B, F-FW2B, F-RV2B, F-FW3B and F-RV3B. For all 
sequencing PCRs, Big Dye Terminator version 3.1 was used (Applied 
Biosystems). All F gene, SH gene and HN gene sequences were submitted to the 
GenBank database and are available with the accession numbers KJ125045-
KJ125051, KJ125053-KJ125059, KJ125061-KJ125067 and KU756625-KU756930. 
Phylogenetic analysis 
BioNumerics software version 7.5 (Applied Maths) and MEGA software version 
6.06 were used to analyse nucleotide sequences. Maximum likelihood trees with 
1000 bootstrap replicates for branch support were created using MEGA software 
version 6.06. F, SH and HN gene sequences were merged for phylogenetic 
analyses of the combined sequences. 
RESULTS 
Phylogenetic analysis 
Complete F gene, SH gene and HN gene sequences were obtained from a set of 
109 mumps virus genotype G outbreak samples obtained between October 2004 
and June 2015 (Table 1). The percentage of variable sites was largest in the SH 
gene (8.2%) as compared with the F gene (5.5%) and the HN gene (4.2%) (Table 
2). Phylogenetic analysis based on solely the mumps virus SH gene sequences 
showed 14 clades and segregation in two groups consisting of mumps virus 
sequences from 67 and 29 mumps patients, respectively (Figure 1A). 
     Additional F gene and HN gene sequence information led to increased 
resolution, with 60 clades when the F gene, SH gene and HN gene sequences 
were combined (Figure 1B). The groups formed when F gene, SH gene and HN 
gene sequences were combined varied in size and included 2 clusters with 
samples from local mumps outbeaks. The first cluster consisted of 13 samples 
obtained between June 2013 and April 2014 (cluster 1). The majority of these 
samples with identical F, SH and HN gene sequences were from mumps patients 
from a local mumps outbreak that started in the summer of 2013 (n=12). The other 
sample in this cluster was from a different geographical area in the Netherlands 
without epidemiological link to any of the other cases in this cluster. The second 
cluster consisted of 10 samples that were from a local mumps outbreak between 
March and June 2015 (cluster 2). Nine of these samples had identical F, SH and 
HN gene sequences and 1 sample contained 2 mumps virus variants; one variant 
was identical to the other 9 mumps viruses and the other variant had a point 
mutation at nucleotide position 44 in the HN gene. 
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     Sequencing both the F gene and the HN gene in addition to the SH gene 
resulted in the most detailed molecular information, but sequencing of either one of 
these genes also added substantial resolution to the data. Analysis of only the F 
gene sequences resulted in 40 clades, as compared with 36 clades when only the 
HN gene sequences were analysed (Figure 2). Beyond the increase in resolution, 
comparison of the phylogenetic trees based on the F gene sequences and HN 
gene sequences showed also discrepancies in tree topology. The variation in 
mumps virus F gene, SH gene and HN gene sequences during the various mumps 
outbreaks in the Netherlands suggested that these outbreaks were caused by 
multiple mumps virus introductions rather than by endemic circulation of mumps 
viruses. 
Table 1. Clinical samples belonging to mumps virus genotype G sequenced in this study (n=109) in 
comparison with the total number of samples sequenced (n=1106) and the number of samples with 
mumps virus genotype G (n=929), stratified by year. 
Year 
No. samples with SH gene 
sequenced (n=1106) 
No. samples with mumps 
virus genotype G (n=929) 
No. genotype G samples with 
F gene, SH gene and HN gene 
sequenced (n=109) 
2004 1 1 1 
2005 7 6 2 
2006 0 0 0 
2007* 10 0 0 
2008* 132 5 0 
2009 25 14 3 
2010 351 342 29 
2011 282 281 14 
2012 165 163 8 
2013 85 79 32 
2014 16 14 5 
2015 32 24 15 
* In 2007 and 2008 there was a mumps outbreak among unvaccinated children in the Netherlands, 
caused by mumps virus genotype D. 
Table 2. Genetic information of the mumps virus F gene, SH gene and HN gene within genotype G 
mumps virus strains (n=109). 
 Length  Variabe sites 
Gene Nucleotide AA  Nucleotide AA 
F 1617 539  89 (5.5%) 27 (5.0%) 
SH 316 76  26 (8.2%) 6 (7.9%) 
HN 1749 583  74 (4.2%) 13 (2.2%) 
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Figure 1. Phylogenetic analysis of genotype G mumps virus samples (n=109) using the maximum 
likelihood method with 1000 bootstrap replicates based on (A) the SH gene and (B) the F gene, SH 
gene and HN gene combined. Bootstrap values are shown at corresponding branches. Colours 
represent the year of sampling. Two clusters with samples from local mumps outbreaks are indicated in 
the trees (clusters 1 and 2). 
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Figure 2. Phylogenetic analysis of genotype G mumps virus samples (n=109) using the maximum 
likelihood method with 1000 bootstrap replicates based on (A) the F gene and (B) the HN gene. 
Bootstrap values are shown at corresponding branches. Colours represent the year of sampling. Two 
clusters with samples from local mumps outbreaks are indicated in the trees (clusters 1 and 2). 
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Epidemiological data supports phylogenetic clustering 
From 1 January 2015 to 30 June 2015, 67 mumps patients were reported in the 
Netherlands, according to Osiris (Figure 3). Two clusters were epidemiologically 
identified. Cluster 1 (n=11) was related to a hockey club, including some team 
mates of the index case. Cluster 2 (n=6) was initially related to a pub in the same 
geographical area as the hockey club but then continued at a school, because a 
patient who visited the pub was a student at that particular school. Furthermore, 
there were 7 mumps cases reported who were thought to be primary or secondary 
import cases. The majority of mumps cases (n=43) could not be linked to one of 
the epidemiological clusters and had an unknown source of infection. 
Out of the 15 samples from 2015 with complete F gene, SH gene and HN gene 
sequences, 9 samples had identical sequences and 1 sample had a nearly 
identical sequence with a double peak at 1 positions in the HN gene sequence. 
The cluster formed by these 10 samples was named molecular cluster A. Cluster A 
included 5 samples from cases who belonged to epidemiological cluster 1 and 1 
sample from a case who belonged to epidemiological cluster 2, thereby indicating a 
link between these clusters. Mumps viruses belonging to cluster A were detected 
during a period of 3 months. Molecular cluster B included 3 samples from patients 
with day of onset of disease all within the same week, but from different 
geographical areas and without epidemiological link, which suggests that part of 
the chain of transmissions for this cluster was missed. Cluster A and cluster B 
were defined based on F gene and HN gene sequences, since the SH gene 
sequences were identical for samples in both clusters. 
DISCUSSION 
Combining mumps virus F gene, SH gene and HN gene sequences enabled us to 
study mumps virus transmission within mumps virus genotype G outbreaks. Our 
data showed endemic circulaton of mumps virus during some local mumps 
outbreaks. However, the diversity in mumps virus strains throughout the recent 
outbreak seasons and the discrepancies in tree topology between the genes 
indicates that there were multiple mumps virus introductions, and therefore shows 
the potential for the identification of geographical clusters in regions where mumps 
is endemic. Currently, there is insufficient genomic data globally to verify this 
assertion, as most phylogenetic analyses are based on solely SH gene sequences 
and show limited variation (11,12). 
The sequences in this study may not be fully representative for the mumps virus 
strains circulating during the study period. Although we have attempted to 
sequence a systematic selection of samples, we were limited by the availability of 
the samples due to asymptomatic mumps virus infections, underreporting of 
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clinical mumps cases and the lack of laboratory confirmation in mumps virus 
diagnosis. Mumps symptoms are often mild and treatment options are limited, 
which makes it likely that not all mumps patients are diagnosed and reported (15). 
Furthermore, mumps diagnosis in the Netherlands does not require laboratory 
testing per se, since mumps can also be diagnosed when there is an 
epidemiological link to a confirmed mumps case. Another limitation is that samples 
with low viral loads often failed for sequencing. The lack of mumps virus 
sequences from samples with low viral loads might lead to a bias in our selection, 
as the effect of strain-specific differences in mumps virus pathogenesis on viral 
load in saliva is unknown. Mumps virus isolates are often used for sequencing of 
genes other than the SH gene. As mumps virus culturing is prone to mutations, we 
have sequenced most of our clinical specimens directly, which probably resulted in 
lower success rates. 
     This study shows that sequencing of the mumps virus F gene and HN gene 
additional to the SH gene increases the resolution of the molecular information. In 
this way, endemic mumps virus circulation can be distinguished from mumps virus 
importations. The F gene, SH gene and HN gene sequences combined have 
sufficient variation to identify multiple mumps virus clusters within a mumps virus 
genotype G outbreak, whereas these clusters could not be identified based on the 
SH gene sequence alone due to a lack of variation within this gene. Furthermore, 
epidemiologically linked mumps cases have identical F gene, SH gene and HN 
gene sequences, which was illustrated by the mumps outbreak in 2015. This latter 
finding was supported by sequencing data from previous local mumps outbreaks in 
the Netherlands. All in all, our data show that sequencing of the F gene, SH gene 
and HN gene combined could serve as a molecular tool during mumps outbreaks 
to identify transmission chains, even when part of the chain of transmissions is 
missed. Although this method is more costly than sequencing of the SH gene 
alone, the identification of new mumps clusters via this method could support 
public health decisions about implementation and evaluation of outbreak control 
measures. 
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SUPPLEMENTARY MATERIAL 
Table 1. Overview of primers used for sequencing of the F gene, SH gene and HN gene. 
 
Name Sequence (5’ – 3’) Location 
FW-F4351 
FW-HN6497 G 
BV6132 SH1 
GGAGTCCATTYAGGAAGTCTGCC 
GAATAATGCCGTTCAATCATGAGAC 
AGTAGTGTCGATGATCTCAT 
4351-4373 
6497-6521 
6133-6152 
BV2013 SH5 GATCCTAAGCTTGTTCTGG 6539-6557 
BV6138 SH3 GTCGATGATCTCATCAGGTAC 6139-6159 
BV2011 SH6 TCCTAAGCTTGTTCTGGCTTG 6535-6555 
FW-HN1 CAAGCCAGAACAARCTTAGGA 6535-6555 
RV-HN1 AGTATCTCATTTAGGCCCG 8442-8460 
FW-HN2 CCAGAACAARCTTAGGATC 6539-6557 
RV-HN2 TCATTTAGGCCCGCCATTCT 8435-8454 
RV-HN8482 G GCTTATATCTAACGATGGGTGAG 8482-8504 
FW-HN6534 CCAAGCCAGAACAAACTTAGGGTC 6534-6557 
RV-HN8433 CTCATTTAGGCCCGCCATTCTGG 8433-8453 
FW-HN7172 GGTAAGACACACTGGTGYTA 7172-7191 
RV-HN7233 GAAGTATGATCCTTGCAGTTGG 7212-7233 
FW-HN7795 AGTTGTCCCCTCAAACAATC 7795-7814 
RV-HN7842 ACTCTTCCTTCTGCACCCAT 7823-7842 
F-FW1A GTCCATTYAGGAAGTCTGCCTC 4354-4375 
F-RV3A AGGGTCACGAGACGTTACGAC 6236-6256 
F-FW1B TYAGGAAGTCTGCCTCAATGAG 4360-4381 
F-RV1B TTGCTTGTACCGCTATAGCTARC 5025-5047 
F-FW2B CAAGCACAGACAAATGCACG 4930-4949 
F-RV2B TTGCCTGCAAGGCATAGTTTTG 5579-5600 
F-FW3B TGCCAATACAATGAGGCAGAGAG 5542-5564 
F-RV3B GTCACGAGACGTTACGACCC 6234-6253 
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ABSTRACT 
The surface proteins of the mumps virus, the fusion protein (F) and hemagglutinin-
neuraminidase protein (HN), are important in mumps pathogenesis and are 
important targets for the immune response to mumps virus. We compared the 
variable amino acid positions in the F and HN proteins between the Jeryl Lynn 
vaccine strains and wild type mumps virus strains, with specific attention for 
genotype G strains, the most frequently detected mumps genotype in outbreaks in 
vaccinated communities. Sequence entropy, defined as a measure to compare 
diversity and the location of the variable sites, showed that the variation for 
genotype G strains is very specific. Differences between Jeryl Lynn strains 
(genotype A) and genotype G strains were found in or near known B cell epitopes, 
and in glycosylation sites, both of which might result in escape from the immune 
responses induced by the Jeryl Lynn vaccine. Of special interest were amino acid 
positions 113, 354, 356, 403 and 442 of the HN protein, which were all located in B 
cell epitope regions and segregated genotype A strains (positions 354, 356 and 
442) and genotype G strains (positions 113 and 403). Additional differences 
between Jeryl Lynn and genotype G strains were found in or near sites that were 
predicted to play a role in pathogenesis, such as the cleavage site in the F protein 
and fusion promotion sites, receptor binding sites, neuraminidase activity regions 
and neurovirulence regions in the HN protein. These differences might contribute 
to the occurrence of genotype G outbreaks in vaccinated communities. 
IMPORTANCE 
Since the introduction of the MMR vaccine in many national immunization 
programs, mumps incidence decreased drastically. However, during the last 
decade several mumps genotype G outbreaks occurred among persons who 
received 2 MMR doses that contain the Jeryl Lynn strains as mumps component. 
In this study, we showed that the Jeryl Lynn vaccine strains and mumps virus 
genotype G strains had unique variable sites that were located in regions of the F 
and HN proteins with important functions in mumps-specific immunity by the host 
and mumps virus pathogenesis. Although not proven in a biological model, these 
variable sites might facilitate the breakthrough infections of genotype G mumps 
virus in persons vaccinated with the Jeryl Lynn strains and should therefore be 
studied further.  
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INTRODUCTION 
Mumps is a contagious childhood disease that is caused by the mumps virus of the 
family Paramyxoviridae. The disease is characterized by unilateral or bilateral 
swelling of the parotid glands, but complications such as orchitis, oophoritis, 
meningitis, encephalitis, and deafness can occur (1,2). Since the introduction of the 
measles, mumps and rubella (MMR) vaccine in many national immunization 
programs, mumps incidence has dramatically decreased. In the last decade 
however, there were several mumps outbreaks among MMR vaccinated 
adolescents (3–6). 
One hypothesis is that the outbreaks are a result of secondary vaccine failure – 
waning of the immune response – because most of the outbreaks affected 
adolescents who received their second MMR dose more than 10 years ago (7–9). 
Another possibility is that the outbreaks in vaccinated communities result from 
immune escape. Mumps virus diverged into genetic lineages, called genotypes, as 
defined based on the nucleotide sequence of the small hydrophobic (SH) gene that 
encodes a membrane protein. The Jeryl Lynn strains are a mixture of 2 mumps 
virus strains that both belong to genotype A, whereas most recently detected 
outbreak strains belong to genotype G (10–13). Although vaccine-induced 
antibodies neutralize mumps virus genotype G strains, the level of neutralization is 
lower than for the vaccine strain (14,15). In addition, in silico analyses suggest 
differences among lineages in predicted B cell and T cell epitopes (16,17). 
However, these studies did not focus on genotype G. Here, we study the 
differences between the Jeryl Lynn vaccine strains and the currently circulating 
genotype G strains with a focus on the fusion protein (F) and the haemagglutinin-
neuraminidase protein (HN). These are the main surface proteins of the mumps 
virus and are important for viral entry, fusion and B cell mediated immunological 
responses. We analysed genomes of mumps virus strains that were isolated from 
patients in the Netherlands before the introduction of the MMR vaccine into the 
Dutch National Immunization Program (1957-1982) and from more recent 
outbreaks. Besides differences in epitope regions and glycosylation sites, which 
point towards an immunological mismatch, we have also studied differences in 
regions that could play a role in mumps virus pathogenesis. 
METHODS 
Mumps virus strains obtained from clinical specimens 
Mumps virus sequences from 46 clinical isolates obtained between 1957 and 1982 
were used. Selection of the mumps virus cultures was based on availability of the 
isolates. According to the available information from these isolates, mumps virus 
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had been cultured from oral swabs, nasal swabs and liquor samples. All but 1 of 
the viruses were isolated from Dutch mumps patients. The non-Dutch isolate was 
from a patient from Albany, USA. Besides the sequences from the 46 clinical 
isolates from the pre-vaccination era, mumps virus genotype G sequences from 
109 clinical samples obtained between 2004 and 2015 were used. All but 1 of 
these samples have been described previously (18). Only 1 sample per mumps 
patient was included. The GenBank accession numbers for these sequences are 
KJ125045-KJ125051, KJ125053-KJ125059, KJ125061-KJ125067, KU756625-
KU756710, KU756712-KU756812, KU756814-KU756914, KU756916-KU756930 
and KX136898-KX137038. In accordance with Dutch law, no informed consent 
was required for this study. 
GenBank sequences 
Besides the 46 F and HN gene sequences from mumps virus strains from the pre-
vaccination era and the 109 F and HN gene sequences from recent mumps virus 
genotype G strains, 17 F gene sequences (genotype A and G) and 33 (genotype A 
and G) HN gene sequences retrieved from GenBank were used for the mapping of 
all regions of interest. For phylogenetic analysis, SH gene sequences from 78 
mumps virus strains were retrieved from GenBank (Supplementary table 1). To 
identify unique sites in genotypes A and G, an additional 11 F gene sequences and 
43 HN gene sequences were retrieved from GenBank (Supplementary table 1). 
These sequences included 27 mumps virus reference strains as defined by the 
World Health Organization, including 2 strains per genotype and 3 unclassified 
strains (19). 
Sequencing and phylogenetic analysis 
RNA extraction, cDNA synthesis and sequencing of the F gene, SH gene and HN 
gene for all genotype G mumps virus strains were performed as described 
previously (18). For sequencing of the strains from the pre-vaccination era, the 
same procedures were followed for the sequencing of the F and SH gene (18). For 
sequencing of the HN gene, cDNA was synthesized with the use of primer FW-
HN1 (nt 6535-6555) and thereafter a PCR was performed with the use of primers 
FW-HN1 and RV-HN1 (nt 8442-8460). The six primers used for sequencing were 
FW-HN2 (nt 6539-6557), FW-HN7172 (nt 7172-7191), RV-HN7233 (nt 7212-7233), 
FW-HN7795 (nt 7795-7814), RV-HN7842 (nt 7823-7842) and RV-HN2 (nt 8435-
8454) as described previously (20). BioNumerics software version 7.5 (Applied 
Maths) was used to analyse nucleotide sequences and to recreate a maximum 
parsimony tree with bootstrap resampling (1000 replicates) based on the SH gene 
sequences. 
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Table 1. Overview of the important functional regions in the F and HN proteins. 
Protein Region Amino acid position* 
F Glycosylation pattern 73-75; 182-184; 352-354; 427-429; 433-435; 457-459 
F B cell epitope 221, 323, 373 
F Fusion promotion 91; 195; 383 
F Cleavage site 98-102 
F Neurovirulence 91 
HN Glycosylation pattern 127-129; 176-178; 284-286; 329-331; 400-402; 448-450; 
464-466; 507-509; 514-516 
HN B cell epitope 113-130; 199-207; 220-240; 261-296; 327-363; 375-403; 
440-443; 533 
HN T cell epitope 279; 287 
HN Fusion promotion 82; 89; 96; 98; 102; 104; 111; 118; 222; 226; 228; 230; 567; 
571 
HN Receptor binding 162; 175; 226; 228; 230; 335; 407; 422; 530; 531; 533; 540; 
566; 567; 575 
HN Neuraminidase activity 180; 204; 239; 264; 268; 303; 407; 422; 466; 512; 540; 551; 
561 
HN Ca2+-binding 268; 270; 272; 302 
HN Neurovirulence 360; 466 
* F protein numbering is based on accession number JN012242 and HN protein numbering is based on 
accession number ABY81903. Regions and amino acid positions are based on references (17,21–31). 
Underlined positions indicate glycosylation recognition patterns, for which structural analysis showed 
burial of N and/or S/T residue, yielding uncertainty of glycosylation. 
Generation of the homology models 
Homology models were generated for both the F and HN proteins, as there are no 
experimentally determined structures of the mumps F and HN proteins available. 
The consensus sequence was calculated for both the F and HN proteins based on 
123 and 196 sequences, respectively, with the cons module of Emboss (32). This 
consensus sequence was then used in a BLAST (33) search against the PDB (34) 
to identify available protein structures of homologs for both proteins. Overall, PDB 
entries 4GIP (35) and 3MAW (36) were used as templates for the F protein in the 
pre- and postfusion conformation, respectively, as the F protein undergoes a 
conformational change during the fusion process (37). PDB entry 4GIP contains 
the structure of the F protein from parainfluenza virus 5 and has an identity and 
similarity score with the mumps F protein consensus sequence of 49% and 69%, 
respectively; whereas PDB entry 3MAW contains the structure of the F protein 
from Newcastle Disease virus and has an identity and similarity score of 35% and 
54%, respectively. PDB entry 1Z4V (38) was selected as template for the HN 
protein. This structure contains the HN protein from parainfluenza virus 5 and has 
an identity and similarity score with the mumps HN protein consensus sequence of 
46% and 66%, respectively. After selection of the templates, FoldX (39) was used 
to replace the amino acids of the template with the mumps F and HN protein 
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consensus sequences. Next, an energy minimization was carried out in YASARA 
with the YASARA force field (40). Finally, the models were evaluated by MolProbity 
(41). 
Multiple sequence al ignment and mapping of the mutations 
Multiple sequence alignments for the F and HN protein sequences were performed 
with the aid of Clustal Omega (42). The sequence variation was subsequently 
mapped onto the protein structures with the aid of Scop3D, a tool to visualize 
variation across multiple sequences on the protein structure (43). The entropy, 
which provides information on the randomness of spread of the observed variation, 
was also calculated for both proteins with the aid of scop3D (43). F protein 
numbering is based on accession number JN012242 and HN protein numbering is 
based on accession number ABY81903. 
Determination and visualization of variable posit ions and 
important functional regions 
Important functional regions were defined based on literature (Table 1). An N-
glycosylation site was defined as the glycosylation recognition pattern N-X-S/T with 
X being any amino acid except proline. Both the N as well as the S/T residue need 
to be surface exposed for the site to be able to be glycosylated (44). All regions 
were subsequently mapped onto the sequences and models of the protein 
structures for analysis (Figure 1), analysed for diversity, and visualized on the 
structures of the homology models with the aid of PyMol (PyMOL Version 11r1, 
Schrödinger LLC). Numbering of the positions is based on the position of the 
residue in the sequence. 
Calculation of the solvent accessible surface area  
To predict accessibility of variable sites, the absolute solvent accessible surface 
area (aSAS), the area of a residue that is accessible by a water molecule (1.4Å), 
was calculated with the aid of DSSP (31,32). The relative solvent accessible 
surface (rSAS) area was then obtained by calculation of the ratio of the aSAS to 
the aSAS of the residue in the tripeptide G-X-G (33,34). A residue is said to be 
surface accessible (exposed) if the relative SAS is >25%, otherwise a residue is 
said to be buried (49,50). 
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Figure 1. Structure of the F and HN protein with the important regions mapped on the structures in 
different colours. (A, B) F protein with glycosylation sites (yellow), fusion promotion sites (orange), 
cleavage site (pink), neurovirulence (dark blue) and known B cell epitope regions (green) mapped on 
the prefusion (A) and postfusion (B) structure. (C) HN protein with glycosylation sites (yellow), fusion 
promotion sites (orange), receptor binding regions (pink), neuraminidase activity regions (blue), Ca2+-
binding sites (red), neurovirulence regions (dark blue), known T cell epitope regions (purple) and known 
B cell epitope regions (green) mapped on the structure. 
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Statist ical analysis 
Fisher’s Exact Test was used to find significant differences in the distribution of the 
variable and non-variable positions in the regions of interest and other regions. 
Only those positions of the protein present in the structure were taken into account. 
All p-values <0.05 were considered statistically significant.	 
Figure 2. Maximum parsimony tree based on SH gene sequences of 46 mumps virus strains from the 
pre-vaccination era and 109 recent mumps virus strains, all indicated by thick lines. Percentages 
indicate bootstrap values (1000 replicates). All but one mumps virus strain were from Dutch patients, 
the non-Dutch strain was isolated from a patient from the USA in 1954. Genotypes are labelled by 
colour. WHO reference strains (n=27) and other mumps virus sequences retrieved from GenBank 
(n=51) are included in the phylogenetic tree and are indicated by thin lines. 
RESULTS 
Phylogenetic analysis 
A phylogenetic analysis based on the SH gene was performed to determine the 
genotypes of the mumps virus strains from the pre-vaccination era (n=46) and from 
recent outbreaks (n=109) (Figure 2). Two strains from the pre-vaccination era 
belonged to genotype A, including a strain that was identical to 
MuVi/Boston.USA/0.45 “Enders” and was isolated from a patient in the USA. 
These strains were isolated in 1954 and 1962, respectively. Three strains from the 
pre-vaccination era belonged to genotype C and were all isolated in 1980-1981. 
The majority of the strains from the pre-vaccination era (n=33) belonged to 
genotype D and were isolated over a longer time period (1961-1982), which 
A
B
C
D
F
G
H
I
J
K
L
N
unclassified
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indicated that this genotype circulated during several decades in the Netherlands 
before the introduction of the MMR vaccine in 1987. Four strains belonged to 
genotype L and were isolated between 1957 and 1964. The 4 remaining strains 
from the pre-vaccination era were isolated between 1962 and 1964 and did not 
cluster with any of the genotypes as defined by the reference strains which 
suggested a genotype that was not previously described. None of the mumps virus 
strains from the pre-vaccination era belonged to genotype G.  
 
Table 2. Overview of variable sites in the F and HN protein that were unique for either genotype A or 
genotype G strains. 
   Variable positions  in 
proximity of important 
region§ 
 
Protein Region† Variable 
positions in 
important region 
Prefusion Postfusion Positions not in or 
not close to an 
important region 
F Glycosylation 
recognition pattern 
- NA NA 24*, 49, 115, 141, 
170*, 177, 238, 
273, 274*, 275, 
298, 326*, 330*, 
331, 343, 345*, 
350*, 360*, 389, 
413, 425, 431, 
439*, 479, 480*, 
488, 492, 530* 
F B cell epitope - - NA 
F Cleavage site 100*, 101 96*, 97* NA 
HN Glycosylation 
recognition pattern 
129*, 330* NA 8*, 37, 63*, 80*, 
135, 153*, 403 
HN B cell epitope 113*,129*, 205, 
224, 330*, 354*, 
356, 403, 442 
214*, 317, 470 
HN Fusion promotion - 94*, 97*, 106*, 113*, 224 
HN Neuraminidase 
activity 
- 205, 468, 552 
HN Neurovirulence - 356, 468, 477 
HN Receptor binding - 224, 577* 
Bold numbers indicate positions that are unique for genotype A, all other positions are unique for 
genotype G. Underlined positions are surface exposed residues (for the F protein: single line indicates 
an exposed location in the prefusion conformation, double line indicates an exposed location in the 
postfusion conformation, dashed line indicates an exposed location in both conformations). NA: not 
applicable. 
* Amino acid substitution is non-conservative. 
† There are no variable sites in or close to the fusion promotion sites and the neurovirulence sites of the 
F protein and the Ca2+-binding sites, known MHC-II binding sites, and CD4+ and CD8+ response sites of 
the HN protein, so these regions are excluded from the table. 
§The postfusion structure is only applicable to the F protein. 
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Figure 3. Overview of important variable positions on both the HN and F protein as described in 
literature. (A, B) The HN protein with important regions which are coloured as in Figure 1. The view in 
(B) is turned over a vertical axis by 180°. (A) Presentation of variable positions 354 and 442 in the Jeryl 
Lynn vaccine strain (brown positions in red circels), with zoom on position 354. (B) Variable regions 
400-402 and 464-466 are shown (brown positions in red circles), with zoom on region 464-466. (C) The 
F protein with variation of position 96, 97 and 100 (red) at or near the cleavage site (pink). 
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Analysis of the F protein  
F protein sequences were compared between the different mumps virus genotypes 
using Scop3D to identify sites that were unique for either the Jeryl Lynn vaccine 
strains or wild type genotype G strains. Out of the 22 variable positions that 
displayed variation within genotype A, 13 were unique for genotype A (Table 2). 
None of these positions was in an important functional region (Table 2). With 
respect to genotype G sequences, 23 out of the 37 variable positions were unique 
for genotype G, of which positions 100 and 101 were located in the cleavage site 
(Table 2, Figure 3C). This cleavage site is the site where a protease furin cleaves 
the protein to expose the fusion peptide that is essential for fusion of the virus and 
the host cell membrane. Both variable positions were found only once in the same 
sample, which suggested a random variation that is most likely not relevant. The 
change of H to Y at position 100 was a non-conservative change, which means 
that the physicochemical properties of this amino acid were altered. Position 101 
showed a conservative change of K to R. Additionally, 2 other variable positions, 
positions 96 and 97, were located near the cleavage site. The change of G to R 
was found in 1 genotype G mumps virus sample, whereas the change of S to L 
was observed in 19 samples. This latter change made the fusion peptide more 
hydrophobic and this might enhance intercalation of the fusion peptide into the host 
cell membrane. The changes of positions 96-97 and 100-101 did not occur in the 
same sample.  
To check the evolution within each genotype separately, we also looked at 
intragenotypic variations. The amino acid sequence variation for the F protein 
within the Jeryl Lynn vaccine strains alone was 11%-45%, as compared with 30%-
40% within genotype G and 30%-36% within the other wild type genotypes 
analysed. The majority of the variation within all genotype groups was non-
conservative (57%-64%). The rather low entropy in the variable positions for the 
Jeryl Lynn vaccine strains (21%) suggested that the amino acid diversity at the 
variable positions was limited. However, the overall entropy for the genotype G 
strains (4%) and other wild type strains (7%) was even lower, which indicated that 
variation seen for genotype G strains and other wild type strains could be of more 
significance. The occurrence of variable and non-variable positions in a region of 
interest or in other regions did not significantly differ within any of the genotypes 
(p≥0.08). Furthermore, variable positions did not overlap between the Jeryl Lynn 
strains and the genotype G strains (data not shown). 
Analysis of the HN protein  
Overall, 15 out of 38 variable positions were unique for genotype A. Five of these 
unique positions were located in known B cell epitope regions (regions 199-207, 
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220-240, 327-363 and 440-443). Three of these positions were surface exposed: 
354, 356 and 442 (rSAS=60%, 40% and 77% respectively, Figures 3A and 4). 
These 3 positions were variable in 7, 13 and 6 samples, respectively, without co-
occurrence. Only position 354 (Q to P) showed non-conservative variation. 
Furthermore, 10 out of 15 unique positions that displayed variation were located in 
proximity of an important protein region, such as a fusion promotion site, a receptor 
binding site, a B cell epitope, a neuraminidase activity site and a neurovirulence 
region (Table 2). Only 4 positions were surface exposed (Figure 4). Ten of 36 
variable positions were unique for genotype G, of which 4 positions were located in 
an important functional region. Positions 129 and 330 were located in a known B 
cell epitope region as well as in a glycosylation recognition pattern (known B cell 
epitope regions 113-170 and 327-363, including the glycosylation recognition 
patterns at positions 127-129 and 329-331), but each of these positions only 
showed variation in 1 sample. Two other positions were located only in a known B 
cell epitope region (regions 113-130 and 375-403). Although neither of these 
positions was surface exposed, they might still influence the tertiary structure and 
could therefore be relevant (Figure 4). Four out of 10 unique variable positions 
were located near an important region: three variable positions were located in 
proximity of a fusion promotion site and 1 position was located near a known B cell 
epitope region (Table 2). Structural comparison between genotype A and G 
showed that the variations in both genotypes occurred in different areas of the 
protein. 
The amino acid variation within the HN protein of the Jeryl Lynn vaccine strains 
was 9%-45%, as compared with 1%-20% within the genotype G strains and 2%-
30% within the other wild type strains. Similar to the variation within the F protein, 
the majority of the variable positions in the HN protein within all genotype groups 
was non-conservative (54%-68%). The entropy for the HN protein for each 
genotype was identical to the entropy for the F protein of the corresponding 
genotype, which indicated that the amino acid diversity at the variable positions 
was limited. Furthermore, the entropy for the genotype G strain at glycosylation 
sites and known B cell epitopes was 1.47% and 4.68% respectively, whereas the 
entropy for the Jeryl Lynn vaccine strain at these positions was 0% and 21.5% 
respectively. The distribution of the variable and non-variable positions was not 
significantly different within any of the genotype groups (p≥0.11). The overlap of 
the variable positions between the different genotype groups was equal for all 
comparisons (data not shown). 
Although the predicted glycosylation sites at regions 400-402 and 464-466 were 
probably not surface exposed, the variation in these regions might be of interest as 
this variation was unique for either the Jeryl Lynn or genotype G strains. Position 
402 was variable within the genotype G strains and the other wild type strains, 
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whereas this position was fully conserved across the Jeryl Lynn strains, which 
resulted in loss of the glycosylation recognition pattern in these latter strains (N-Q-
T à N-Q-A/M). In addition, this position was also located in a known B cell epitope 
region, which may influence antibody recognition. The glycosylation recognition 
pattern at positions 464-466 was only present in the genotype G and other wild 
type strains, whereas in all Jeryl Lynn strains, variation at position 464 induced 
loss of this pattern (N-C-S to H/K-C-S/R). Two genotype G strains showed 
variation at position 466 (S to N). Furthermore, position 464 was located in 
proximity of a known B cell epitope region and was surface exposed (Figures 3B 
and 4) When a variable position is located in both a glycosylation recognition 
pattern and a known B cell epitope, the loss of the glycosylation recognition pattern 
could change the B cell epitope structure, which could lead to loss of recognition by 
antibodies that target that B cell epitope. Taken together, these sequence variants 
might affect mumps virus pathogenesis and could result in escape from the 
immune responses induced by the Jeryl Lynn vaccine.  
DISCUSSION 
In this study, we compared the mumps virus surface proteins of the Jeryl Lynn 
vaccine strains with genotype G strains and other wild type strains using homology 
models to determine if strain variation may have been a contributing factor to the 
occurrence of the recent mumps outbreaks among vaccinated persons. Sequence 
variation is relatively limited in both the F and HN proteins (about 5% for both the 
Jeryl Lynn and the genotype G strains and about 11% for the other wild type 
strains), as compared to the SH protein (11%, 84% and 51% for Jeryl Lynn, 
genotype G strains and other wild type strains, respectively), which is the most 
variable protein of the mumps virus (13). The low sequence entropy for the 
genotype G and other wild type strains in both F and HN proteins indicates that the 
amino acid diversity at the variable positions is limited in the wild type mumps virus 
strains, which suggests that only specific changes occur in these latter strains. 
We identified 5 variable positions in known B cell epitope regions in the HN 
protein that might have an effect on the ability of the host to recognize these 
epitopes, which needs to be validated by functional assays. Although we studied 
only known B cell epitope regions, it is likely that more B cell epitope regions exist 
that are currently unknown. We also found a small number of differences in or near 
other important functional regions such as the cleavage site and fusion related 
regions of the F protein. These variations are mostly conservative, as they do not 
tolerate much change due to their primary function of virus-cell fusion. However, 
overall, the variation seen in the F protein is rather limited and mostly related to 
regions not associated with functional domains. We did not find any variable sites 
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in regions important for Ca2+-binding, which plays a role in structural stability and 
may therefore be conserved. 
Some of the variable sites described in this study were previously described by 
others. Variation at positions 279 and 287 (change of I to T and V to I, respectively) 
of the HN protein has been reported previously, and it was suggested that this 
variation could lead to a mismatch in CD4+ T cell epitopes, which might result in 
the loss of important T cell help for an immunological recognition and recall (16). 
Positions 279 and 287 could both individually and additively lead to a mismatch 
between T cell responses against the Jeryl Lynn vaccine strains and other wild 
type strains. In a study by Kulkarni-Kale et al., variation at positions 266 and 354 in 
the HN protein, which are located in a known B cell epitope, was also described 
(17). Especially position 354 is of interest, because this variable position is unique 
for genotype A strains in our analysis. This position shows variation in other wild 
type strains as well, such as the SBL-1 and Kilham strains, which were not 
included in our analysis (17). Another study by Vaidya et al. compared mumps 
virus genome sequences from 8 Indian mumps cases, including 2 genotype G and 
6 genotype C strains, with several vaccine strains, including the Jeryl Lynn strain 
(51). Their analysis showed that for the HN protein, variation was found in the 
regions that encompass positions 35-53, 240-245, 265-288, 329-340, 352-360 and 
405-410. In all of these regions, except for the region of 240-245, we also found 
variations for the HN protein, which confirms our results once again. Additionally, 
we show that most of these regions, except for regions 240-245 and 405-410, are 
also surface exposed (Figure 4). 
To conclude, we found differences in important functional regions in the F and 
HN proteins between the Jeryl Lynn vaccine strains and mumps virus wild type 
strains, which include the currently circulating mumps virus genotype G strains. 
Unique variations for both genotype A and G strains could indicate reduced 
recognition of genotype G strains by vaccine-induced immune responses. This 
could contribute to the occurrence of the recent genotype G mumps outbreaks 
among Jeryl Lynn vaccinated persons. As this study does not provide biological 
evidence that these regions are indeed responsible for the occurrence of genotype 
G outbreaks among Jeryl Lynn vaccinated young adults, functional assays need to 
be set up to confirm these results. 
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SUPPLEMENTARY MATERIAL 
Table 1. Overview of the GenBank sequences used for phylogenetic analysis and for analysis of the F 
and HN protein. 
 GenBank accession number 
Genotype SH gene F gene HN gene 
A AF201473, AF338106*, 
AF345290, FJ211586, 
FN431985, GU980052*, 
HQ416906, HQ416907 
AF201473, AF338106*, 
AF345290, AJ010821, 
AJ133693, FJ211586, 
FN431985, HQ416906, 
HQ416907 
AF201473, AF338106*, 
AF345290, AY584603, 
AY584604, FJ211586, 
FN431985, HQ416906, 
HQ416907, X93178, 
X93179, 
B AB000388*, AB823535, 
AB827968, JQ945269* 
AB823535, AB827968 AB823535, AB827968, 
JQ946041* 
C AY669145, EU370206*, 
JQ034465, JQ034466, 
JQ945268* 
AY669145 AY669145, JQ034465, 
JQ034466, JQ999999* 
D JQ034452*, JQ945275*  JQ034464*, JQ946039* 
F DQ649478, EU780221*, 
EU884413,  FJ556896, 
HQ693823, HQ693825, 
JQ034459, JQ034460, 
JQ034461, JQ945272* 
EU884413, FJ556896 DQ649478, EU884413, 
FJ556896, HQ693823, 
HQ693824, HQ693825, 
HQ693826, JQ034459, 
JQ034460, JQ034461, 
JQ034462, JQ034463*, 
JQ946034* 
G AF280799*, EU370207, 
EU597478*, JN012242, 
JN635498, JX287385, 
JX287387, JX287389, 
JX287390, JX287391, 
JX390987, JX390988, 
JX390989, JX390990, 
JX390991, JX390992, 
JX390993, JX390994, 
JX390995, JX878447, 
KF481689 
JN012242, JN635498, 
JX287385, JX287387, 
JX287389, JX287390, 
JX287391, KF481689 
EU370207, JN012242, 
JN635498, JQ946046*, 
JX287385, JX287387, 
JX287389, JX287390, 
JX287391, JX390987, 
JX390988, JX390989, 
JX390990, JX390991, 
JX390992, JX390993, 
JX390994, JX390995, 
JX878447, KC852187, 
KC852188,  KF481689 
H AB600843*, AF467767, 
AY681495, JN687469, 
JQ388690, JQ388691, 
JQ945273*, JX287388 
AF467767, AY681495, 
JQ388690, JQ388691, 
JX287388 
AF467767, AY681495, 
JN687469, JQ388690, 
JQ388691, JQ946035*, 
JX287388 
I JQ945274*, AY309060*  JQ946037* 
J JQ945271*, AB105475*  JQ946033*, JQ946044* 
K EU082458, JQ945276*, 
JQ945270*, JX287386, 
KC921200, KC921201, 
KC921202, KC921203, 
KF212191 
JX287386 JQ946040*, JQ946045*, 
JX287386, KC921200, 
KC921201, KX921202, 
KX921203, KF212191, 
JF268685 
L AB105483*, AB105480*  JQ946036*, JQ946043* 
N AY508995*, AY685920*   
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Unclassified AF142774*, AB003415*, 
AY380077* 
  
* WHO reference strain. 
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ABSTRACT 
Background 
Since 2009, various mumps outbreaks have occurred in the Netherlands, affecting 
mostly young adults vaccinated against mumps. In this retrospective study, we 
estimated attack rates for symptomatic and asymptomatic mumps virus infection 
based on mumps-specific immunoglobulin (Ig)G concentrations in paired blood 
samples obtained before and after the mumps outbreaks, collected in 2 university 
cities. We aimed to identify a serological correlate of immune protection and risk 
factors for mumps virus infection. 
Methods 
Mumps-specific IgG levels were measured by Luminex technology in paired pre- 
and post-outbreak samples from students from Leiden (n=135) and Utrecht 
(n=619). Persons with a 4-fold increase in mumps IgG concentrations or mumps 
IgG concentrations >1500 RU/ml were assumed to have had a mumps virus 
infection. 
Results 
Attack rates for symptomatic and asymptomatic mumps virus infection were 2.0% 
and 3.8%, respectively. Pre-outbreak mumps-specific IgG concentrations were 
lower among cases than among noncases (p=0.005) despite vaccination history, 
but no serological cutoff for immune protection could be established. Mumps 
among housemates was significantly associated with serological evidence for 
mumps virus infection (odds ratio, 7.25 [95% confidence interval, 3.20–16.40]; p< 
0.001). 
Conclusions 
Symptomatic and asymptomatic mumps virus infections in vaccinated persons can 
be identified by retrospective assessment of mumps-specific IgG antibodies in 
blood samples. 
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INTRODUCTION 
Since the end of 2009, various mumps outbreaks have occurred in the 
Netherlands. The outbreaks affected mostly young adults, who had been twice 
vaccinated with the measles, mumps, and rubella (MMR) vaccine in childhood (1). 
This phenomenon could be due to waning immunity in this age group, because 
antibody responses after vaccination last shorter than after natural infection. In the 
absence of mumps virus circulation, a substantial proportion of persons is 
seronegative 15 years after the second MMR vaccination (2,3). Furthermore, 
recent findings suggest that the MMR vaccine is not very effective in eliciting an 
antibody response of high avidity against mumps compared with measles and 
rubella (4), which also could explain the poor protection of vaccinated adolescents. 
Mumps attack rates above 10% among vaccinated university students have 
been reported during various recent outbreaks (5,6). Those attack rates were 
based on a particular setting within a specific time frame, and they are therefore 
probably higher than overall attack rates in a nationwide outbreak. In contrast, 
attack rates may be underestimated because calculations are based on self-
reporting of mumps symptoms, whereas many mumps virus infections run an 
asymptomatic course (7–9). In theory, more reliable attack rates could be obtained 
from measuring mumps-specific immunoglobulin (Ig)G concentrations, because 
these generally increase after mumps virus infection (10). However, a challenge is 
the lack of a serological correlate of protection in vaccinated individuals. Only 1 
study has shown that pre-outbreak mumps antibody neutralization titers in patients 
with mumps were lower than in persons who were not infected with mumps virus 
during the outbreak, but it was not possible to set a cutoff point separating all 
clinical patients with mumps from nonpatients (3). 
In this study, we first measured mumps-specific IgG antibody concentrations in 
paired pre- and post-outbreak samples from exposed students in 2 Dutch 
university cities to identify mumps virus infections. In this way, we could calculate 
the proportions of symptomatic and asymptomatic infections and determine attack 
rates and risk factors for mumps virus infection, irrespective of clinical outcome. 
Second, to identify a correlate of protection, mumps-specific IgG concentrations in 
pre-outbreak samples were compared between infected and non-infected persons. 
METHODS 
Study design 
A retrospective study was performed including 2 student cohorts from the cities of 
Leiden and Utrecht. The study in Leiden served as a pilot for a larger serological 
study in Utrecht. Questionnaires for both cohorts were comparable and included 
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questions on MMR vaccination status, mumps history, and possible risk factors 
such as age, gender, membership of a student association, residence in a student 
house, number of housemates, and circulation of mumps in the environment. 
Students were included if pre-outbreak serum samples were available that were 
collected during their first year of (bio)medical school for posthepatitis B 
vaccination titer control. After informed consent was obtained from the students, 
these serum samples were retrospectively tested, along with post-outbreak blood 
samples collected as described below. Studies were approved by the medical 
ethics committee of the Leiden University Medical Center and the University 
Medical Center Utrecht. 
 
Figure 1. A flowchart for inclusion of samples is shown. (A) The flowchart for the Leiden cohort is 
illustrated. In total, 135 paired samples were included for analysis. The paired samples that were 
excluded (n=17) were all excluded on the basis of the measles and rubella concentration differences 
between the pre- and post-outbreak samples. (B) The flowchart of the Utrecht study is shown. In total, 
samples from 619 persons were included for analysis. Years in the right column are the years in which 
serum samples were drawn. All dried blot spots (DBS) were obtained between March and June 2012. 
  
1065 
participants
1020 DBS 
received
40 DBS
not received
839 paired 
samples 
(serum + DBS)
181 DBS 
samples 
without sera
619 paired 
samples included 
for analysis
220 paired
samples excluded 
for analysis
MMR vaccination 
since 2008 (n=5)
fourfold difference in 
measles and/or rubella 
titers (n=12) 
111 sera from 2007
105 sera from 2008
203 sera from 2009
200 sera from 2010
MMR vaccination status 
verified via Praeventis 
(n=498)
MMR vaccination status 
not verified via Praeventis 
(n=121)
sera not from 
2007-2010 (n=203)
203 
participants
152 pairs of pre 
and post-outbreak 
samples received
51 post-
outbreak 
samples
not received
135 paired 
samples included 
for analysis
17 paired
samples excluded 
for analysis
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Leiden study 
In total, 135 paired pre- and post-outbreak samples from medical students were 
included (Figure 1A). Pre-outbreak sera were taken between 2008 and 2010. 
Students were approached directly at the university by a medical team from the 
academic hospital to participate in this study. They filled out a questionnaire and 
gave permission to test their pre-outbreak serum sample retrospectively. The post-
outbreak sera were taken between January and February 2011. 
Utrecht study 
Based on the results from the serological pilot study in Leiden, a larger study was 
performed among biomedical and medical students in Utrecht. Here, all students 
received a dried blot spot (DBS) self-sampling kit for post-outbreak sampling and a 
permission form to check vaccination status in the nationwide vaccination 
registration system (Praeventis), along with the questionnaire and informed 
consent form. All DBSs were sampled between March and June 2012. Stored sera 
from these students dated back to 2007–2012, depending on the year the student 
enrolled. Based on the reported mumps cases in Utrecht and other parts of the 
Netherlands in the national mandatory notification system, all sera collected 
between 2007 and 2010 were considered to be pre-outbreak samples. Using the 
inclusion criteria described below, samples from 619 students were included for 
analysis (Figure 1B). The vaccination status provided in the questionnaire was 
used for analysis, after verification of vaccination history for 498 (80.5%) of these 
students from the data recorded in Praeventis (data not shown). Of these 498 
students, 469 students (94.2%) had received 2 MMR doses, which is in line with 
national MMR vaccination coverage data (11). When students’ vaccination status 
was not reported and could not be retrieved via Praeventis, they were not included 
in the analyses restricted to fully vaccinated persons. 
Inclusion and exclusion criteria 
In total, 754 of 788 students with pre- and post-outbreak blood samples were 
included. Besides measurement of the mumps-specific IgG concentration in the 
sera and DBS samples, IgG concentrations for measles and rubella were 
measured as external control for antibody concentration fluctuations between 
samples within a person over time. Persons were excluded for further analyses 
(n=29) when their ratio of measles and/or rubella IgG concentrations of both 
samples was at least factor 4 (12). In addition, all persons in the Utrecht study who 
had received an MMR vaccination since 2008 were excluded (n=5). This latter 
criterion could not be applied for the Leiden cohort, because data on recent MMR 
vaccinations were lacking (Figure 1). 
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Mumps-specif ic immunoglobulin G assay 
Samples were stored at −20°C until use. For all samples, IgG antibody 
concentrations for MMR were determined with a fluorescent bead-based multiplex 
immunoassay using Luminex technology as described previously (13). In short, 5 
μL serum was 1:200 diluted in assay buffer (phosphate-buffered saline containing 
0.1% Tween-20 and 3% bovine serum albumin). A punch (r=3.175 mm) of each 
DBS sample was dissolved in 300 μL assay buffer, resulting in a solution 
comparable to the 1:200 dilution of serum samples. When the 1:200 dilution fell 
outside the range of the reference serum curve, the results of a 1:4000 dilution 
were used for analysis. 
On each plate, the WHO International Standard Anti Rubella Immunoglobulin 
RUBI-1-94 (The National Institute for Biological Standards and Control), controls, 
and blanks were included. The fluorescent intensity of the samples was 
interpolated in the reference serum curve to obtain antibody concentrations, which 
were expressed in RIVM units per milliliter (RU/ml) for mumps. The RIVM units for 
mumps used in this assay were previously standardized against other mumps 
standards, in which mumps IgG-positive test results were equivalent to values 
higher than 45 RU/ml (14,15). RUBI-1-94 has a mumps-specific IgG concentration 
of 4384.512 RU/ml and was selected as alternative serological standard for 
mumps, thus enabling comparison and bridging of our results to other studies. For 
measles and rubella, IgG concentrations were expressed as international units per 
milliliter (IU/ml). 
Definit ion of mumps virus infection 
The period between the 2 blood samples varied between 2 and 5 years. Because 
no major outbreaks of measles and rubella were reported between 2007 and 2012, 
most subjects were assumed not to have been exposed to measles or rubella in 
this time period. Therefore, mumps-specific IgG antibody concentration rises were 
normalized against the concentration changes for measles and rubella, to correct 
for possible differences due to quality issues and technical differences related to 
sample storage and recovery of antibodies from DBS. The mumps-specific IgG 
concentrations were individually corrected using the average ratios of both 
measles- and rubella-specific IgG concentrations between the 2 consecutive blood 
samples.  
Two criteria were set for the detection of mumps virus infections. First, a 4-fold 
increase or more of mumps-specific IgG in the 2 consecutive blood samples, 
acknowledged as the most specific criterion to confirm mumps virus infection, was 
used (12). Second, a single-point cutoff criterion was calculated by the use of a 
receiver operator characteristics (ROC) curve. The positive reference group for this 
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analysis consisted of laboratory-confirmed mumps cases who had been vaccinated 
twice with the MMR vaccine in childhood (n=15). These persons were identified 
through enhanced surveillance of mumps in the Netherlands and were contacted in 
the context of a medically ethically approved clinical study to collect samples 
between 6 and 10 months after mumps virus infection. The negative control group 
consisted of 451 twice MMR vaccinated age-matched individuals (between 18 and 
25 years of age) from a large Dutch serosurveillance study in 2006/2007 (16). 
Persons who fulfilled at least 1 of the 2 serological criteria and had reported clinical 
mumps in the questionnaire were regarded as symptomatically infected, whereas 
persons who had not reported clinical mumps in the questionnaire were regarded 
as asymptomatically infected. 
Statist ical analysis 
SPSS version 19 and GraphPad Prism version 6 were used for data analyses. The 
attack rates for symptomatic and asymptomatic mumps virus infection were 
calculated for the entire outbreak period, assuming that students were exposed 
since January 2010 and that the exposure period was similar for all students 
included. Because the time frame and geographic region differed between the 2 
student cohorts, attack rates were calculated separately. Distributions of pre-
outbreak mumps-specific IgG concentrations in serum samples were compared 
using the Mann-Whitney U test. Median IgG concentrations, ROC analysis, and 
mixture modeling were used to identify a correlate of protection against mumps 
virus infection. For all analyses, p values <0.05 were considered as statistically 
significant. Risk factors in the Leiden and Utrecht student cohorts were compared 
with multilevel analysis. Thereafter, possible risk factors for symptomatic and 
asymptomatic mumps virus infection were determined with logistic regression 
analysis. Factors with a p value ≤0.10 were included in the multivariate analysis to 
calculate odds ratios (OR) and 95% confidence intervals (CIs). 
RESULTS 
Cohort description 
In total, 135 students in Leiden and 619 students in Utrecht were included (Figure 
1). The majority of students were female (n=606; 80.4%) and median year of birth 
was 1989 (interquartile range [IQR], 1988–1990). Of 498 students of whom 
vaccination status could be checked, 469 (94.2%) had received 2 MMR doses. 
This is in line with MMR vaccination coverage data in these birth cohorts (11), and 
it was therefore assumed that most of the students in Leiden and Utrecht with 
unknown vaccination status were vaccinated twice in childhood according to the 
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National Immunization Program. Data on vaccination status of the students are 
shown in Table 1. 
Table 1. Vaccination status for the 2 separate cohorts and the total cohort 
Cohort description MMR vaccinations No. (%) participants 
Leiden* At least 2x MMR 
1x MMR 
Vaccinated, but unknown doses 
No MMR 
Unknown vaccination status 
47 (34.8) 
5 (3.7) 
76 (56.3) 
2 (1.5) 
5 (3.7) 
Utrecht† At least 2x MMR 
1x MMR 
Vaccinated, but unknown doses 
No MMR 
Unknown vaccination status 
534 (86.3) 
14 (2.3) 
52 (8.4) 
14 (2.3) 
5 (0.8) 
Total At least 2x MMR 
1x MMR 
Vaccinated, but unknown doses 
No MMR 
Unknown vaccination status 
581 (77.1) 
19 (2.5) 
128 (17.0) 
16 (2.1) 
10 (1.3) 
* Based on self-reported vaccination history. Five students (3.7%) did not know whether they were 
vaccinated. Seventy-six students (56.3%) indicated that they were vaccinated, but they did not know the 
number of MMR doses. 
† Vaccination status of 121 students (19.5%) could not be verified via Praeventis. 
Identif ication of Mumps Virus Infections 
The median mumps-specific IgG concentrations in the reference group sampled 6–
10 months after proven mumps virus infection were 6648 RU/ml (IQR, 5923–8136 
RU/ml), whereas the median concentrations in the negative control group were 139 
RU/ml (IQR, 82–256 RU/mL). Receiver operator characteristics analysis showed 
that at 1500 RU/ml, sensitivity and specificity were 100% and 99.6%, respectively, 
with an area under the curve (AUC) of 0.99 (95% CI, 0.99–1.00; p<0.001). From 
the negative controls, 0.4% of vaccinated persons had a mumps-specific IgG 
concentration higher than 1500 RU/ml (Figure 2A). The majority of pre-outbreak 
samples from the Utrecht study cohort had IgG concentrations below 1500 RU/ml, 
except for 3 students for whom the first serum samples were obtained in 2010 
(Figure 2B). 
When applying our criteria for infection, defined as a 4-fold or more increase in 
IgG concentration or a post-outbreak IgG concentration higher than 1500 RU/ml, 
44 of 754 students (5.8%) had a mumps virus infection, and 15 of these persons 
had a symptomatic infection, whereas 29 persons had an asymptomatic infection 
(Table 2). The cutoff of 1500 RU/ml led to the identification of 4 additional mumps 
virus infections that did not result in a 4-fold or more increase in IgG concentration. 
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With respect to symptomatic mumps virus infections, 13 of 15 blood samples 
fulfilled both serological criteria (Figure 3). However, for asymptomatic mumps 
virus infections, only 6 persons fulfilled both serological criteria, whereas a 4-fold or 
higher increase in IgG concentration could be detected in 26 students (Figure 3). 
This result indicates that the mumps-specific IgG concentrations after symptomatic 
mumps virus infections are higher than after asymptomatic infections. In addition, 3 
persons with asymptomatic mumps virus infection had an IgG concentration in 
their post-outbreak blood sample above 1500 RU/ml but no 4-fold increase (Figure 
3). Of the 25 persons who reported clinical mumps in the questionnaire, samples 
from 10 persons did not meet the serological criteria. Post-outbreak IgG 
concentrations in these 10 persons varied between 32 and 787 RU/ml. 
Figure 2. The graphic illustrates determination of a cutoff for mumps virus infections. (A) Based on an 
ROC analysis, a cutoff of 1500 RU/ml (range, 1384-2288 RU/ml) was calculated for mumps virus 
infection (dashed line). Patient samples were from fully MMR-vaccinated mumps patients, sampled 
between 6 and 10 months after infection (n=15). For the control group, we used IgG levels from 
vaccinated age-matched participants in a Dutch national serosurveillance study carried out in 
2006/2007 (n=451). (B) The graphic shows mumps-specific IgG concentrations of pre- and post-
outbreak samples from participants included in the Utrecht and Leiden cohort (n=754). Orange dots 
represent the pre- and post-outbreak IgG concentrations in individuals infected with mumps vius (n=44). 
Dashed line indicates the cutoff of 1500 RU/ml. Median IgG concentrations did not significantly differ 
between pre-outbreak samples and post-outbreak samples (158 vs 167 RU/ml; p=0.166). 
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Figure 3. Distribution of the post-outbreak mumps-specific IgG concentrations in persons with 
symptomatic and asymptomatic mumps virus infections from the Leiden cohort (n=135) and Utrecht 
cohort (n=619). Mumps-specific IgG concentrations were higher in the post-outbreak samples of 
persons with a symptomatic mumps virus infection compared with persons with an asymptomatic 
mumps virus infection. Grey dots represent post-outbreak samples with a 4-fold or more increase in IgG 
concentrations. Black triangles represent post-outbreak samples with no 4-fold increase in IgG 
concentration. Dashed line indicates the single-point cutoff at 1500 RU/ml. 
Table 2. Attack rates for symptomatic and asymptomatic mumps virus infection for the 2 separate 
cohorts and the total cohort, stratified by vaccination status* 
  No. (%) mumps virus infections 
Cohort description No. participants Symptomatic Asymptomatic Total 
Leiden† 
   At least 2x MMR 
   At least 1x MMR 
   All students 
 
47 
128 
135 
 
2 (4.3) 
3 (2.3) 
3 (2.2) 
 
0 (0.0) 
4 (3.1) 
5 (3.7) 
 
2 (4.3) 
7 (5.5) 
8 (5.9) 
Utrecht§ 
   At least 2x MMR 
   At least 1x MMR 
   All students 
 
534 
600 
619 
 
11 (2.1) 
12 (2.0) 
12 (1.9) 
 
19 (3.6) 
22 (3.7) 
24 (3.9) 
 
30 (5.6) 
34 (5.7) 
36 (5.8) 
Total 
   At least 2x MMR 
   At least 1x MMR 
   All students 
 
581 
728 
754 
 
13 (2.2) 
15 (2.1) 
15 (2.0) 
 
19 (3.3) 
26 (3.6) 
29 (3.8) 
 
32 (5.5) 
41 (5.6) 
44 (5.8) 
* Mumps virus infections were defined as either a 4-fold increase or more in mumps-specific IgG 
concentrations in the 2 consecutive blood samples or an IgG concentration higher than 1500 RU/ml in 
the post-outbreak sample. 
† Based on self-reported vaccination history. Five students (3.7%) did not know whether they were 
vaccinated. Seventy-six students (56.3%) indicated that they were vaccinated, but they did not know the 
number of MMR doses. 
§ Vaccination status of 121 students (19.5%) could not be verified via Praeventis. 
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Attack rates 
Eight students from the Leiden cohort (n=135) had serological evidence for mumps 
virus infection, resulting in an attack rate of 5.9% (Table 2). Three of those 
students had symptomatic mumps (attack rate 2.2%), diagnosed by a physician in 
1 case. In the Utrecht cohort, 36 of the 619 students had a mumps virus infection 
during the outbreak based on their IgG concentrations, resulting in an attack rate of 
5.8% (Table 2). Twelve of these 36 students (attack rate 1.9%) had a symptomatic 
mumps virus infection according to the questionnaires, and 6 of these were 
diagnosed by a physician. Attack rates in students who had received at least 2 
MMR doses (n=534) were comparable with the total Utrecht cohort (Table 2). 
Figure 4. Comparison of pre-outbreak 
antibody levels between persons who 
were infected with mumps during the 
outbreak and persons who were not 
infected. All persons from the Leiden 
and Utrecht cohort with at least 2 MMR 
vaccinations were included (n=571). 
(A) Distribution of pre-outbreak 
mumps-specific IgG concentrations in 
persons with and without a mumps 
virus infection. Median IgG 
concentrations were lower in infected 
persons (p=0.005). Sensitivity and 
specificity were 87.5% and 34.1%, 
respectively, with a cutoff at 243 
RU/mL (dashed line). (B) ROC 
analysis of the mumps-specific IgG 
pre-outbreak concentrations of 
persons with and without a mumps 
virus infection. Dashed line indicates 
the cutoff at 243 RU/mL. (C) Relative 
frequency distribution of pre-outbreak 
mumps-specific IgG concentrations in 
persons with and without a mumps 
virus infection. Dashed line indicates 
the cutoff at 243 RU/ml. 
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Correlate of protection for vaccinated students  
To determine whether individuals with low mumps-specific IgG concentrations 
have an increased risk for mumps virus infection, serological data from pre-
outbreak samples from Utrecht (2007–2010) and Leiden (2008–2010) were 
merged for all persons who had received 2 MMR doses (n=571). Thirty-two 
persons (5.6%) had been infected with mumps virus based on serological analysis. 
Sera from the others (n=539) were considered negative controls. Median mumps-
specific IgG concentrations in the pre-outbreak sera of the infected students were 
significantly lower than median concentrations in the control group (97 RU/ml [IQR, 
59–175 RU/ml] vs 169 RU/ml [IQR, 94–304 RU/ml]; p=0.005; Figure 4A). A ROC 
analysis showed an AUC of 0.65 (95% CI, 0.54–0.75). However, no clear pre-
outbreak cutoff could be identified that separated infected persons from 
noninfected persons. Mixture modeling did not substantiate this difference. The 
cutoff value that discriminated best between the pre-outbreak IgG concentrations 
from infected and noninfected persons was 243 RU/ml, resulting in a sensitivity 
and specificity of 87.5% (95% CI, 71.0%–96.5%) and 34.1% (95% CI, 30.1%–
38.3%), respectively. However, specificity percentages have to be interpreted with 
caution, because probably not all persons were exposed to mumps (Figures 4B 
and C). Among persons exposed to mumps, the IgG concentrations between 
infected and noninfected persons overlapped as well (data not shown), which 
indicates that pre-outbreak IgG concentrations are not the only protective factor 
against mumps virus infection. There was no significant difference in pre-outbreak 
concentrations between persons with symptomatic and asymptomatic infection 
(data not shown). 
Risk factors for mumps virus infection 
Risk factors for mumps virus infection were determined from analysis of the 
questionnaire responses. Questionnaires used in Leiden and Utrecht were 
comparable, and because multilevel analysis did not result in significant 
differences between the 2 student cohorts, the data were merged in logistic 
regression analysis. The risk factor significantly associated with mumps virus 
infection in both univariate and multivariate analyses was circulation of mumps 
among housemates (OR, 7.25 [95% CI, 3.20–16.40]; p<0.001) (Table 3). 
DISCUSSION 
This study has shown that serological analysis can be used to define mumps virus 
infection in vaccinated persons during outbreak situations with high sensitivity and 
specificity. Approximately two thirds of these serologically confirmed mumps virus 
infections were asymptomatic, judged from the fact that those persons had not 
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reported clinical mumps in the questionnaire. This percentage is comparable to the 
percentage asymptomatic mumps virus infections estimated previously (8). 
Besides the 4-fold increase in mumps-specific IgG concentrations that serves as 
the gold standard in serological studies, we have added a single-point cutoff value 
of 1500 RU/ml to discriminate antibodies acquired through vaccination from 
antibodies induced by mumps virus infection. Although this cutoff value is very 
conservative, some individuals classified as being infected with mumps virus would 
have been missed on the basis of solely a 4-fold increase in mumps-specific IgG 
concentration. When less conservative serological criteria were applied, more 
asymptomatic infections compared with symptomatic infections were identified, 
thereby changing the ratio between symptomatic and asymptomatic infections 
(data not shown). In total, 10 clinical mumps cases could not be confirmed as such 
based on our serological approach. Because these cases had indicated in the 
questionnaire that mumps was not laboratory confirmed by either polymerase 
chain reaction or IgM serology during period of disease, it is possible that the 
symptoms were not caused by a mumps virus infection. Four of these mumps 
cases were diagnosed by a physician, but no further information was provided 
regarding whether samples of these 4 cases tested negative for infection or 
whether there were no laboratory tests performed. The other 6 mumps cases were 
not diagnosed by a physician and therefore no laboratory tests were performed. 
Attack rate calculations were based on the assumption that mumps had not 
circulated among these cohorts before January 2010. However, it cannot be 
excluded that some students had been exposed to mumps earlier. Mumps 
outbreaks have occurred in the Netherlands in 2004 at an international university of 
hospitality management and between 2007 and 2009 in an orthodox religious 
community with low vaccination coverage (17,18). Still, the latter outbreak involved 
another age group and genotype mumps virus (D), and surveillance data showed 
no evidence for previous mumps virus infections in our study cohort. Three 
persons in the Utrecht cohort had pre-outbreak IgG concentrations higher than 
1500 RU/ml, and they potentially had a mumps virus infection before the pre-
outbreak serum was drawn. Sera from these 3 persons had been banked at the 
beginning of 2010. 
In a previous study, no cutoff point could separate all mumps patients from 
nonpatients based on pre-outbreak mumps neutralization titers (3). In this study, a  
potential explanation for the lack of a cutoff is that it remains unknown who was 
exposed, and lack of exposure in part of the study population will result in an 
underestimation of the specificity. Furthermore, the Luminex assay uses purified 
whole-virus antigens, and therefore the assay will also detect nonneutralizing IgG 
antibodies, which do not prevent the virus from entering the cells (19). The failure 
to define a specific concentration of mumps-specific antibodies that is protective 
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against mumps virus infection suggests that effective protection against mumps 
virus infection is governed by host immune mechanisms other than IgG 
concentrations in serum. 
Median IgG concentrations in pre-outbreak samples from persons who became 
infected with mumps after serum sampling were 97 RU/ml. This concentration is 
higher than the 45 RU/ml, which is used as a measure to confer immune protection 
(13–15). When applying these cutoffs to mumps-specific IgG concentrations from 
451 vaccinated age-matched individuals included in a large Dutch serosurveillance 
study, the IgG concentration was below 97 RU/ml in 147 persons (32.6%) and 
below 45 RU/ml in only 42 (9.3%) persons (16). 
To conclude, serological analysis enabled us to calculate attack rates for both 
symptomatic and asymptomatic mumps virus infection and to determine risk 
factors for mumps virus infection. This study shows the usefulness of serological 
analysis in addition to questionnaires and the possibility to retrospectively identify 
mumps virus infections based on mumps-specific IgG concentrations in paired pre- 
and post-outbreak samples. 
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Table 3. Univariate and multivariate analysis of risk factors for mumps virus infection* 
 
* All persons with a 4-fold or more increase in mumps-specific IgG concentration or pre-outbreak IgG 
concentration ≥ 1500 RU/ml were considered to have had a mumps virus infection (n=44). 
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ABSTRACT 
Background 
Similar to other recent mumps genotype G outbreaks worldwide, most mumps 
patients during the recent mumps genotype G outbreaks in the Netherlands had 
received 2 doses of measles, mumps and rubella (MMR) vaccine during childhood. 
Here, we investigate the capacity of vaccine-induced antibodies to neutralize wild 
type mumps virus strains, including mumps virus genotype G.  
Methods 
In this study, we tested 105 pre-outbreak serum samples from students who had 
received 2 MMR vaccine doses and who had no mumps virus infection (n=76), 
symptomatic mumps virus infection (n=10) or asymptomatic mumps virus infection 
(n=19) during the mumps outbreaks. In all samples, mumps-specific IgG 
concentrations were measured by multiplex immunoassay and neutralization titers 
were measured against the Jeryl Lynn vaccine strain and against wild type 
genotype G and genotype D mumps virus strains. 
Results 
The correlation between mumps-specific IgG concentrations and neutralization 
titers against Jeryl Lynn was poor, which suggests that IgG concentrations do not 
adequately represent immunological protection against mumps virus infection by 
antibody neutralization. Pre-outbreak neutralization titers in infected persons were 
significantly lower against genotype G than against the vaccine strain. 
Furthermore, antibody neutralization of wild type mumps virus genotype G and 
genotype D was significantly reduced in pre-outbreak samples from infected 
persons as compared with non-infected persons. No statistically significant 
difference was found for the vaccine strain. The sensitivity/specificity ratio was 
largest for neutralization of the genotype G strain as compared with the genotype D 
strain and the vaccine strain.  
Conclusions 
The reduced neutralization of wild type mumps virus strains in MMR vaccinated 
persons prior to infection indicates that pre-outbreak mumps virus neutralization is 
partly strain-specific and that neutralization differs between infected and non-
infected persons. Therefore, we recommend the use of wild type mumps virus 
neutralization assays as preferred tool for surveillance of protection against mumps 
virus infection.  
MUMPS-SPECIFIC CROSS-NEUTRALIZATION 
	 117 
INTRODUCTION 
At the end of 2009, large mumps outbreaks started in the Netherlands and 
continued for 3 years, followed by some years with smaller and more local mumps 
outbreaks (1,2). Most of the patients were young adults who had received 2 
measles, mumps, and rubella (MMR) vaccinations during childhood at 14 months 
and 9 years of age, according to the Dutch national immunization program (3,4). 
Similar to other recent mumps outbreaks among MMR vaccinated persons 
worldwide, the mumps outbreaks in the Netherlands were dominated by mumps 
genotype G virus strains, whereas the Jeryl Lynn mumps strain of the MMR 
vaccine belongs to genotype A. It has been shown previously that vaccinated 
persons develop sufficient neutralizing antibodies against wild type mumps 
genotype G virus, although the neutralization capacity is lower against the wild type 
strain as compared with the vaccine strain (5,6). However, no correlate of 
protection has been defined so far that distinguishes MMR vaccinated persons with 
sufficient immunological protection from those who are not protected against 
mumps virus infection.  
Here, we aimed to investigate the capacity of vaccine-induced antibodies to 
neutralize various mumps virus strains and to establish a correlate of protection 
based on pre-outbreak neutralizing antibody titers. Pre-outbreak serum samples 
were selected from MMR vaccinated students who were infected with mumps virus 
during the outbreak and these samples were compared with samples from non-
infected students. The correlation between mumps-specific IgG concentrations and 
functional antibodies against the Jeryl Lynn vaccine strain was determined. 
Furthermore, we studied strain-specific neutralization between the Jeryl Lynn 
vaccine strain, mumps virus genotype G, which circulated in the Netherlands 
during the recent mumps outbreaks among vaccinated persons, and mumps virus 
genotype D, which caused a mumps outbreak among unvaccinated children in 
2007-2009 in the Netherlands (7). We investigated pre-outbreak samples from 
both persons with symptomatic and asymptomatic infections to determine if 
reduced neutralization of wild type strains affects the occurrence of clinical mumps 
in mumps virus infected persons. 
METHODS 
Study subjects and pre-outbreak serum samples 
All pre-outbreak sera used in this study were samples from a medically ethically 
approved serological study previously described (NL38042.041.11) (8). This 
retrospective study was performed among students from the city of Utrecht in 
2012. Besides a self-sampled dried blot spot sample and a filled out questionnaire 
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concerning MMR vaccination history, risk factors and mumps symptoms, a serum 
sample was retrospectively obtained from each student. In addition, MMR 
vaccination history was verified for 80.5% of the students from the data recorded in 
the nationwide vaccination registration system (Praeventis) (8). In total, 619 pre-
outbreak serum samples collected between 2007 and 2010 were obtained and 
included for the initial analysis to identify mumps virus infections based on mumps-
specific antibody concentrations (8). For this study, a selection was made 
consisting of 105 pre-outbreak serum samples from persons who had received 2 
MMR doses and who had symptomatic mumps virus infection, asymptomatic 
mumps virus infection or no mumps virus infection during the mumps outbreaks 
that followed. The serological criteria for mumps virus infection were a fourfold 
increase in IgG concentration or a single-point cutoff at 1500 RU/ml (8). Persons 
with symptomatic mumps virus infection fulfilled at least one of these serological 
criteria and indicated in the questionnaire that they developed mumps symptoms 
during the period 2009-2012 (n=10). Persons with asymptomatic mumps virus 
infection fulfilled also at least one of the serological criteria, but they did not report 
any mumps symptoms in the questionnaire (n=19). Non-infected persons did not 
fulfill any of the serological criteria for mumps virus infection and did not report 
mumps symptoms (n=76). The 105 pre-outbreak serum samples selected for this 
study included all available samples from infected persons that fulfilled the criteria 
in this study and a selection of the samples from non-infected persons. The 
geometric mean IgG concentrations in the selected pre-outbreak samples from 
persons without a mumps virus infection did not differ from the total cohort from the 
initial study (192 RU/ml versus 171 RU/ml; p=0.618) (8). 
 
Cell culturing and mumps virus isolation 
Vero cells (Monkey African Green Kidney, ECACC) were cultured at 37°C in 5% 
CO2 in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 5% fetal 
calf serum (FCS), penicillin, streptomycin, and L-glutamine. For inoculation of the 
Jeryl Lynn mumps virus strain, DMEM supplemented with 2% FCS, penicillin, 
streptomycin, and L-glutamine was used. The same medium composition was 
used for isolation of wild type mumps virus strains, with the addition of nystatin. 
Virus culturing was performed at 36°C in 5% CO2. Mumps virus Jeryl Lynn strain 
was seeded on Vero cells and passaged 2 times before harvesting. Mumps virus 
strains belonging to genotype G (MuVi/Utrecht.NLD/40.10) and genotype D 
(MuVi/Sint Philipsland.NLD/02.08) were isolated from laboratory-confirmed mumps 
virus-positive throat swabs and were passaged 2 times and 4 times respectively 
before harvesting. Virus stocks were stored at -80°C until use. Aliquots were made 
from all virus stocks to avoid multiple freeze-thaw cycles. 
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Multiplex IgG immunoassay 
Mumps-specific IgG concentrations were measured with a fluorescent bead-based 
multiplex immunoassay (MIA) using Luminex technology as described previously 
(9). Purified Jeryl Lynn antigen was coupled to carboxylated beads for detection of 
mumps-specific IgG. Samples were 1:200 diluted in assay buffer (phosphate 
buffered saline (PBS) containing 0.1% Tween-20 and 3% bovine serum albumin). 
On each plate, the WHO International Standard Anti Rubella Immunoglobulin 
RUBI-1-94 (The National Institute for Biological Standards and Control), controls 
and blanks were included. Antibody concentrations were expressed in local (RIVM) 
units per milliliter (RU/ml) and were based on the fluorescent intensity of the 
reference serum curve RUBI-1-94, which has a mumps-specific IgG concentrations 
of 4384.512 RU/ml and was selected as alternative serological standard for 
mumps to enable comparison and bridging of our results to other studies (8). When 
the 1:200 sample dilution fell outside the range of the reference serum curve, 
further dilutions up to 1:50,000 were used for analysis. 
Focus-reduction neutral ization test (FRNT) 
Neutralization by vaccine-induced antibodies was tested by FRNT, partly based on 
the protocol described by Vaidya et al. (10). Neutralization tests were performed in 
96-wells plates. Fourfold dilutions were made in DMEM supplemented with 2% 
FCS, penicillin, streptomycin, and L-glutamine. Viruses and samples were mixed 
and incubated for 2 hours at 37°C. Medium was removed from pre-cultured Vero 
cells and 50 µl of virus mixture was added to each well. Plates were incubated for 
4 hours at 36°C, before the mixture was removed from the Vero cells and 200 µl of 
0.8% carboxymethylcellulose in DMEM was added to each well. Plates were 
incubated for 40 hours at 36°C with 5% CO2 before they were washed with PBS 
and thereafter fixed with a mixture of aceton and methanol (2:3). After 10 minutes, 
plates were washed with ice cold PBS, and then incubated with block buffer (PBS 
containing 1% bovine serum albumin) for 30 minutes at 36°C. Anti-mumps 
nucleoprotein antibody (7B10, Abcam) was diluted in block buffer (1:3000) and 100 
µl was added to each well. After incubation for one hour at 36°C, plates were 
washed 3 times with PBS containing 0.1% Tween-20 (PBST) before 100 µl of goat-
anti-mouse IgG-HRP (DAKO) diluted in block buffer (1:2000) was added to each 
well and plates were incubated for one hour at 36°C. Plates were washed 3 times 
with PBST and wells were stained with 50 µl of True Blue peroxidase substrate 
(Kirkegaard & Perry Laboratories). The numbers of plaques were counted and the 
50% neutralizing dose (ND50) of each sample was calculated with the Kärber 
formula, using the serum dilution factor as calculated from the virus mixture (10). 
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The WHO international standard RUBI-1-94 was used as positive control in 
each assay run. For a valid assay, the titer of RUBI-1-94 was required to be within 
2 standard deviations of its cumulative historical mean value. Furthermore, assays 
were only valid if the mean plaque number of the virus controls was in the range of 
20-80 and cell controls had no plaques. If assays did not meet the validation 
criteria, samples were retested. Only samples with at least two valid results per 
virus strain in separate runs were used for analyses. To correct for inter-assay 
differences, we normalized the ND50 values by multiplying the raw ND50 titers by 
the RUBI-1-94 factor, which was defined as the cumulative historical mean value of 
RUBI-1-94 divided by the measured ND50 of RUBI-1-94. 
Statist ical analysis 
Geometric mean (with 95% confidence interval [CI]) IgG concentrations and 
neutralization titers were compared between infected and non-infected persons 
using the Kolmogorov-Smirnov test. Correlations between IgG concentrations and 
neutralization titers were computed using nonlinear regression with the Spearman 
correlation coefficient. For comparison of neutralization titers against different 
mumps virus strains, the Friedman test was used. With a receiver operator 
characteristics (ROC) analysis, the area under the curve (AUC) with 95% 
confidence limits was calculated for mumps-specific IgG concentrations and 
neutralizing antibodies against the different mumps virus strains to determine a 
correlate of immune protection. The DeLong test was used for comparison of 
AUCs, using the genotype G neutralization titer as reference (11). All analyses 
were performed using SPSS version 22, SAS version 9 and GraphPad Prism 
version 6. P values <0.05 were considered as statistically significant. 
RESULTS 
Mumps-specif ic IgG concentrations 
Since mumps-specific IgG concentrations are widely used to define levels of 
mumps immunity, mumps-specific IgG concentrations were studied in pre-outbreak 
serum samples from infected and non-infected persons. Mumps-specific IgG 
concentrations were measured by MIA using purified Jeryl Lynn as antigen and 
these results were compared with neutralization titers against the same mumps 
virus Jeryl Lynn strain. In this way, we could study the correlation between mumps-
specific IgG concentrations and neutralization titers. 
Mumps-specific IgG concentrations were significantly lower in pre-outbreak 
samples from infected persons than in samples from non-infected persons (122 
RU/ml (86-173 RU/ml) versus 192 RU/ml (161-228 RU.ml); p=0.008). The Jeryl 
Lynn-specific neutralization titer in pre-outbreak samples from infected and non-
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infected persons was ND50 67 (47-95) and ND50 115 (87-152), respectively 
(p=0.078). The correlation between IgG concentrations and neutralization titers 
against Jeryl Lynn in pre-outbreak samples was poor for both the infected and non-
infected persons (r2=0.017 and r2=0.165, respectively) (Figure 1). There was no 
difference in mumps-specific IgG concentrations and neutralization titers between 
symptomatic and asymptomatic mumps virus infections.  
Figure 1. Correlation between mumps-specific IgG concentrations and neutralization titers against Jeryl 
Lynn in pre-outbreak samples from vaccinated students (n=105). Lines represent the best fit lines with 
nonlinear regression. 
Strain-specif ic neutral ization in pre-outbreak samples 
To investigate if antigenic differences between the vaccine strain and wild type 
strains resulted in reduced neutralization of the wild type strains, we measured 
virus neutralization in pre-outbreak serum samples against the Jeryl Lynn vaccine 
strain as well as against wild type genotype G and genotype D strains. In pre-
outbreak samples from persons without a mumps virus infection, neutralization 
titers against the different mumps virus strains did not significantly differ (p>0.105) 
(Figure 2A). For infected persons pre-outbreak neutralization titers against 
genotype G were significantly lower than neutralization titers against Jeryl Lynn 
(p=0.009) (Figures 2A and 3). When the mumps virus infected group was further 
divided into symptomatic and asymptomatic mumps virus infections, only in the 
asymptomatic group neutralization titers against genotype G were significantly 
lower than neutralization titers against Jeryl Lynn (p=0.036) (Figure 2B). The lack 
of significant results in the symptomatic group may be due to the low number of 
symptomatic infections in our study cohort. 
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Figure 2. Neutralization titers against the different mumps virus strains. P values <0.10 are shown 
above the graphs. Geometric mean neutralization titers with 95% confidence interval are shown on the 
X axes. A) Neutralization titers in persons with or without a mumps virus infection. B) Neutralization 
titers in mumps virus infected persons, further differentiated into symptomatic and asymptomatic 
mumps virus infections. 
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 Figure 3   Paired neutralization titers 
against the different mumps virus 
strains in pre-outbreak samples from 
infected persons. Neutralization titers 
were significantly lower against the wild 
type genotype G strain than against the 
Jeryl Lynn vaccine strain (p=0.009). 
There were no significant differences 
between the wild type genotype D strain 
and any of the other strains. 
Correlate of protection 
To establish a correlate of 
protection based on mumps-
specific neutralizing antibodies, 
pre-outbreak neutralization titers 
were compared between 
infected and non-infected 
persons. The difference in pre-
outbreak neutralization titers 
against Jeryl Lynn between 
infected and non-infected persons was not significant (p=0.078) (Figure 2A). 
However, neutralization titers against the wild type mumps virus genotype G and 
genotype D strains were significantly lower in infected persons than in non-infected 
persons (p=0.011 and p=0.022, respectively) (Figure 2A), which suggests that the 
capacity of vaccine-induced antibodies to neutralize wild type strains is a more 
appropriate marker for protection. The difference in neutralization titers between 
symptomatic and asymptomatic infections was not significant (Figure 2B).  
A ROC analysis with the 3 different mumps virus strains to compare 
sensitivity/specificity ratios resulted in an AUC of 0.703 (0.595-0.812) for genotype 
G, which is larger than the AUCs for Jeryl Lynn (0.628 (0.516-0.741); p=0.071) and 
for genotype D (0.638 (0.526-0.750); p=0.090), although the differences were not 
statistically significant (Figure 4). A ROC analysis based on the IgG concentrations 
resulted in an AUC of 0.689 (0.564-0.813), which is also not significantly different 
from the AUC for genotype G (p=0.841) (Figure 4). No cutoff could be established 
that separated all mumps virus infections from all non-infections. For mumps-
specific IgG concentrations, the cutoff at 243 RU/ml, as published previously, 
resulted in a sensitivity of 86.21% and a specificity of 39.47% when applied to the 
pre-outbreak samples from this study (8). When this sensitivity of 86.21% was 
used to calculate a cutoff for the neutralization titers, the cutoff for Jeryl Lynn-
specific neutralization was at ND50 167 (89.66% sensitivity and 38.16% specificity), 
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which was comparable with the cutoff for genotype D-specific neutralization (ND50 
169 with 86.21% sensitivity and 30.26% specificity). The cutoff value for genotype 
G-specific neutralization was lower (ND50 97 with 86.21% sensitivity and 43.42% 
specificity). These data indicate that the sensitivity/specificity ratio was most 
optimal for neutralizing antibody titers against the mumps virus genotype G strain, 
although differences were not statistically significant. Furthermore, the specificity at 
these cutoffs was highest for genotype G-specific neutralization. 
Figure 4   Receiver operator characteristics analysis based on IgG concentrations and neutralization 
titers against Jeryl Lynn, genotype G and genotype D mumps virus strains. 
DISCUSSION 
In pre-outbreak serum samples from mumps virus infected persons who had 
received 2 MMR doses, neutralization titers against mumps virus genotype G were 
lower than against the Jeryl Lynn strain, which suggests that neutralization by 
vaccine-induced antibodies is partly strain-specific. This difference in neutralization 
between the vaccine strain and a wild type mumps virus genotype G strain was 
previously described by others (5,6). Contrary to those previous studies, we only 
observed this difference in pre-outbreak serum samples from infected persons. 
Furthermore, in our study only neutralization titers against the wild type genotype G 
and genotype D mumps viruses differed between infected and non-infected 
persons, whereas in one of the previous studies the neutralization titers against 
Jeryl Lynn were lower for infected persons than for non-infected persons (5). 
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In our study, both symptomatic and asymptomatic mumps virus infections were 
identified using reported symptoms as well as mumps-specific IgG concentrations 
as criteria for mumps virus infection. In this way, asymptomatic mumps virus 
infections could be identified and these were excluded from the non-infected group. 
Inclusion of asymptomatically infected persons in the non-infected group could 
affect the results. This might explain the difference in results between our study 
and previous studies in which pre-outbreak neutralization titers were compared 
between mumps patients and non-patients. In spite of the use of mumps-specific 
IgG concentrations as criteria for mumps virus infection, it cannot be excluded that 
some students had been exposed to mumps earlier. The high neutralization titers 
against the wild type viruses in 2 pre-outbreak samples from infected students 
suggest that these persons may have been previously infected with mumps virus, 
although surveillance data showed no evidence for previous mumps virus 
infections in our study cohort (Figure 3). 
The poor correlation between mumps-specific IgG concentrations and 
neutralization titers observed in our study confirmed results from other studies 
(10,12–14). The MIA that was used to measure the mumps-specific IgG 
concentrations is based on purified Jeryl Lynn virus and measures the total amount 
of mumps-specific IgG present in the sample. In contrast, the neutralization assay 
was used to measure virus neutralizing antibodies, which may be an important 
immunological mechanism in protection against mumps virus infection (15,16). 
ROC analysis showed that the sensitivity/specificity ratio is largest for genotype G-
specific neutralization titers. Although no cutoff value for pre-outbreak 
neutralization titers could be identified that separates all infected persons from non-
infected persons, our data suggest that genotype G-specific neutralization is a 
more adequate serological marker for protection against mumps virus infection, as 
most of the recent mumps outbreaks among MMR vaccinated persons were 
caused by mumps virus genotype G strains. 
The results from this study suggest that antigenic differences between the 
mumps virus vaccine strain and wild type strains affect mumps-specific humoral 
immune responses in MMR vaccinated persons. Two mumps virus membrane 
proteins that play a major role in virus neutralization are the fusion (F) protein and 
the haemagglutinin-neuraminidase (HN) protein (17–19). As was hypothesized 
previously, the difference in neutralization between Jeryl Lynn and the wild type 
strains may result from antigenic differences in the neutralizing epitopes of the F 
and HN proteins (6). Because of the potential biological relevance of mumps virus 
neutralization and the difference in strain-specific neutralization between infected 
and non-infected persons, we recommend the use of wild type mumps virus 
neutralization assays as preferred tool for surveillance of protection against mumps 
virus infection. 
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ABSTRACT 
Background 
During recent years, various mumps outbreaks have occurred among measles, 
mumps, and rubella (MMR) vaccinated persons in various countries worldwide, 
including the Netherlands. We studied mumps virus shedding in MMR vaccinated 
and unvaccinated mumps patients and related these findings to clinical data. 
Methods 
In this study, we included 1112 mumps patients of whom diagnostic samples were 
tested positive in our laboratory between 1 January 2007 and 31 December 2014. 
We compared mumps virus shedding and severity of disease between patients 
who had received 2 doses of MMR (n=592) and unvaccinated mumps patients 
(n=195). Mumps virus shedding in saliva and urine specimens was measured by 
qPCR. Severity of disease was studied in a subset of patients with clinical data 
available. 
Results 
Mumps patients who had received 2 MMR doses shed less often mumps virus in 
their urine than unvaccinated patients. Salivary viral loads were higher at day of 
onset of disease in twice MMR vaccinated patients with viruria than in twice MMR 
vaccinated patients without viruria. However, salivary viral loads did not 
significantly differ between patients who had received 2 MMR doses and 
unvaccinated patients. Bilateral parotitis and orchitis were less often reported in 
patients who had received 2 MMR doses than in unvaccinated patients. 
Furthermore, the prevalence of bilateral parotitis and orchitis was higher among 
twice MMR vaccinated patients with viruria than among twice MMR vaccinated 
patients without viruria. 
Conclusions 
MMR vaccination was associated with less severe disease among mumps 
patients. Systemic spread of virus was associated with more severe disease. The 
elevated salivary viral loads in patients with systemic mumps disease suggest that 
these patients pose a higher risk for mumps virus transmission. Our study 
contributes to the understanding of mumps virus pathogenesis and shows the 
protective effect of MMR vaccination on severity of disease. 
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INTRODUCTION 
Mumps is characterized by parotitis, usually bilateral. However, at least one third of 
the mumps virus infections are asymptomatic or cause non-specific symptoms 
such as fever, headache, malaise and myalgia without parotitis (1–4). The most 
common complication is orchitis, which occurred in up to 12.7% of the post-
pubertal males with mumps reported during the recent mumps outbreaks (5–8). 
The Netherlands began measles, mumps, and rubella (MMR) vaccination in 1987. 
The vaccine, containing the Jeryl Lynn mumps virus strain, is administered via the 
national immunization program in a 2-dose schedule at 14 months and 9 years of 
age. During recent years mumps outbreaks have occurred among MMR 
vaccinated persons in the Netherlands as well as in other countries worldwide (9–
12). The majority of mumps patients in the Netherlands were between 18 and 25 
years of age and had received 2 MMR doses (7). After a mumps outbreak among 
unvaccinated persons caused by mumps virus genotype D in 2007–2009, the 
predominant mumps virus genotype during the recent mumps outbreaks from 2009 
onwards was genotype G (12,13). 
The incubation period of mumps varies between 15 and 24 days, with a median 
of 19 days (14). The virus has been isolated from mumps patients as early as 7 
days before up to 8 days after onset of symptoms. However, virus shedding 
decreases rapidly after onset of symptoms (15,16). When the virus spreads from 
the respiratory tract through the body, systemic mumps virus infection can occur. 
Infection of the kidneys results in viruria, which can last for up to 14 days after 
onset of symptoms (17). Viruria occurs less often in MMR vaccinated mumps 
patients than in unvaccinated patients (18–20). 
It has been shown previously in a selection of children with mumps that viral 
loads in saliva are lower in MMR vaccinated mumps patients than in unvaccinated 
patients, suggesting a lower risk for mumps virus transmission via salivary droplets 
(20). However, contrary to the adult mumps patients during the recent outbreaks, 
the vaccinated mumps patients in that study were children who had mumps shortly 
after the second MMR dose, since the median time between onset of disease and 
second MMR vaccination was 4 years. Secondly, there are indications that MMR 
vaccination reduces the risk for mumps-associated complications, such as orchitis 
(7,8). These findings suggest that although MMR vaccination does not fully protect 
against mumps virus infection, it may prevent virus transmission and 
complications. 
We set out to study this hypothesis by assessing the association between 
mumps symptoms and viral shedding in saliva and urine in both patients who had 
received 2 MMR doses and unvaccinated mumps patients. Since salivary droplets 
are an important mode of transmission, elevated salivary viral loads are probably 
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associated with an increased risk for mumps virus transmission (16). On the other 
hand, mumps virus shedding in urine indicates systemic infection and may 
therefore be associated with more severe symptoms. Here, we have studied the 
association between mumps symptoms such as parotitis, fever and orchitis and 
viral shedding in saliva and urine to better understand the pathogenesis of mumps 
in both MMR vaccinated and unvaccinated patients. 
METHODS 
Clinical samples and patient data 
Since December 2008, mumps is a notifiable disease in the Netherlands. Mumps 
surveillance is carried out by the National Institute for Public Health and the 
Environment (RIVM) in collaboration with municipal health services and peripheral 
laboratories. The majority of samples from suspected mumps cases sent to the 
RIVM laboratory for mumps virus testing between 1 January 2007 and 31 
December 2014 were saliva samples, urine specimens and throat swabs, which 
were tested for the presence of mumps virus RNA by quantitative PCR (qPCR). All 
laboratory-confirmed cases were reported to the national registration system for 
notifiable diseases in the Netherlands (Osiris). Data from the laboratory database 
were linked to the notification database by matching patients by date of onset of 
disease, postal code, gender and year of birth. In this way, a database was created 
that included patient characteristics, test results and epidemiological data. 
Information on MMR vaccination status and clinical symptoms was primarily 
retrieved from Osiris. If this information was missing in Osiris, the information from 
the laboratory database was used. Only samples from unvaccinated and from 
twice MMR vaccinated persons were included in this study, since 2 MMR vaccine 
doses are offered by the national immunization program in the Netherlands. In 
accordance with Dutch law, no informed consent was required for this study. 
RNA extraction and cDNA synthesis 
RNA was extracted from specimens with either the High Pure Viral Nucleic Acid Kit 
or the MagNA Pure 96 (Roche Diagnostics) following the manufacturer's protocol. 
20 μl of RNA was transcribed into cDNA with 200 U MuLV reverse transcriptase 
(Invitrogen), 0.2 mM dNTP mix (Roche Diagnostics), PCR buffer (Applied 
Biosystems), 1.5 mM magnesium chloride (Applied Biosystems), 20 U RNase 
inhibitor (Applied Biosystems), and 2.5 μM of random hexameres (Invitrogen). 
cDNA mix was incubated at room temperature for 10 min, 37 °C for 50 min, 95 °C 
for 5 min, and then cooled down to 4 °C. 
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Quantitative PCR  
Until March 2010, the SH gene was used as target for the qPCR. For all samples 
tested from then onwards, the mumps F gene was used as target. For analysis of 
viral loads, only quantitative results of the qPCR using the F gene as target were 
used. The qPCR was performed with either the LightCycler 2.0 (until April 2011) or 
the LightCycler 480 (Roche Diagnostics). In each run, mumps virus Jeryl Lynn was 
included as a positive control with a viral load of 3540 plaque forming units per 
milliliter (pfu/ml) for quantification of the PCR results. 
Statist ical analysis  
SPSS version 22 and GraphPad Prism version 6.04 were used for data analyses. 
Median age in the unvaccinated and twice MMR vaccinated groups was compared 
using the Mann–Whitney test. Viral loads were log(10) transformed and analysed 
using the student's t-test. Trends over time were performed using linear regression. 
We assessed differences in clinical symptoms and virus shedding between 
vaccinated and unvaccinated patients by using logistic regression. All p values 
below 0.05 were considered statistically significant. 
 
Figure 1. Flowchart of saliva samples and urine samples used for analyses from unvaccinated (red) 
and twice MMR vaccinated (blue) mumps patients. All samples were obtained between 1 January 2007 
and 31 December 2014. Clinical information about mumps-specific symptoms and complications was 
available for a subset of the mumps patients, as indicated in the right upper box. In total, 33 saliva 
samples from unvaccinated patients and 187 saliva samples from twice MMR vaccinated patients were 
included for quantitative analysis. Urine samples from 150 unvaccinated patients and 379 twice MMR 
vaccinated patients were included for qualitative analysis. Of the urine samples, 31 samples were from 
unvaccinated patients and 177 samples were from twice MMR vaccinated patients of whom also a 
saliva samples was tested quantitatively. 
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RESULTS 
Mumps diagnostics  
From 1 January 2007 until 31 December 2014, 1112 suspected mumps cases 
were tested positive by PCR at the RIVM (Figure 1). The median age in this group 
was 22 years (IQR 20–24 years), and of the 1099 patients of whom sex was 
known, 637 were males (58.0%). Of the 907 patients of whom vaccination status 
was known, 195 patients (21.5%) were unvaccinated, 111 patients (12.2%) had 
received 1 MMR dose, 592 patients (65.3%) had received 2 MMR doses, and 9 
patients (1.0%) had received 3 or more MMR doses. The median age and the sex 
distribution of the patients did not differ between the unvaccinated patients and the 
patients who had received 2 MMR doses (p=0.799 and p=0.754, respectively). For 
quantitative analyses, only samples up to day 6 after onset of disease were 
included due to the low number of samples available after this period.  
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Figure 2. Mean viral loads 
in saliva by day after onset 
of disease. (A) Viral loads 
in saliva in twice MMR 
vaccinated patients and 
unvaccinated patients. 
Each circle represents one 
patient; (B) mean viral 
loads in saliva from twice 
MMR vaccinated patients 
with and without viruria. 
Dotted lines represent 95% 
confidence interval. 
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Viral load in sal iva and urine specimens   
Viral load in saliva was highest at day of onset of disease (3.96 ± 0.19 pfu/ml for 
patients who had received 2 MMR doses and 3.86 ± 0.46 pfu/ml for unvaccinated 
patients; p=0.821) and declined within the first 6 days after onset of disease with a 
viral decay of 0.544 ± 0.056 pfu/ml per day for patients who had received 2 MMR 
doses and 0.50 ± 0.13 pfu/ml per day for unvaccinated patients (p=0.731) (Figure 
2A). Salivary viral load at day of onset of disease was higher for twice MMR 
vaccinated mumps patients with viruria than for twice MMR vaccinated patients 
without viruria (4.13 ± 0.28 pfu/ml versus 3.68 ± 0.27 pfu/ml) (p<0.001), but the 
decline after onset of disease did not significantly differ between patients with 
viruria and patients without viruria (0.42 ± 0.09 pfu/ml per day versus 
0.55 ± 0.08 pfu/ml per day; p=0.262) (Figure 2B). The percentage of mumps 
patients with viruria during the first 6 days after onset of disease was higher among 
unvaccinated patients than among patients who had received 2 MMR doses 
(62.1% versus 38.9%; p=0.002) (Figure 3). Too few samples were available from 
unvaccinated mumps patients to determine the correlation between salivary viral 
loads and viruria. 
 
 
 
 
 
 
 
 
Figure 3. Mean viral loads in saliva and 
frequency of viruria. Mean salivary viral 
loads are indicated by black circles with 
error bars showing the 95% confidence 
interval of the mean. Frequency of viruria 
is shown by gray bars. (A) Salivary viral 
loads and frequency of viruria in 
unvaccinated patients; (B) salivary viral 
loads and frequency of viruria in twice 
MMR vaccinated patients. 
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Figure 4. Model for mumps virus pathogenesis in MMR vaccinated and unvaccinated mumps patients. 
Salivary viral loads (2) did not differ between twice MMR vaccinated and unvaccinated patients, 
whereas bilateral parotitis (3), viruria (6) and orchitis (7) occurred less often in twice MMR vaccinated 
mumps patients. These findings indicate that the risk for a systemic mumps virus infection (4), which 
can result in infection of organs (5), viruria (6) and orchitis (7), is lower in MMR vaccinated patients than 
in unvaccinated patients. 1: viral entry; 2: replication in the upper respiratory tract; 3: parotitis; 4: 
systemic infection; 5: infection of the organs; 6: viruria; 7: orchitis. * p ≤ 0.005. 
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Clinical symptoms 
Bilateral parotitis was more often reported among unvaccinated patients than 
among patients who had received 2 MMR doses (56.0% versus 37.1%; p<0.001) 
(Figure 4). With respect to patients who had received 2 MMR doses, bilateral 
parotitis was more frequent in those with viruria than in those without viruria (54.1% 
versus 27.3%; p<0.001). Among unvaccinated patients, there was no difference in 
the frequency of bilateral parotitis between those with viruria and those without 
viruria (62.1% versus 52.8%; p=0.374). There was no association between the viral 
load in saliva per day after onset of disease and the occurrence of bilateral parotitis 
in patients who had received 2 MMR doses (p=0.308). 
Fever was reported in 68.3% of the unvaccinated patients and in 64.6% of the 
patients who had received 2 MMR doses (p=0.475). There was no association 
between fever and viruria, irrespective of vaccination status (p≥0.243). 
Furthermore, no correlation was found between salivary viral load per day after 
onset of disease and fever in patients who had received 2 MMR doses (p=0.590). 
Among males, the prevalence of orchitis was lower in patients who had 
received 2 MMR doses than in unvaccinated patients (18.7% versus 35.8%; 
p=0.005) (Figure 4). A positive association was found between the occurrence of 
orchitis and mumps virus shedding in urine. Orchitis was reported in 22.9% of the 
twice MMR vaccinated male patients who shed virus in urine as compared with 
2.7% of the twice MMR vaccinated male patients without mumps virus in their urine 
(p<0.001). Unvaccinated male patients with viruria had also more often orchitis 
than unvaccinated male patients without viruria (46.7% versus 6.7%; p=0.005). 
Too few saliva samples were available from mumps patients with orchitis to 
determine the correlation between salivary viral load and orchitis. 
DISCUSSION 
Our results indicate that mumps virus detection in urine is a marker for severity of 
disease, as shown here for the occurrence of orchitis and bilateral parotitis. The 
observation that mumps patients who had received 2 MMR doses shed less often 
mumps virus in their urine and have less often bilateral parotitis or orchitis than 
unvaccinated patients supports previous notions that although the vaccine does 
not fully protect against mumps virus infection, MMR vaccination has a protective 
effect on severity of mumps disease (7,8) (Figure 4). Furthermore, we found a 
positive correlation between viruria and salivary viral loads at day of onset of 
disease in mumps patients who had received 2 MMR doses, showing that mumps 
patients with a systemic mumps virus infection have an increased risk for 
transmitting virus via salivary droplets. 
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The percentage of orchitis cases captured in our patient selection was higher 
than the percentages reported in other studies (5–7,21,22). The most likely reason 
for this difference is a bias in the reporting of orchitis cases in our study. Firstly, it is 
probable that information from many males without orchitis was not filled out on the 
patients’ forms, whereas probably most of the orchitis cases among male patients 
were explicitly reported on the forms. Secondly, it may be that samples from 
orchitis patients were more often sent in for laboratory testing whereas mumps 
patients without orchitis were more often reported based on solely an 
epidemiological link to a confirmed mumps case or were not reported at all. 
However, this bias does not influence the effect of vaccination status and viruria on 
orchitis, since these factors are not expected to influence reporting and sampling of 
orchitis cases. 
As the knowledge on mumps virus pathogenesis and the immunological factors 
involved in clearance of the virus is limited, the mechanism behind the positive 
correlation found in this study between salivary viral loads and viruria is unknown. 
Our findings that mumps patients who had received 2 MMR doses have less often 
viruria, bilateral parotitis and orchitis indicate that immunological factors play an 
important role in mumps virus pathogenesis and that vaccine-induced immunity 
limits mumps virus spread. Whether the spread of mumps virus through the body is 
limited by local immune responses in the upper respiratory tract or by other 
immunological factors needs to be determined. Our study contributes to the 
understanding of mumps virus pathogenesis; a correlation between mumps virus 
shedding and severity of disease is shown here in both vaccinated and 
unvaccinated mumps patients. Furthermore, these results underline the importance 
of urine samples in mumps diagnostics, because they can serve as positive 
prognostic markers for severity of disease. 
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SUMMARY 
The recent mumps outbreaks among MMR vaccinated persons in various countries 
worldwide have raised questions about MMR vaccine failure, vaccine-induced 
protection and mumps virus pathogenesis. This thesis contributes to the insights 
into possible causes for the recent mumps outbreaks among MMR vaccinated 
persons and provides an overview of my research on sequencing as a tool to 
support outbreak control measures. The results presented in this thesis could 
therefore be used for public health decision making about future mumps outbreaks. 
In Part II we focused on the recent mumps outbreaks in the Netherlands. In 
Chapter 2, we analysed the epidemiology of a nationwide mumps epidemic. Our 
data showed a slight shift in age and geographic distribution throughout the 
outbreak seasons, which may reflect increased immunity among students as a 
result of exposure to circulating mumps virus. Furthermore, we found that a history 
of MMR vaccination significantly reduced the risk for complications. Besides the 
SH gene, which is used for mumps virus genotyping, the F gene and HN gene 
were sequenced (Chapter 3). Phylogenetic analysis showed that the genetic 
diversity of the mumps virus strains during this period was a result of separate 
introductions of mumps virus rather than ongoing transmission and evolution. 
Moreover, combining F, SH and HN gene sequences enabled us to study mumps 
virus transmission during local mumps outbreaks, even in the absence of an 
epidemiological link (Chapter 4). In Chapter 5, the mumps virus surface proteins 
were analysed to study differences between mumps virus genotype G strains and 
other mumps virus genotypes, including the vaccine strain that belongs to 
genotype A. We have identified multiple variable sites in the mumps virus surface 
proteins of the Jeryl Lynn vaccine strain and genotype G strains which could affect 
mumps virus immunity and pathogenesis, and therefore may contribute to the 
occurrence of mumps virus genotype G outbreaks among MMR vaccinated 
persons. 
In Part III we concentrated on MMR vaccine-induced immunity and the 
protective effect of MMR vaccination on severity of disease. In Chapter 6, mumps-
specific IgG concentrations were measured in paired pre- and post-outbreak 
samples from MMR vaccinated students to study attack rates and risk factors for 
mumps virus infection. According to our serological criteria, 5.8% of the 
participants had a mumps virus infection. Two-thirds of the mumps virus infections 
in this group were asymptomatic. Circulation of mumps among housemates was a 
significant risk factor for mumps virus infection, which confirms the theory that 
close contact environments increase the risk for mumps (1). Pre-outbreak mumps-
specific IgG concentrations were lower for infected persons than for non-infected 
persons, although no cutoff point could separate all mumps virus infections from 
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non-infections. We studied vaccine-induced humoral immune responses further 
using the neutralization assay (Chapter 7). The results indicate that strain-specific 
neutralization differs between pre-outbreak samples from infected and non-infected 
persons. Furthermore, our data suggest that genotype G-specific neutralization 
assays are preferred as tool for surveillance of protection against mumps virus 
infection. Besides the effect of MMR vaccination on humoral immune responses, 
we investigated the protective effect of MMR vaccination on severity of disease in 
mumps patients (Chapter 8). MMR vaccination was associated with less severe 
disease among mumps patients and with less mumps virus shedding in urine, 
which is an indicator for systemic spread. Furthermore, patients with systemic 
disease showed elevated salivary viral loads, which suggests that these patients 
pose a higher risk for mumps virus transmission. This study does not only show 
the protective effect of MMR vaccination on severity of disease, but also 
contributes to the understanding of mumps virus pathogenesis.  
MUMPS SURVEILLANCE 
Mumps was a notifiable disease in the Netherlands until 1999 and was made 
notifiable again in December 2008 (2). However, mumps cases during the recent 
outbreak seasons were probably underreported. Since mumps symptoms are often 
mild and treatment options are limited, it is likely that not all mumps patients are 
diagnosed and reported (3). Furthermore, many mumps virus infections, especially 
among MMR vaccinated persons, are asymptomatic or cause non-specific 
symptoms (Chapter 6). Underreporting of the number of mumps cases and the 
lack of data about asymptomatic mumps virus infections interfere with an adequate 
mumps virus surveillance based on epidemiological data, because transmission 
events may be missed. Molecular surveillance could serve to overcome these 
difficulties, as this method enables the identification of outbreak clusters in the 
absence of an epidemiological link. 
Routine mumps surveillance provides knowledge about the geographic 
distribution of mumps virus genotypes (4,5). Mumps virus genotyping – typically 
based on the SH gene – may therefore be a useful method to distinguish imported 
mumps cases from endemically circulating mumps virus strains, but the molecular 
resolution is not sufficient to study mumps virus transmission during an outbreak 
season. Sequencing of the F gene and HN gene in addition to the SH gene 
increases the molecular resolution and can therefore be used as a tool to study 
mumps virus transmission during outbreaks (Chapter 4). The F gene and the HN 
gene encode surface proteins that play a role in mumps virus pathogenesis and 
may be less conserved than the SH gene (6–10). By increasing the targets for 
genotyping, the size and spread of mumps outbreak clusters can be estimated 
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more precisely, which supports public health decisions about implementation and 
evaluation of outbreak measures. However, it is recommended that complete 
mumps virus genomes are sequenced from a selection of mumps viruses to 
confirm that the F gene and HN gene are the most appropriate genes to study 
mumps virus transmission within mumps virus genotype G outbreaks. In addition, 
the molecular information available from mumps virus strains circulating in other 
countries is still limited, and therefore we cannot always distinguish endemically 
circulating mumps virus strains from strains that were imported multiple times. For 
example, the number of reported mumps cases since 2009 strongly fluctuated and 
during some months the number of reported cases was too low for endemic 
circulation. Based on these data we expect that some strains, despite identical F, 
SH and HN gene sequences, were imported multiple times. 
MUMPS VIRUS PATHOGENESIS 
The understanding of mumps virus pathogenesis and the role of immunity is 
limited. Analysis of saliva and urine specimens from twice MMR vaccinated mumps 
patients in relation to clinical data shows that mumps virus shedding in urine is 
positively associated with high salivary viral loads at day of onset of disease and 
with the occurrence of bilateral parotitis and orchitis (Chapter 8). Because viruria is 
a consequence of infection of the kidneys, mumps virus shedding in urine indicates 
systemic mumps virus infection (11). However, it remains unclear how the virus 
reaches organs such as the kidneys, because the virus has only been sporadically 
detected in blood during infection (12–14). Results presented in this thesis show 
that immunological factors play an important role in the development of clinical 
mumps and severity of disease. MMR vaccination provides protection against 
clinical mumps, because 66% of the mumps virus infections among MMR 
vaccinated persons were asymptomatic (Chapter 6), compared with 30-40% of the 
mumps virus infections among unvaccinated persons in previous studies (15,16). 
Furthermore, MMR vaccination has a protective effect on the development of 
bilateral parotitis and orchitis and on shedding of mumps virus in urine (Chapter 
8). Once the virus has entered the body via the upper respiratory tract, vaccine-
induced adaptive immune responses seem to prevent mumps virus spread, 
although it is not clear which immune responses are essential for protection 
against mumps virus infection. T cell immunity plays a major role in control and 
clearance of respiratory syncytial virus (RSV) and measles virus infections and 
may therefore also be involved in the resolution of mumps virus infection (17,18). 
Furthermore, the level of mumps virus exposure probably determines whether the 
vaccine-induced immunological responses are sufficient to prevent mumps virus 
infection, as there is no clear cutoff for pre-outbreak serum antibody titers between 
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infected and non-infected persons (Chapters 6 and 7) and various mumps 
outbreaks among MMR vaccinated persons occurred in high exposure settings. 
VACCINE-INDUCED PROTECTION AGAINST MUMPS 
As primary vaccine failure is unlikely, the recent mumps outbreaks are probably 
caused by a combination of waning immune responses and a mismatch in epitope 
regions between the vaccine strain and the circulating wild type strains. The recent 
mumps outbreaks among MMR vaccinated persons were caused by mumps virus 
genotype G strains, whereas the Jeryl Lynn vaccine strain belongs to genotype A. 
Comparison of the mumps virus surface proteins showed that the Jeryl Lynn 
vaccine strain and mumps virus genotype G strains have unique variable sites that 
are located in regions of the F and HN proteins with important biological functions 
(Chapter 5). Especially amino acid positions 113, 354, 356, 403 and 442 in the HN 
protein are of interest, because these positions are located in predicted B cell 
epitope regions. These positions differ between the Jeryl Lynn vaccine strain and 
genotype G strains and may therefore cause reduced neutralization of circulating 
wild type mumps virus strains by vaccine-induced antibodies (Chapter 7). In vitro 
studies are required to confirm the importance of these predicted epitopes in 
vaccine-induced protection against mumps virus wild type strains. 
It has previously been shown that mumps-specific humoral immune responses 
wane after MMR vaccination (19). This may contribute to the occurrence of the 
recent mumps outbreaks, as vaccine-induced humoral immune responses are 
lower in pre-outbreak serum samples from infected persons than in samples from 
non-infected persons (Chapters 6 and 7). Other immunological mechanisms, such 
as mucosal and cellular immune responses, could also be involved in vaccine-
induced protection. No studies have been performed so far on the protective effect 
of vaccine-induced mucosal immunity on mumps virus infection, although mucosal 
immunity might play an important role in mumps virus pathogenesis. Parenteral 
vaccination could induce mucosal immunty via transudation of plasma antibodies 
(20). However, parenteral vaccination may be less effective in inducing mucosal 
immune responses in the absence of circulating wild type mumps virus, as was 
shown for the inactivated polio vaccine (21). Mumps virus infection starts in the 
upper respiratory tract, including infection of the salivary glands, which results in 
parotitis. The virus can spread further through the body, but systemic infection 
does not occur in all patients. Neutralization of the virus in the upper respiratory 
tract by mucosal antibodies might limit mumps virus spread, as was shown for 
measles virus: IgA can effectively inhibit virus replication in polarized epithelial 
cells by intracellular neutralization (22). Furthermore, tissue-resident memory T 
cells might prevent viral entry (23). Therefore, it is important to study the mucosal 
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immune responses induced by MMR vaccination further, especially with respect to 
its potentially protective role during mumps virus infection. Moreover, mumps 
vaccination induces strong T cell responses, but understanding of the role of T cell 
immunity in protection against mumps is limited and additional research could 
provide new insights into vaccine-induced protection. 
Another research topic that deserves further study is the potential cross-
immunity resulting from infection with other paramyxoviruses. Mumps-specific IgG 
responses induced by MMR vaccination are enhanced in persons who had a prior 
infection by RSV or parainfluenza virus (24). Furthermore, T cell responses against 
RSV and mumps virus seem to cross-react (25). Many children are infected by 
RSV prior to their first MMR vaccine dose at 14 months of age, and it is 
hypothesized that T cells induced by RSV could influence the development of the 
mumps-specific immune responses upon MMR vaccination (25). However, it is 
unknown whether this potential cross-immunity between paramyxoviruses has a 
beneficial effect on the long term and which epitope regions are responsible for 
cross-immunity. 
RISK FOR FUTURE MUMPS OUTBREAKS IN THE NETHERLANDS 
In the pre-vaccination era, mumps had an inter-epidemic period of approximately 3 
years (26,27). Before introduction of the MMR vaccine, it was predicted that a 
vaccination coverage of 75% would lengthen the inter-epidemic period up to 25 
years after introduction of the MMR vaccine (26). Although the vaccination 
coverage in the Netherlands is higher, this prediction proved to be true, given the 
mumps outbreaks among vaccinated persons that started to occur in 2009. After 
the mumps outbreaks in 2009-2012, the number of reported mumps cases 
decreased. Some small mumps outbreaks occurred in 2013-2015, but these 
outbreaks were limited to a particular geographic region in the Netherlands, 
whereas the mumps outbreaks during 2009-2012 were nationwide (Chapter 4). 
Since 2013 various stand-alone mumps cases were reported without further 
transmission of the virus, which is probably a result of increased herd protection. 
Contrary to the predicted inter-epidemic period of 25 years after introduction of the 
MMR vaccine on population level, the inter-epidemic period in certain 
subpopulations such as students may be shorter. Students account for up to 26% 
of the population in some of the university cities (28,29). In the absence of 
nationwide mumps outbreaks during the last 3 years, the herd protection among 
students has decreased again. In addition, the decrease in this subpopulation is 
expected to be larger than the decrease on population level, because most 
students who had a mumps virus infection during the last mumps outbreak 
graduated and students who entered university after 2012 were probably not 
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exposed to mumps during the outbreaks in 2009-2012. The absence of nationwide 
mumps outbreaks during the last 3 years may therefore be sufficient to increase 
the risk for mumps outbreaks among specific risk groups in the upcoming years. 
To explore the risk for future mumps outbreaks, it is essential to estimate herd 
protection levels. Since mumps is probably underreported because of 
asymptomatic infections or reluctance to seek care, the actual number of mumps 
cases during the mumps outbreaks in the Netherlands is expected to be much 
higher than the number of mumps cases reported. This complicates estimations 
about potential increases in herd protection levels as a result of mumps virus 
circulation. The latest nationwide seroprevalence study (Pienter3 study) could give 
insights into the effect of the mumps outbreaks on mumps seroprevalence. Data 
from the Pienter3 study could be compared with data from the Pienter2 study, that 
was performed before the start of the mumps outbreaks among MMR vaccinated 
persons, to study changes in seroprevalence as a result of mumps virus circulation 
(30). In this way, the risk for future mumps outbreaks in the Netherlands could be 
predicted for specific subpopulations based on seroprevalence data.  
The recent mumps outbreaks among MMR vaccinated persons were caused by 
mumps virus genotype G strains, whereas the genotypes circulating in the pre-
vaccination era were more diverse (Chapter 5). Genotype G strains have some 
unique variable sites, including 5 sites that are located in B cell epitope regions in 
the HN protein (Chapter 5). This might explain the occurrence of mumps genotype 
G outbreaks among MMR vaccinated persons. It is therefore likely that future 
mumps outbreaks will also be caused by mumps virus strains with epitope regions 
that differ from the vaccine strain. 
PREVENTION OF MUMPS OUTBREAKS IN THE FUTURE 
Because of the risk for future mumps outbreaks among MMR vaccinated persons, 
it is important to develop preventive measures. One relatively easy way to control 
mumps outbreaks is to prevent mumps virus transmission via its major routes, but 
these are not exactly known. Indirect contact may be an important mode of 
transmission for respiratory viruses, such as rhinovirus and RSV (31,32). RSV, a 
virus that also belongs to the Paramyxoviridae family, survives for more than 5 
hours on impervious surfaces (31). There are several indications that mumps virus 
could also be transmitted via indirect contact, although transmission studies during 
future mumps outbreaks are required to confirm this theory. As mumps among 
housemates is a risk factor for mumps virus infection, mumps virus may be 
transmitted via shared glasses and cutlery (Chapter 6). Secondly, glasses could 
also be an important transmission route of mumps virus in parties and pubs. 
Furthermore, during some local mumps outbreaks in the Netherlands, mumps virus 
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transmission within sport teams was reported. Given the salivary shedding, 
transmission within sport teams may occur via shared drinking bottles. As mumps 
runs an asymptomatic course in the majority of infections and the virus can be 
transmitted before onset of symptoms, the whole population at risk in a mumps 
outbreak setting should be informed about risk factors for mumps virus 
transmission and ways to prevent further transmission. 
The mismatch in epitope regions between the vaccine strain and circulating wild 
type strains suggests that future mumps outbreaks could be prevented by an 
improved mumps vaccine (Chapter 5). Although a new mumps vaccine with 
improved protection against the currently circulating wild type mumps virus strains 
is desirable, the safety of the current mumps vaccines and the relatively low 
burden of disease make it unlikely that this will be developed in the forthcoming 
years. Furthermore, new mumps vaccines created via conventional vaccinology 
will probably not be developed as long as the vaccine-induced immune responses 
that are important for protection against mumps virus infection are unclear. A 
vaccine development approach based on vaccinomics in combination with reverse 
vaccinology can tackle this issue. Vaccinomics is a useful method to discover the 
human immune responses and the changes in responses that occur upon 
vaccination (33). With this approach, human clinical trials could be conducted to 
improve the understanding of MMR vaccine-induced immune responses and to 
define more appropriate correlates of protection for mumps. Reverse vaccinology 
allows the identification of new protein antigens using genomic information (34). 
This approach, that has proven successful for meningococcus B vaccine design, 
enables the development of a new mumps vaccine that induces a protective 
immune response against all relevant wild type strains based on mumps virus 
genome sequences from all wild type mumps virus strains (35). Nevertheless, the 
development of a new mumps vaccine will be a costly and lengthy project. 
Without changing the current mumps vaccine, waning mumps-specific immune 
responses could be boosted by a third MMR vaccination. Alternatively, the second 
MMR vaccination could be administered at an older age, but this is not preferred 
because a prolonged time period between first and second MMR vaccine dose 
increases the risk for mumps outbreaks among primary school children. A third 
MMR vaccination could be administered either at a specific age via the NIP or as 
an outbreak control method. If the MMR vaccine is administered via the NIP, the 
vaccine must elicit immunological responses that last long enough to provide 
protection during potential future mumps outbreaks. One year after third MMR 
vaccine administration, 3.1% of the subjects are seronegative or low-seropositive, 
as compared with 6.6% of the subjects at baseline (36). Furthermore, the shift in 
mumps-specific neutralization titers is minimal (36). These small effects of a third 
MMR vaccination on the long term suggest that routine MMR3 vaccination via the 
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NIP would not be cost-effective. An alternative would be to use a third MMR 
vaccine as an outbreak control method, where MMR vaccine is only administered 
during mumps outbreaks to the population at risk to prevent further spread of the 
virus. In this strategy, the vaccine has to elicit protective immunological responses 
during a relatively short period. Offering a third MMR vaccination in a mumps 
outbreak setting seems to decrease the number of mumps cases substantially 
(37,38). However, in the published reports, it is difficult to rule out that other 
factors, such as increased herd protection due to high attack rates, contribute to 
the reduction in mumps cases. The effect of a third MMR vaccine dose on both 
humoral and cellular immune responses should therefore be studied in depth. It 
was shown previously that seronegative persons have detectable mumps-specific 
IgG concentrations for at least 2-3 months after third MMR vaccine administration 
(39). These data, in combination with the data from the intervention study, suggest 
that offering a third MMR vaccination during mumps outbreaks is probably an 
effective method to control a mumps outbreak. 
CONCLUDING REMARKS 
In conclusion, the evidence described in this thesis suggests that recent mumps 
outbreaks among MMR vaccinated persons are probably a result of both a 
mismatch in epitope regions and waning immune responses. Since the mumps-
specific immune responses induced by a third MMR vaccine dose seem to last for 
a short period and development of a new mumps virus vaccine in the forthcoming 
years is unlikely, the preferred mumps outbreak control measure is to offer a third 
MMR vaccine dose during mumps outbreaks among MMR vaccinated persons. 
Additionally, informing the public about potential mumps virus transmission routes 
and preventive measures could reduce mumps virus transmission, although the 
mumps virus transmission routes are yet not fully understood. Further investigation 
of mumps virus transmission, pathogenesis and protective immune responses is 
required to better control as well as prevent future mumps outbreaks. Moreover, 
molecular surveillance remains important to quickly identify mumps outbreaks and 
to measure the effect of public health decisions.  
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NEDERLANDSE SAMENVATTING 
Bof is een infectieziekte die wordt gekenmerkt door ontsteking van de 
speekselklier (parotitis) en meestal mild verloopt. Bij sommige patiënten 
veroorzaakt het bofvirus echter complicaties, waaronder hersenvliesontsteking 
(meningitis), hersenontsteking (encefalitis), zaadbalontsteking (orchitis), 
eierstokontsteking (oöforitis), borstontsteking (mastitis), ontsteking van de 
alvleesklier (pancreatitis) en doofheid. De invoering van het BMR-vaccin (bof, 
mazelen, rodehond) in het Rijksvaccinatieprogramma in 1987 heeft de 
ziektelast van bof sterk teruggedrongen. In het afgelopen decennium zijn er 
wereldwijd echter verscheidene bofuitbraken onder BMR-gevaccineerde 
personen geweest, onder meer in Nederland. Tijdens deze bofuitbraken waren 
de meeste bofpatiënten jong volwassenen. De eerste bofuitbraak in Nederland 
onder BMR-gevaccineerde personen vond plaats in 2004 op de hotelschool in 
Den Haag. Na deze uitbraak volgde er een uitbraakcluster in Brabant, dat net 
als het cluster in Den Haag door genotype G bofvirus werd veroorzaakt. In 
2007-2009 vond er een genotype D bofuitbraak plaats onder bevindelijk 
gereformeerde groeperingen met een lage vaccinatiegraad. De grootste 
genotype G bofuitbraak in Nederland begon in 2009 en breidde zich snel uit na 
een groot studentenfeest in februari 2010, resulterend in een landelijke uitbraak 
die tot in 2012 aanhield. Sinds 2012 zijn er alleen nog enkele lokale 
bofuitbraken geweest. 
Het bofvirus is een RNA virus en behoort tot de Paramyxovirus familie. Het 
virale genoom bestaat uit 7 genen, die coderen voor 7 structurele en 2 niet-
structurele eiwitten. Het hemagglutinine-neuraminidase (HN) gen en het fusie 
(F) gen coderen voor twee oppervlakte-eiwitten die belangrijk zijn in de 
pathogenese van het virus. Het HN eiwit bindt aan siaalzuur en faciliteert op 
deze manier de toegang tot de gastheercel. Ook maakt het HN eiwit de 
verspreiding van bofvirus mogelijk en wordt het fusieproces door dit eiwit 
bevorderd. Het F eiwit faciliteert de membraanfusie en de productie van 
viruspartikels. Het HN eiwit en het F eiwit zijn een belangrijk doelwit van de bof-
specifieke immuunresponsen. Het ‘small hydrophobic’ (SH) gen wordt gebruikt 
om de bofvirussen te classificeren in 12 genotypen. De bofvirusstam (‘Jeryl 
Lynn’) die in het Nederlandse BMR-vaccin zit behoort tot genotype A, terwijl de 
recente bofuitbraken onder BMR-gevaccineerde personen door genotype G 
bofvirussen werden veroorzaakt. 
Na besmetting met het bofvirus kan het 2 tot 4 weken duren voor de eerste 
symptomen ontstaan. Het virus kan echter wel al worden overgedragen voordat 
de eerste symptomen zichtbaar zijn, waardoor het lastig is om transmissie van 
het virus in kaart te brengen. Het bofvirus dringt de epitheelcellen in de 
luchtwegen binnen, maar het is onduidelijk hoe het virus zich daarna verder 
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verspreidt. In bofpatiënten zijn zowel humorale als cellulaire immuunresponsen 
gemeten, maar de precieze rol van deze responsen in bescherming tegen bof is 
niet bekend. Mogelijk helpt het V eiwit van het bofvirus om te ontsnappen aan 
de bof-specifieke immuunresponsen. Een deel van de bofpatiënten scheidt ook 
bofvirus via de urine uit, een gevolg van verspreiding van het virus naar de 
nieren. Het is echter niet bekend hoe het virus in de nieren terecht komt. Ook 
over het ontstaan van parotitits en orchitis is weinig bekend. Er zijn daarom 
meer studies noodzakelijk om de gebrekkige kennis over bofviruspathogenese 
en de rol van het immuunsysteem tijdens een bofvirusinfectie te vergroten. 
De recente genotype G bofuitbraken onder BMR-gevaccineerde personen 
roepen de vraag op of het huidige vaccin wel voldoende kruisbescherming biedt 
tegen genotype G bofvirussen. De bofuitbraken zijn in ieder geval geen gevolg 
van primair vaccinfalen aangezien bof-specifieke immuunresponsen zijn 
aangetoond in BMR-gevaccineerde bofpatiënten voorafgaand aan een 
bofvirusinfectie. Secundair vaccinfalen speelt mogelijk ook een rol in het 
ontstaan van de recente bofuitbraken. De meeste patiënten tijdens deze 
bofuitbraken waren 18 tot 25 jaar oud, wat betekent dat deze leeftijdsgroep het 
eerste cohort is dat het BMR-vaccin toegediend heeft gekregen. Waarschijnlijk 
zijn deze personen tot het begin van de landelijke bofuitbraken in 2009 niet 
blootgesteld geweest aan het bofvirus, waardoor de immuunresponsen na de 
tweede BMR-vaccinatie op 9-jarige leeftijd geleidelijk zijn afgenomen. Ook het 
sociale gedrag van studenten speelt naar verwachting een rol in transmissie 
van het virus tijdens de recente uitbraken. Studenten leven over het algemeen 
dicht op elkaar, waardoor het risico op bofvirustransmissie groter is. Daarnaast 
zijn bepaalde evenementen, waaronder studentenfeesten, in verband gebracht 
met bofuitbraken. Verdere studies naar bofvirustransmissie zijn nodig om 
factoren die een rol spelen in transmissie van het virus tijdens uitbraken te 
identificeren en om in de toekomst preventieve maatregelen te kunnen nemen. 
In dit promotieonderzoek zijn de verschillende factoren die mogelijk hebben 
bijgedragen aan het ontstaan van de recente bofuitbraken onder BMR-
gevaccineerde personen onderzocht, om zo BMR-vaccinatie te kunnen 
evalueren in het licht van de recente bofuitbraken. Verder is er een moleculaire 
tool ontwikkeld om uitbraakclusters te identificeren en bofvirustransmissie 
tijdens uitbraken op deze manier in kaart te brengen. Ten slotte is onderzocht of 
BMR-vaccinatie bescherming biedt tegen het ontwikkelen van een 
bofvirusinfectie en of vaccinatie een beschermend effect heeft op het 
ziektebeloop. 
In Deel II ligt de focus op de recente bofuitbraken en de circulerende 
bofvirussen in Nederland. In Hoofdstuk 2 is de epidemiologie van de landelijke 
bofuitbraken onderzocht. Gedurende de uitbraakseizoenen veranderden de 
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leeftijdsverdeling en geografische verdeling. Tijdens het eerste uitbraakseizoen 
hadden voornamelijk studenten bof, maar in de daaropvolgende seizoenen 
waren bofpatiënten steeds vaker niet-studenten. Dit komt waarschijnlijk door 
verhoogde immuniteit na blootstelling aan het virus. Verder blijkt dat BMR-
vaccinatie het risico op complicaties verkleint. 
De  RNA sequenties van bofvirussen uit de recente bofuitbraken in 
Nederland zijn geanalyseerd om uitbraakclusters en nieuwe introducties van 
het virus te onderzoeken (Hoofdstuk 3). Analyses op basis van het SH gen 
toonden aan dat twee genotype G varianten domineerden tijdens de 
uitbraakseizoenen 2009-2012. De eerste variant werd voornamelijk in het 
eerste seizoen gevonden, terwijl de meeste bofvirussen vanaf het eind van het 
eerste uitbraakseizoen tot de tweede variant behoorden. Ook bleek orchitis 
vaker voor te komen onder mannen met deze tweede virusvariant. Omdat er 
geen epidemiologische factoren zijn gevonden die deze verschillen kunnen 
verklaren, is het waarschijnlijk dat er virologische verschillen tussen deze twee 
virusvarianten zijn. 
Vanwege de kleine variatie in het SH gen binnen een genotype is dit gen 
niet geschikt om transmissie van het virus in kaart te brengen. Daarom hebben 
we naast het SH gen ook het F gen en het HN gen geanalyseerd. De 
genetische diversiteit tijdens de recente bofuitbraken blijkt niet het gevolg te zijn 
van evolutie, maar van meerdere introducties van het virus. Het combineren 
van de moleculaire informatie van het F gen, SH gen en HN gen maakt het 
mogelijk om clusters te identificeren en bofvirustransmissie in kaart te brengen, 
ook in gevallen waarbij een epidemiologische link ontbreekt (Hoofdstuk 4). Op 
deze manier kunnen nieuwe bofuitbraken sneller worden ontdekt en kan het 
effect van eventuele maatregelen op virustransmissie tijdens een uitbraak 
gemeten worden. 
In Hoofdstuk 5 zijn de sequenties van het F gen en het HN gen gebruikt om 
de oppervlakte-eiwitten van het bofvirus te onderzoeken om zo een mogelijke 
verklaring te vinden voor de verschillen tussen genotype G bofvirussen en 
andere bofvirussen, waaronder de Jeryl Lynn vaccinstam die tot genotype A 
behoort. We hebben meerdere posities gevonden die verschillen tussen 
genotype G bofvirussen en de Jeryl Lynn vaccin stam. Met name 5 variabele 
posities in het HN eiwit zijn interessant, omdat deze posities in regio’s liggen die 
door ihet immuunsysteem worden herkend. Variatie in deze regio’s kan daarom 
wellicht zorgen voor een lagere immuunrespons tegen genotype G bofvirussen. 
In Deel III is het effect van BMR-vaccinatie op het ontwikkelen van een 
bofvirusinfectie en op het ziektebeloop geëvalueerd. In Hoofdstuk 6 zijn 
bofvirusinfecties retrospectief geïdentificeerd in een groep BMR-gevaccineerde 
studenten op basis van de immunoglobuline (Ig)G concentraties in gepaarde 
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bloedmonsters die voor en na de bofuitbraak zijn afgenomen. Door het gebruik 
van een vragenlijst kon onderscheid worden gemaakt tussen symptomatische 
en asymptomatische infecties en konden risicofactoren worden onderzocht. 
Volgens onze serologische criteria had 5,8% van de studenten in deze groep 
een bofvirusinfectie en was twee derde van deze infecties asymptomatisch. 
Verder bleek het circuleren van bof onder huisgenoten een risicofactor voor 
bofvirusinfectie te zijn. Voor de bofuitbraak waren de bof-specifieke IgG 
concentraties lager in monsters van personen met een bofvirusinfectie tijdens 
de uitbraak dan in monters van personen zonder bofvirusinfectie. 
De immunologische responsen in deze groep BMR-gevaccineerde 
studenten zijn verder onderzocht met behulp van de neutralisatietest in de 
bloedmonsters die voor de bofuitbraak zijn afgenomen (Hoofdstuk 7). In de 
monsters is de virusneutralisatie gemeten tegen de Jeryl Lynn vaccinstam en 
tegen wildtype genotype G en genotype D bofvirussen. De stam-specificiteit 
van de virusneutralisatie verschilt tussen geïnfecteerde en niet-geïnfecteerde 
personen. Verder blijkt dat de verschillen tussen geïnfecteerde en niet-
geïnfecteerde personen het grootste zijn voor de virusneutralisatie tegen 
genotype G bofvirus, hetgeen aantoont dat serologische bescherming tegen 
bofvirusinfectie het beste kan worden gemonitord met behulp van genotype G-
specifieke neutralisatietesten in plaats van neutralisatietesten met andere 
bofvirussen of IgG testen. 
Naast het effect van BMR-vaccinatie op de humorale immuunresponsen 
hebben we het effect van BMR-vaccinatie op het ziektebeloop in bofpatiënten 
onderzocht (Hoofdstuk 8). BMR-gevaccineerde bofpatiënten hadden over het 
algemeen een milder ziektebeloop en scheidden minder vaak virus uit in urine – 
een indicator voor een systemische infectie – dan ongevaccineerde 
bofpatiënten. Daarnaast hadden patiënten met een systemische infectie 
verhoogde virusuitscheiding in speeksel, wat suggereert dat deze patiënten een 
hoger risico op transmissie van het virus vormen. Deze studie toont daarmee 
niet alleen het beschermende effect van BMR-vaccinatie op ziektebeloop aan, 
maar draagt ook bij aan de huidige kennis over bofviruspathogenese. 
Ten slotte zijn in Deel IV de belangrijkste bevindingen van dit proefschrift 
samengevat en zijn de risico’s op toekomstige bofuitbraken in Nederland en 
preventieve maatregelen om toekomstige uitbraken te voorkomen 
bediscussieerd in relatie tot de huidige inzichten (Hoofdstuk 9). De recente 
bofuitbraken onder BMR-gevaccineerde personen zijn waarschijnlijk een gevolg 
van een combinatie van secundair vaccinfalen en verschillen in epitoopregio’s 
tussen de vaccinstam en de circulerende wildtype bofvirussen. Daarnaast 
vergroot het sociale gedrag van studenten waarschijnlijk het risico op 
bofvirustransmissie. Omdat de groep studenten elk jaar wordt aangevuld met 
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nieuwe studenten en er de laatste 3 jaren geen grote landelijke bofuitbraken zijn 
geweest, is de immuniteit in deze subpopulatie naar verwachting sterk 
afgenomen. Hierdoor is er een risico op nieuwe bofuitbraken de komende jaren. 
Gezien de effectiviteit en veiligheid van het huidige vaccin, het relatief milde 
ziektebeloop, de beperkte kennis over bofviruspathogenese en de hoge kosten 
voor het ontwikkelen van een nieuw vaccin is de kans klein dat er de komende 
jaren een nieuw bofvaccin ontwikkeld zal worden. Een alternatief is om een 
derde BMR-vaccinatie toe te dienen. Ondanks de kortdurende immunologische 
responsen zou een derde BMR-vaccinatie tijdens bofuitbraken kunnen worden 
toegediend om tijdelijk de immuniteit te verhogen en op deze manier 
bofvirustransmissie te stoppen. Onderzoek naar de immuunresponsen na een 
derde BMR-vaccinatie is daarom belangrijk. Bovendien kan het informeren van 
burgers over mogelijke transmissieroutes en over preventieve maatregelen 
helpen om bofvirustransmissie tijdens uitbraken te stoppen. Een mogelijke 
transmissieroute is indirect contact via bijvoorbeeld glazen of bidons. Het is 
echter noodzakelijk dat er meer onderzoek naar bofvirustransmissie wordt 
gedaan, aangezien de transmissieroutes en de rol van asymptomatische 
infecties in de verspreiding van het virus tijdens de huidige uitbraken 
onvoldoende duidelijk zijn. Ook zijn verdere studies naar bofviruspathogenese 
en de immunologische responsen die bescherming bieden tegen 
bofvirusinfectie nodig om toekomstige bofuitbraken te voorkomen en 
transmissie te beperken. Daarnaast blijft moleculaire surveillance belangrijk 
teneinde snel bofuitbraken te kunnen identificeren en het effect van publieke 
gezondheidsmaatregelen te kunnen meten.   
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